The role of the endothelial cell endothelin B receptor in cardiovascular function by Kelland, Nicholas
THE ROLE OF THE ENDOTHELIAL CELL
ENDOTHELIN B RECEPTOR IN
CARDIOVASCULAR FUNCTION
Dr Nicholas Kelland





This thesis and the data presented within it are entirely the results of my own efforts,
except where stated otherwise. This work contains no material that has been accepted
for the award of any other degree or diploma in any university or tertiary institution
and, to the best of my knowledge, contains no material previously published or
written by another person, except where stated in the text.
………………………..2007




TABLE OF CONTENTS................................................................................. II
FIGURES .....................................................................................................VII
TABLES........................................................................................................IX







1 CHAPTER 1: GENERAL INTRODUCTION............................................1
1.1 Pharmacology of Endothelin....................................................................................................... 1
1.1.1 Structure of ET-1....................................................................................................................... 1
1.1.2 Production of ET-1.................................................................................................................... 2
1.1.3 Endothelin Converting Enzyme................................................................................................ 6
1.1.4 Endothelin receptors.................................................................................................................. 7
1.1.5 Internalisation of receptors...................................................................................................... 10
1.1.6 Clearance of ET-1.................................................................................................................... 11
1.2 Physiological roles of Endothelin.............................................................................................. 12
1.2.1 Role of Endothelins in development....................................................................................... 12
1.2.2 Role of Endothelins in vessels ................................................................................................ 14
1.2.3 Role of Endothelin in the kidney ............................................................................................ 20
1.2.4 Role of endothelin in the lungs ............................................................................................... 24
1.3 Generation of EC-specific ETB receptor Down-regulated mice ........................................... 37
1.3.1 Gene targeting: The classical approach .................................................................................. 37
1.3.2 Refining classical gene targeting by the Cre-loxP recombination system ............................ 37
1.3.3 Conditional gene targeting: Tissue specific knockout/downregulation ................................ 39
1.3.4 Endothelial cell specific downregulation ............................................................................... 41
1.3.5 Generation of EC-specific ETB receptor down-regulated mice............................................. 42
1.3.6 Initial characterisation of the EC-specific ETB receptor down-regulated mice .................... 43
1.4 Aims of the project ..................................................................................................................... 46
iii
2 CHAPTER 2: MATERIALS AND METHODS .......................................48
2.1 Animals ........................................................................................................................................ 48
2.2 Breeding....................................................................................................................................... 48
2.2.1 Breeding strategy to generate ETB null animals..................................................................... 48
2.2.2 Analytical breeding crosses to assess sex linkage of recombination events ......................... 48
2.2.3 Breeding strategy to generate experimental animals ............................................................. 50
2.3 Genotyping .................................................................................................................................. 50
2.3.1 Preparation of genomic DNA from tail/ ear biopsy ............................................................... 50
2.3.2 Polymerase Chain Reaction of genomic DNA....................................................................... 51
2.3.3 Quantitation of nucleic acids................................................................................................... 53
2.3.4 Agarose gel electrophoresis .................................................................................................... 53
2.4 Genotyping approaches ............................................................................................................. 54
2.4.1 ‘Comparative’ PCR of tail biopsies ........................................................................................ 54
2.4.2 PCR of ‘EC free’ tissue........................................................................................................... 54
2.4.3 Southern blot............................................................................................................................ 55
2.5 EC specific Cre expression in Tie2-Cre mice.......................................................................... 58
2.5.1 LacZ staining and histology.................................................................................................... 58
2.5.2 Staining for β-galactosidase activity....................................................................................... 58
2.5.3 Immunohistological staining of ECs....................................................................................... 59
2.5.4 GFP reporter mice ................................................................................................................... 60
2.6 Expression studies in EC ETB down-regulated mice ............................................................. 60
2.6.1 Quantitative autoradiography.................................................................................................. 60
2.6.2 Image analysis ......................................................................................................................... 61
2.6.3 Semi quantitative RT–PCR of the ET system........................................................................ 61
2.6.4 RT-PCR ................................................................................................................................... 63
2.6.5 Agarose gel electrophoresis and densitometry....................................................................... 64
2.7 BP measurement in unconscious animals................................................................................ 65
2.8 BP measurement in conscious animals .................................................................................... 66
2.8.1 Salt diet .................................................................................................................................... 66
2.8.2 Indwelling carotid artery catheters.......................................................................................... 67
2.8.3 Surgical implantation of telemetry devices ............................................................................ 69
2.8.4 Haematocrit measurements ..................................................................................................... 70
2.9 ET-1 clearance studies ............................................................................................................... 71
2.9.1 Measurement of plasma ET-1 and big ET-1 concentrations ................................................. 71
2.9.2 Clearance studies ..................................................................................................................... 71
2.10 Pulmonary Arterial Hypertension Study ................................................................................ 72
2.10.1 Hypobaric chamber ............................................................................................................ 72
2.10.2 Haemodynamic studies ...................................................................................................... 73
2.10.3 Measurement of RV hypertrophy ...................................................................................... 74
2.10.4 Wire myography................................................................................................................. 74
2.10.5 Lung histology.................................................................................................................... 77
2.11 Statistical Analysis of Results ................................................................................................... 78




3.1.1 Deletion of exons 3 and 4 prevents ETB expression .............................................................. 79
3.1.2 Tie2-Cre restricts expression of Cre recombinase to the endothelium.................................. 80
3.1.3 EC-specific ETB down-regulation in FF/Tie2 mice ............................................................... 81
3.2 Results .......................................................................................................................................... 84
3.2.1 Genotyping of experimental animals...................................................................................... 84
3.2.2 Generation of null ETB mice ................................................................................................... 85
3.2.3 Analytical crosses.................................................................................................................... 88
3.2.4 Genotyping strategies .............................................................................................................. 88
3.2.5 Tie2-Cre restricts Cre expression to ECs ............................................................................... 94
3.2.6 Autoradiography to demonstrate ET receptor expression...................................................... 97
3.2.7 RT-PCR to demonstrate renal ET system expression..........................................................105
3.3 Discussion ..................................................................................................................................112
3.3.1 Knockout of exons 3 and 4 is sufficient to prevent expression of ETB ...............................112
3.3.2 Sex linked germ line recombination .....................................................................................112
3.3.3 Genotyping strategies ............................................................................................................115
3.3.4 Endothelial cell specific Cre expression...............................................................................117
3.3.5 EC specific ETB down-regulation in FF/Tie2 mice..............................................................118
3.3.6 Expression of other components of the ET system in the FF/Tie2 mouse..........................119
4 CHAPTER 4: ROLE OF THE EC-ETB RECEPTOR IN THE CONTROL
OF SYSTEMIC BP..................................................................................... 123
4.1 Introduction...............................................................................................................................123
4.2 Methods/Protocols ....................................................................................................................125
4.2.1 Measurement of BP under anaesthesia .................................................................................125
4.2.2 Measurement of BP under conscious unrestrained conditions using fluid filled catheters
125
4.2.3 Continuous measurement of BP under conscious unrestrained conditions using
radiotelemetry.......................................................................................................................................125
4.3 Results ........................................................................................................................................129
4.3.1 Measurement of BP under anaesthesia .................................................................................129
4.3.2 Continuous measurement of BP under conscious unrestrained conditions using
radiotelemetry.......................................................................................................................................134
4.3.3 Influence of age on heart/ body weight ratio........................................................................177
4.4 Discussion ..................................................................................................................................179
4.4.1 Deletion of the EC ETB receptor does not alter the BP response to salt .............................179
4.4.2 BP measurement in mice.......................................................................................................182
4.4.3 Why did the results from the radiotelemetry and direct catheter BP studies differ? ..........185
5 CHAPTER 5: ROLE OF THE EC-ETB RECEPTOR IN THE PLASMA
CLEARANCE OF ET-1 .............................................................................. 189
5.1 Introduction...............................................................................................................................189
5.2 Methods/Protocols ....................................................................................................................190
5.2.1 Plasma ET-1 and big ET-1 concentrations...........................................................................190
5.2.2 Clearance studies ...................................................................................................................190
5.3 Results ........................................................................................................................................191
v
5.3.1 Plasma ET-1 concentrations..................................................................................................191
5.3.2 Plasma big ET-1 concentrations ...........................................................................................192
5.3.3 Effect of genotype on clearance of ET-1..............................................................................193
5.3.4 Effect of pharmacological ETB blockade on clearance of ET-1 ..........................................195
5.4 Discussion ..................................................................................................................................200
5.4.1 Plasma ET-1 and big ET-1 concentrations...........................................................................200
5.4.2 Plasma clearance studies .......................................................................................................202
5.4.3 Non ETB receptor mediated ET-1 clearance.........................................................................203
5.4.4 Technical considerations in plasma clearance studies .........................................................203
6 CHAPTER 6: ROLE OF THE EC-ETB RECEPTOR IN THE CONTROL
OF PULMONARY VASCULAR TONE AND THE DEVELOPMENT OF
PULMONARY ARTERIAL HYPERTENSION............................................ 206
6.1 Introduction...............................................................................................................................206
6.2 Methods/Protocols ....................................................................................................................208
6.2.1 Myography protocol ..............................................................................................................208
6.3 Results ........................................................................................................................................209
6.3.1 Weights ..................................................................................................................................209
6.3.2 Haemodynamic studies .........................................................................................................209




6.4.1 Mechanisms responsible for PAH ........................................................................................224
6.4.2 Influence of vascular remodeling and vasoconstriction in chronic hypoxic PAH..............225
6.4.3 Study limitations....................................................................................................................227
7 CHAPTER 7: CONCLUSIONS AND FUTURE WORK....................... 230
7.1 Introduction...............................................................................................................................230
7.2 Limitations of the project as a whole .....................................................................................230
7.2.1 Genetic background...............................................................................................................230
7.2.2 Possible compensatory mechanisms.....................................................................................231
7.3 Body Weight of EC ETB down-regulated mice.....................................................................231
7.4 Expression of ET receptors in EC ETB down-regulated mice............................................233
7.5 Role of EC ETB in control of systemic vascular tone and response to salt .......................234
7.6 Contribution of EC ETB receptor to the clearance of plasma ET-1 ..................................235
7.7 The EC ETB receptor in the control of pulmonary vascular tone......................................236
7.8 Summary....................................................................................................................................237




Figure 1-1: Structure of ET-1, ET-2, ET-3 and S6c..................................................................................... 2
Figure 1-2: Factors affecting the synthesis of ET-1..................................................................................... 4
Figure 1-3: ET receptor intracellular signalling ........................................................................................... 8
Figure 1-4: Autocrine versus paracrine control of ETB mediated natriuresis ........................................... 22
Figure 1-5: Pathogenesis of PAH ............................................................................................................... 30
Figure 1-6: Endothelial dysfunction in PAH.............................................................................................. 33
Figure 1-7: Generation of mice with loxP-flanked target genes (flox). .................................................... 39
Figure 1-8: Gene targeting of the ETB gene ............................................................................................... 42
Figure 1-9: Reduced ET-1 binding in pulmonary ECs from FF/Tie2 mice .............................................. 44
Figure 1-10: Functional evidence of EC ETB down-regulation in FF/Tie2 mice ..................................... 45
Figure 2-1: Breeding strategy to generate piebalds and analytical crosses............................................... 49
Figure 2-2: Breeding strategy for experimental animals ........................................................................... 50
Figure 2-3: PCR genotyping strategy ......................................................................................................... 52
Figure 2-4: Southern blot strategy .............................................................................................................. 56
Figure 2-5: Procedure for mounting of pulmonary artery rings onto the wire myograph........................ 75
Figure 3-1: Cre mediated recombination.................................................................................................... 81
Figure 3-2: Flox PCR .................................................................................................................................. 84
Figure 3-3: Tie2 PCR .................................................................................................................................. 85
Figure 3-4: Piebald mice ............................................................................................................................. 87
Figure 3-5: Semi-quantitative PCR............................................................................................................. 89
Figure 3-6: Hair DNA PCR......................................................................................................................... 91
Figure 3-7: Testes DNA PCR ..................................................................................................................... 92
Figure 3-8: Cardiomyocyte DNA PCR....................................................................................................... 93
Figure 3-9: Southern blot genotyping......................................................................................................... 94
Figure 3-10: LacZ and CD31 antibody staining in kidneys from WW/Tie2-Cre and WW/Tie2-
Cre/R26R mice. ................................................................................................................................. 95
Figure 3-11: GFP autofluorescence in day 11 FF/Tie2-Cre/GFP embryos............................................... 96
Figure 3-12: Total ETB binding in FF/Tie2 and control mice ................................................................... 99
Figure 3-13 ETB binding in lung and kidney............................................................................................100
Figure 3-14: Specific ETB binding in lung, kidney and liver...................................................................101
Figure 3-15: Autoradiographs of total binding of the radiolabelled ETA selective ligand [125I]-
PD151242 in WW/-- (A) FF/-- (B) and FF/Tie2 (C) mice. ...........................................................103
Figure 3-16: Specific ETA binding in kidney, lung and liver. .................................................................104
Figure 3-17: Denaturing gel ......................................................................................................................105
Figure 3-18: Optimisation of PCR temperature .......................................................................................106
Figure 3-19: Optimisation of PCR cycle number.....................................................................................107
Figure 3-20: Serial dilution of cDNA.......................................................................................................109
Figure 3-21: Effect of genotype on the relative expression of the renal ET system...............................110
Figure 3-22 Effect of age and sex on the relative expression of the renal ET system............................111
Figure 4-1: Study protocol for the first phase of the telemetry BP study................................................126
Figure 4-2: Study protocol for the second phase of the telemetry BP study...........................................127
Figure 4-3 Representative BP trace of an anaesthetised WW/-- mouse..................................................129
Figure 4-4 Representative BP trace of an anaesthetised FF/Tie2 mouse. ...............................................130
Figure 4-5: MABP of anaesthetized animals............................................................................................130
Figure 4-6 Representative BP traces of conscious unrestrained mice.....................................................132
Figure 4-7: MABP of unrestrained conscious mice.................................................................................133
Figure 4-8: HR of unrestrained conscious mice.......................................................................................134
Figure 4-9: 12 hourly SBP ........................................................................................................................135
Figure 4-10: SBP of telemetered mice during the 7 days of normal salt (0.76% NaCl) diet (week 1)
[A] and during the 7 days of low salt (0.076% NaCl) diet (week 2) [B]. .....................................136
Figure 4-11: SBP of telemetered mice during the 7 days of high salt (7.6% NaCl) diet (week 3) [A]
and during the 7 days of high salt + A627 (5 mg.kg-1) diet (week 4) [B]. ....................................137
viii
Figure 4-12: Comparison of: the averaged SBP of FF/-- (n=12) and FF/Tie2 (n=10) mice during the
last 72 hours of each week-long dietary period [A]; the averaged minimal SBP values during the
day [B]; and the averaged maximal SBP values during the night [C]...........................................139
Figure 4-13: 12 hourly DBP......................................................................................................................139
Figure 4-14: DBP of telemetered mice during the 7 days of normal salt (0.76% NaCl) diet (week 1)
[A] and during the 7 days of low salt (0.076% NaCl) diet (week 2) [B]. .....................................140
Figure 4-15: DBP of telemetered mice during the 7 days of high salt (7.6% NaCl) diet (week 3) [A]
and during the 7 days of high salt + A627 (5 mg.kg-1) diet (week 4) [B]. ....................................141
Figure 4-16: Comparison of: the averaged DBP of FF/-- (n=12) and FF/Tie2 (n=10) mice during the
last 72 hours of each dietary period [A]; the averaged minimal DBP values during the day [B];
and the averaged minimal DBP values during the night [C]. ........................................................143
Figure 4-17: 12 hourly MBP.....................................................................................................................143
Figure 4-18: MBP of telemetered mice during the 7 days of normal salt (0.76% NaCl) diet (week 1)
[A] and during the 7 days of low salt (0.076% NaCl) diet (week 2)[B]. ......................................144
Figure 4-19: MBP of telemetered mice during the 7 days of high salt (7.6% NaCl) diet (week 3) [A]
and during the 7 days of high salt + A627 (5 mg.kg-1) diet (week 4) [B]. ....................................145
Figure 4-20: Comparison of: the averaged MBP of FF/-- (n=12) and FF/Tie2 (n=10) mice during the
last 72 hours of each week-long dietary period [A]; the averaged minimal MBP values during
the day [B]; and the averaged minimal MBP values during the night [C]....................................147
Figure 4-21: 12 hourly heart rate. .............................................................................................................147
Figure 4-22: Heart rate of telemetered mice during the 7 days of normal salt (0.76% NaCl) diet (week
1) [A] and during the 7 days of low salt (0.076% NaCl) diet (week 2) [B]..................................148
Figure 4-23: Heart rate of telemetered mice during the 7 days of high salt (7.6% NaCl) diet (week 3)
[A] and during the 7 days of high salt + A627 (5 mg.kg-1) diet (week 4) [B]. .............................149
Figure 4-24: Comparison of: the averaged HR of FF/-- (n=12) and FF/Tie2 (n=10) mice during the
last 72 hours of each week-long dietary period [A]; the averaged minimal HR during the day
[B]; and the averaged maximal HR values during night [C]. ........................................................151
Figure 4-25: Average daily water consumption.......................................................................................151
Figure 4-26: Average daily gel intake ......................................................................................................152
Figure 4-27: Average body weight ...........................................................................................................153
Figure 4-28: Weight change versus the previous day ..............................................................................154
Figure 4-29: 12 hourly SBP ......................................................................................................................155
Figure 4-30: SBP of telemetered mice during the second week of normal salt (0.76% NaCl) diet (week
5) [A], during the 7-days of high salt (7.6% NaCl) + A192621 (week 6) [B] and during the 7
days of 2.5% NaCl diet (week 7) [C]. ............................................................................................157
Figure 4-31: Comparison of: the averaged SBP of FF/-- (n=7) and FF/Tie2 (n=6) mice during the last
72 hours of each week-long dietary period [A]; the averaged minimal SBP values during the day
[B]; and the averaged maximal SBP values during the night [C]..................................................159
Figure 4-32: 12 hourly DBP......................................................................................................................160
Figure 4-33: DBP of telemetered mice during the second week of normal salt (0.76% NaCl) diet
(week 5) [A], during the 7-days of high salt (7.6% NaCl) + A192621 (week 6) [B] and during
the 7 days of 2.5% NaCl diet (week 7) [C]. ...................................................................................162
Figure 4-34: Comparison of: the averaged DBP of FF/-- (n=7) and FF/Tie2 (n=6) mice during the last
72 hours of each week-long dietary period [A]; the averaged minimal DBP values during the
day [B]; and the averaged maximal DBP values during the night [C]..........................................164
Figure 4-35: 12 hourly MBP.....................................................................................................................165
Figure 4-36: MBP of telemetered mice during the second week of normal salt (0.76% NaCl) diet
(week 5) [A], during the 7-days of high salt (7.6% NaCl) + A192621 (week 6) [B] and during
the 7 days of 2.5% NaCl diet (week 7) [C]. ...................................................................................167
Figure 4-37: Comparison of: the averaged MBP of FF/-- (n=7) and FF/Tie2 (n=6) mice during the last
72 hours of each week-long dietary period [A]; the averaged minimal MBP values during the
day [B]; and the averaged maximal MBP values during the night [C]. ........................................169
Figure 4-38: 12 hourly HR........................................................................................................................170
Figure 4-39: HR of telemetered mice during the second week of normal salt (0.76% NaCl) diet (week
5) [A], during the 7-days of high salt (7.6% NaCl) + A192621 (week 6) [B] and during the 7
days of 2.5% NaCl diet (week 7) [C]. ............................................................................................172
ix
Figure 4-40: Comparison of: the averaged HR of FF/-- (n=7) and FF/Tie2 (n=6) mice during the last
72 hours of each week-long dietary period [A]; the averaged minimal HR values during the day
[B]; and the averaged maximal HR values during the night [C]. ..................................................174
Figure 4-41: Average daily water consumption (second extended study only)......................................174
Figure 4-42: Average daily gel intake (second extended study only). ....................................................175
Figure 4-43: Average daily body weight (second extended study only).................................................176
Figure 4-44: Packed cell volume of mice in second study ......................................................................176
Figure 4-45: Heart to body weight ratio for young and old mice............................................................177
Figure 5-1: Plasma concentrations of ET-1 were elevated in FF/Tie2 mice...........................................191
Figure 5-2: Plasma concentration of big ET-1 was only marginally elevated in FF/Tie2 mice.............192
Figure 5-3: Concentration – time graph showing that elimination of a bolus of radiolabelled ET-1 was
impaired in FF/Tie2 compared to WW/-- mice..............................................................................193
Figure 5-4: Clearance of ET-1 was similar in WW/-- and FF/-- mice. ...................................................194
Figure 5-5: ETB blockade with A192621 impaired ET-1 clearance in WW/-- mice to a similar extent
to that of untreated FF/Tie2 mice....................................................................................................196
Figure 5-6: Both low and high dose A192621 had similar effects on ET-1 clearance in WW/-- mice.
..........................................................................................................................................................197
Figure 5-7: Logarithmic plot of concentration against time was not different between genotypes.......198
Figure 5-8: Clearance of ET-1 was impaired in FF/Tie2 mice, and in mice of both genotypes treated
with ETB blockade. ..........................................................................................................................200
Figure 6-1: Systemic haemodynamics did not differ between genotypes under both normoxic and
hypoxic conditions...........................................................................................................................209
Figure 6-2: The systolic RVP of FF/Tie2 mice was significantly elevated under hypoxic conditions
..........................................................................................................................................................210
Figure 6-3: Hypoxia results in right ventricular hypertrophy in hypoxic mice FF/Tie2 mice ...............212
Figure 6-4: (previous 2 pages). Representative tracing of a wire myography study of a 3rd order PA
ring from FF/-- mouse, housed under normoxic conditions, not exposed to L-NAME. ..............215
Figure 6-5: Length (internal circumference) – tension relationship for all PA rings .............................216
Figure 6-6: CRC of PAs to ET-1 under normoxia and hypoxia ..............................................................217
Figure 6-7: CRC of normoxic PA rings to ET-1 in the presence and absence of L-NAME..................219
Figure 6-8: CRC of hypoxic PA rings to ET-1 in the presence and absence of L-NAME.....................220
Figure 6-9: Micrograph showing hypoxic remodeling ............................................................................222
Figure 6-10: The percentage of remodeled pulmonary vessels was increased in hypoxic FF/Tie2 mice
..........................................................................................................................................................223
Figure 7-1: Summary bar chart showing trend of EC ETB down-regulated mice to reduced body
weights .............................................................................................................................................232
Tables
Table 1-1 Classification of pulmonary hypertension ................................................................................. 27
Table 2-1: PCR conditions .......................................................................................................................... 53
Table 3-1: Results of analytical breeding pairs .......................................................................................... 88
Table 3-2: Optimum conditions for semi-quantitative PCR of ET system .............................................108
Table 4-1: Pre-surgery weights .................................................................................................................132
Table 4-2: Heart and body weights for young (2 month old) and old (4 month) mice...........................178
Table 5-1: Body weights on day of clearance study ................................................................................195
Table 5-2: Pharmacokinetic data for elimination of a bolus of [125I]-ET-1.............................................199
Table 6-1: Weights of mice.......................................................................................................................209
Table 6-2: Indices of right ventricular hypertrophy .................................................................................211
Table 6-3: Potency and maximum effect of ET-1 in PA rings from FF/Tie2 and FF/-- animals...........221
x
Presentations, Prizes and Publications
The following presentations, prizes awarded and publications have arisen from the
work described in this thesis:
PRESENTATIONS
Kelland NF, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Kotelevtsev YV, Webb DJ.
Endothelial cell endothelin B receptors mediate a tonic hypotensive effect that is
insensitive to salt. Proceedings of the British Pharmacological Society. 2003;
http://www.pa2online.org/Vol1Issue4abst070P, [Poster presentation at the Winter BPS
Meeting, London UK]
Kelland NF, Bagnall AJ, Gulliver-Sloan FH, Gray GA, Kotelevtsev YV, Webb DJ.
Endothelial cell-specific knockout of the endothelin B receptor results in
hypertension that is resistant to salt. Journal of Hypertension. 2004;22:S9. [Oral
presentation at the European Society of Hypertension, Paris, France]
Kelland NF, Bagnall AJ, Gulliver-Sloan FH, Gray GA, Kotelevtsev YV, Webb DJ.
The endothelial cell endothelin B receptor plays an important role in the clearance of
ET-1. Journal of Hypertension. 2004;22:S49. [Poster presentation at the European
Society of Hypertension, Paris, France]
Kelland NF, Bagnall AJ, Gulliver-Sloan FH, Kuc RE, Davenport AP, Gray GA,
Kotelevtsev YV and Webb DJ. Investigation of the clearance of endothelin–1 from
plasma using a murine endothelial cell specific endothelin B receptor knockout
model. Heart 2004; 90:e68. http://www.heartjnl.com/cgi/content/full/90/12/e68. [Poster
presentation at the British Society for Cardiovascular Research Autumn Meeting,
London]
Kelland NF, Bagnall AJ, Gulliver-Sloan F, Gray GA, Kotelevtsev Y, Webb DJ. The
endothelial cell ETBR exerts a hypotensive effect and is responsible for the clearance
xi
of endothelin-1. Hypertension 2004; 44(4):51. [Oral presentation at the AHA
Council for High BP research, Chicago, USA]
Armour DL, Kelland NF, Bagnall AB, Gulliver-Sloan FH, Kotelevtsev YV and
Webb DJ. The effect of targeted disruption of the endothelial cell endothelin B
receptor on gene expression of the renal endothelin system. [Poster presentation at
the Ninth International Conference on Endothelin. Salt Lake City, Utah, USA]
Bagnall AB, Kelland NF, Gulliver-Sloan FH, Davenport AP, Gray GA, Yanagisawa
M, Kotelevtsev YV and Webb DJ. Targeted Disruption of the Endothelial Cell
Endothelin B Receptor does not affect the BP Response to Salt. Ninth International
Conference on Endothelin. Salt Lake City, Utah, USA.
Kelland NF, Bagnall AJ, Gulliver-Sloan F, Kuc RE, Maguire JJ, Davenport AP,
Gray GA, Kotelevtsev Y and Webb DJ. Scavenging of plasma endothelin-1 is
mediated by the endothelial cell endothelin B receptors. [Oral presentation at the
Ninth International Conference on Endothelin. Salt Lake City, Utah, USA]
Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan F, Dempsie FH, Nilson M,
MacLean MR, Kotelevtsev Y and Webb DJ. Endothelial cell-specific knockout of
the ETB receptor exaggerates hypoxia induced pulmonary arterial hypertension. [Oral
presentation at the Winter BPS Meeting, London UK].
xii
PRIZES
Young Investigator Award, Centre for Cardiovascular Science Day, Edinburgh
University, July 2004
Pfizer Academic Travel Award, Aug 2004
New Investigator Award for European Fellows, AHA Council for High Blood
Pressure Research, Chicago, USA, Oct 2004
Sir Stanley Davidson Travel Award, University of Edinburgh, April 2005




Bagnall AB and Kelland NF, Gulliver-Sloan FH, Davenport AP, Gray GA,
Yanagisawa M, Webb DJ and Kotelevtsev YV. (2006). Deletion of endothelial cell
endothelin B receptors does not affect blood pressure or sensitivity to salt.
Hypertension: 48; 286-93.
Kelland NF, Webb, DJ. (2006). Clinical Trials of Endothelin Antagonists in Heart
Failure: A Question of Dose? Experimental Biology and Medicine: 231; 696-699.
Battistini B, Berthiaume N, Kelland NF, Webb DJ and Kohan DE. (2006). Profile of
Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The
Novel "-Sentan" Class of Drug. Experimental Biology and Medicine: 231; 653-695.
Kelland NF and Webb DJ. (2007). Clinical trials of endothelin antagonists in heart
failure: publication is good for the public health. Heart: 93; 2-4.
Kelland NF, Kuc RE, Armour DL, Bagnall AJ, Gulliver-Sloan F, Maguire JJ,
Davenport AP, Gray GA, Kotelevtsev Y and Webb DJ. Endothelial Cell Specific
Knockout of the Endothelin B Receptor Demonstrates Its Crucial Role In The
Clearance Of Endothelin-1. (Manuscript in preparation).
Kelland NF, Bagnall AJ, Morecroft I, Gulliver-Sloan F, Dempsie Y, Nilsen M,
Kotelevtsev Y and Webb DJ. Endothelial cell ETB receptors limit vascular




I would like to thank my supervisors Drs Yuri Kotelevtsev, Gillian Gray and
Professor David Webb. Yuri supervised Alan Bagnall during his PhD, resulting in
the generation of the mouse model, and has continued to lead the project, giving me
limitless advice and guidance, allowing me to characterise the cardiovascular
phenotype of the animal. Gillian’s direction and support, not only during the writing
of my BHF Junior Research Fellowship, but in overcoming the many difficulties and
obstacles posed by physiological experiments in small rodents, has been crucial to
the success of this project. David provided support whilst the pilot experiments
necessary for my BHF Fellowship were performed, and greatly assisted me in
writing the resulting successful application. Without his overview of the project,
objective assessment of experimental design and critical review of the data, the work
would not have been possible.
Alan Bagnall’s commitment to the project and ethusiasm to extend the possible
applications of the mouse he generated with Yuri has resulted in many useful
discussions and new approaches being followed. Without Fiona Gulliver-Sloan’s
ceaseless efforts, contributing significantly to the genotyping and management of the
colony as well as her great experience of physiological and pharmacological
experiments, much of this project would have stumbled and faltered.
I am also indebted to my wife Cathy, whose support throughout this project has been
crucial to its success.
I would also like to thank:
Neil Johnson, Amie Bowler and Nicola Brewster for carrying out the plasma ET-1
radioimmunoassay;
Danielle Armour who worked tirelessly with the renal ET system RT-PCR for her
Pharmacology BSc Honours project, and more latterly with the LacZ studies and
endothelial cell microscopy;
xv
Ian Megson for countless discussions about the most suitable method of data
analysis;
Animal house staff: Carole, Pat, Vince, Keith and Julie for their husbandry of the
colony;
Masashi Yanagisawa for the generous donation of the Tie2-Cre mice;
Alexander Medvinsky for the donation of EGFP reporter mice and for carrying out
the EGFP expression studies;
Nathalie Berthiaume and Pedro d’Orlean-Juste for helpful advice concerning the
radiolabelled [125I]-ET-1 clearance experiments;
Hans van Wyk (Quintiles), Gillian Brooker, Isam Sharif and Veterinary Surgeons
Jane Conole and Eleanor Weir for surgical advice and assistance;
Abbott Pharmaceuticals, Il, USA for donation of A192621 and ABT627 and David
Pollock for advice about how best to administer them to mice;
Ruth Andrew for discussions about the ET-1 clearance data, and for her help in
analysing the results;
Don Kohan for advice about salt feeding;
Chris Kenyon and Janice Paterson for useful discussions concerning telemetry data
analysis;
John Mullins, Head of the Centre for Cardiovascular Science, for cooperation to use
the BHF telemetry facilities;
Pete Hodgson for surgical insertion of telemetry devices;
all in Cambridge who worked with me on the autoradiography experiments -
Anthony Davenport, Rhoda Kuc and Janet Maguire;
Mandy MacLean, Ian Morecroft, Yvonne, and Margaret Nelson (University of
Glasgow) for their collaboration and assistance with the PAH study;
the other students in our lab for making the place a great place to work: Adele, Kat,
Mike, Katie, Markus, Mark, Helen, Sarah and Katsuaki;
and the British Heart Foundation for funding me during my PhD.
xvi
Abbreviations
ACE Angiotensin Converting Enzyme
ANF Atrial Natriuretic Factor
ANOVA Analysis of Variance
AQ2-Cre Aquaporin2 Promoter/ enhancer Cre transgene (Inner medullary
collecting duct cell specific)
AUC Area Under the Curve
β-gal β-galactosidase
BMPR2 Bone Morphogenetic Protein Receptor II
bp Base Pair
BP Blood Pressure
bpm Beats per minute (Heart rate)
BSA Bovine serum albumin
BW Body Weight
CL Clearance









ECE Endothelin Converting Enzyme
EDTA Ethylenediaminetetraacetic acid
EGFP Enhanced Green Fluorescent Peptide
Emax Maximal observed response
ENaC Epithelial Sodium Channel
eNOS Endothelial Nitric Oxide Synthase
ES Cells Embryonic Stem Cells
ET Endothelin
ETA Endothelin A Receptor
ETB Endothelin B Receptor
EVG Elastica–van Gieson stain
FiO2 Percentage of oxygen in inhaled air
Flox Floxed ETB Receptor Allele
G Gravity
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GFP Green Fluorescent Peptide
GPCR G-protein Coupled Receptor
IC Internal Circumference
I.D. Internal Diameter






Lac Z Galactosidase Gene
L-NAME Nω-Nitro-L-Arginine Methyl Ester Hydrochloride
LV Left Ventricle
LV + S Left Ventricle + Septum
MABP Mean Arterial Blood Pressure
MMPs Metalloproteinases
mRNA Messenger Ribonucleic Acid
NAD(P)H Nicotinamide adenine dinucleotide phoshate
NO Nitric Oxide




PAH Pulmonary Arterial Hypertension
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PCV Packed Cell Volume (Haematocrit)




PVR Pulmonary Vascular Resistance
R26R Rosa 26 reporter mouse strain
RIA Radioimmunoassay
RT-PCR Reverse Transcriptase – Polymerase Chain Reaction
RV Right Ventricle
RVP Right Ventricular Pressure
S6c Sarafotoxin 6c
SBP Systolic BP
SDS Sodium Duodecyl Sulphate Buffer
Smads Stimulatory mothers against decapentaplegic proteins
SMS Smooth Muscle Cell
SSC Sodium Sodium Citrate Buffer
Tie2 Tie2 Promoter/ enhancer of Cre transgene (endothelial cell specific)
TV Total Ventricles
v/v Volume per Volume
Vd Volume of distribution
VSMC Vascular Smooth Muscle Cell
vWF von Willibrand factor
W Wild type ETB Receptor Allele
w/v Weight per Volume
xviii
Abstract
Endothelin-1 (ET-1) binds to endothelin A (ETA) and B (ETB) receptors on vascular
smooth muscle cells, resulting in profound vasoconstriction and cellular
proliferation. In contrast, activation of endothelial cell (EC) ETB receptors releases
nitric oxide (NO) and prostacyclin (PGI2), which are anti-mitotic and mediate
vasodilatation. ETB receptors are also responsible for the clearance of ET-1 from the
circulation and renal ETB receptors contribute to sodium and water balance.
Pharmacological blockade and genetic models featuring total ETB ablation,
demonstrate salt sensitive hypertension. However, these do not allow the role of the
EC ETB in cardiovascular homeostasis to be determined. Mice featuring loxP sites
flanking exons 3 and 4 of the ETB gene (floxed ETB mice: FF/--) were crossed with
Tie2-Cre mice (WW/Tie2-Cre), in which the expression of a Cre recombinase cDNA
transgene is limited to EC, to generate EC-specific ETB down-regulated mice
(FF/Tie2-Cre). Having demonstrated EC-specific down-regulation of ETB receptors
using autoradiography, the role and relative contribution of the EC ETB to the
regulation of systemic BP, to the clearance of ET-1 from the plasma, as well as to the
development of pulmonary arterial hypertension were investigated.
Autoradiography revealed significant down-regulation of ETB in EC-rich tissues such
as lung of FF/Tie2-Cre animals (8 ± 3 amol.mm-2) compared to controls (80 ± 21
amol.mm-2) (n=4; p<0.05). Levels of ETA expression were preserved despite higher
concentrations of plasma ET-1 in the FF/Tie2-Cre samples (12.4 ± 3.0 pg.ml-1)
compared to controls (3.0 ± 0.8 pg.ml-1) (n=6; p<0.001). Using radiotelemetry, mean
arterial blood pressure of FF/Tie2 mice was not significantly different to that of FF/-
controls on low salt (FF/Tie2-Cre: 122.7 ± 1.52 mmHg, n=10; FF/--: 125.7 ± 0.58
mmHg, n=12), normal salt (FF/Tie2-Cre: 133.8 ± 4.0 mmHg, n=10; FF/--: 131.5 ±
3.33 mmHg, n=12) or high salt diet (FF/Tie2-Cre: 149.2 ± 2.71 mmHg, n=10; FF/--:
143.9 ± 2.97 mmHg, n=12). Similarly no differences in SBP, DBP or HR were seen
between genotypes. The clearance of an intravenous bolus of radiolabelled ET-1 was
significantly impaired in FF/Tie2-Cre mice (0.054 ± 0.006 ml.sec-1) compared to
control mice (0.175 ± 0.032 ml.sec-1) (n=5; p<0.01). ETB blockade of control mice
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reduced ET-1 clearance to that of untreated FF/Tie2-Cre animals (n=4). Two weeks
of hypobaric hypoxia induced an exaggerated increase in systolic right ventricular
pressure in FF/Tie2-Cre mice (34.4 ± 1.2 mmHg, n=10) compared with FF/-- mice
(24.6 ± 1.4mmHg, n=10; p<0.05), associated with an increased right ventricular/ left
ventricular + septum ratio in FF/Tie2-Cre mice (normoxia: 0.224 ± 0.009; hypoxia:
0.285 ± 0.017; p<0.01), but not in FF/-- mice. Hypoxia increased the percentage of
remodeled vessels in FF/-- mice (normoxia: 5.6 ± 0.6%; hypoxia: 11.4 ± 0.6%; n=6;
p<0.001), and this was augmented in FF/Tie2-Cre mice (normoxia: 7.1 ± 0.5%;
hypoxia: 18.5 ± 1.2%; n=6; p<0.001).
The EC ETB receptor does not play a significant role in the BP response to salt,
suggesting that ETB signalling on other cell types is responsible for ETB mediated
natriuresis. However, the EC ETB receptor is crucial to the elimination of ET-1 from
the circulation and is protective against the development of pulmonary arterial
hypertension, most likely by preventing remodeling of small pulmonary arteries.
1
1 CHAPTER 1: GENERAL INTRODUCTION
1.1 PHARMACOLOGY OF ENDOTHELIN
1.1.1 Structure of ET-1
Endothelin-1 (ET-1) was first isolated and characterised as a novel vasoconstrictor
peptide derived from cultured porcine aortic ECs (Yanagisawa et al., 1988). As well
as controlling basal vascular tone, the ET system plays a pivotal role in embryonic
development, fluid balance, cardiac and respiratory function. There are 2 other
isoforms of the peptide: endothelin 2 and endothelin 3. All 3 share structural
homology: a 21 amino acid peptide whose secondary structure is stabilised by 2 N-
terminal disulphide bonds, with a highly preserved hydrophobic C terminal sequence
(see Figure 1-1). ET-1 is the only isoform constitutively expressed in EC (Inoue et
al., 1989; Levin, 1995).
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Figure 1-1: Structure of ET-1, ET-2, ET-3 and S6c
1.1.2 Production of ET-1
The human genes for ET-1, ET-2 and ET-3 are located on chromosomes 6, 1, and 20
respectively. These peptides are synthesised as large ~200–residue precursors before












































peptides such as endothelin can occur at the level of synthesis, storage and release.
Much of the control of ET-1 production occurs at the level of transcription.
Transcription of ET-1 mRNA is upregulated by cytokines (transforming growth
factor β, tumor necrosis factor α, interleukins and endotoxin), hormones (insulin,
catecholamines, angiotensin II, vasopressin, cortisol, and endothelin) and thrombin
(Emori et al., 1992; Kurihara et al., 1989; Yanagisawa et al., 1988). In ECs, ET-1
transcription is increased by hypoxia and low shear stress, but inhibited by higher
stretch forces (Malek et al., 1999). Inhibition of ET-1 transcription is caused by atrial
natriuretic factor (ANF) and endothelial derived relaxing factors such as prostacyclin
(PGI2) and nitric oxide (NO) (Boulanger et al., 1990; Kohno et al., 1992; Prins et al.,
1994) (see Figure 1-2).
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Figure 1-2: Factors affecting the synthesis of ET-1.
(For references see text)
The ~200 - amino acid preproendothelins are cleaved at dibasic sites by furin-like
endopeptidases to form biologically inactive intermediates: 37 to 41 amino acid
peptides termed big endothelins (big ETs). Next, cleavage at Trp21-Val22 of ET-1 and
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ET-2, and Trp21-Ile22 of ET-3, catalysed by the metalloprotease endothelin-
converting enzymes (ECEs), generates mature ET-1, ET-2 and ET-3 respectively.
The release of ET-1 may occur by both constitutive and regulated pathways. Using
immuno-electron microscopy, ET-1 immunoreactivity has been identified in both
secretory granules (involved in the constitutive pathway) as well as EC-specific
storage granules known as Weibel-Palade bodies (likely to be involved in the
regulated pathway) (Russell et al., 1998a). It is thought that these Weibel-Palade
bodies degranulate after chemical or mechanical stimuli that result in cytosolic
calcium influx (Russell et al., 1998b). ECE-1 has also been identified within these
Weibel-Palade bodies, allowing the release of mature ET-1 when intracellular
calcium rises.
ET-1 is synthesised by a range of different cell types. As well as ECs (Yanagisawa et
al., 1988), the predominant source of the peptide in vivo, ET-1 is produced by airway
epithelial cells (Giaid et al., 1991; MacCumber et al., 1989), macrophages (Rubanyi
et al., 1991), fibroblasts (Rubanyi et al., 1991), cardiomyocytes (Sakai et al., 1996),
renal epithelial cells (Karet et al., 1996; Kohan, 1991), various brain neurons (Lee et
al., 1990) and other cells (Rubanyi et al., 1991).
The plasma concentration of ET-1 in many species is ~ 1 pM (3 pg.ml-1) (Battistini et
al., 1993), more than 100 fold lower than the pharmacological threshold. Originally
this was taken as evidence that endogenously produced ET-1 had little or no effect
on basal vascular tone. However administration of ET antagonists has a marked
haemodynamic effect both locally (Haynes et al., 1994) and systemically (Spratt et
al., 2001; Strachan et al., 1999), clearly demonstrating that ET-1 has endogenous
activity.
Therefore, under normal physiological conditions, ET-1 is not a circulating hormone,
rather acting as a local autocrine or paracrine mediator at multiple sites throughout
the body.
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1.1.3 Endothelin Converting Enzyme
Three isoforms of ECE have been identified in animals (ECE-1, ECE-2 and ECE-3)
but only ECE-1 and ECE-2 have been identified in humans (Russell et al., 1999).
ECE-1 has an optimum pH of 6.8, suggesting that ECE-1 is involved in the
constitutive production of ET-1 (Russell et al., 1999) both intracellularly and at the
cell surface (Xu et al., 1994). In contrast, ECE-2 has a pH optimum of 5.5 and has
been shown to be present in acidic secretory vesicles within ECs, suggesting that this
enzyme has a pathogenic role in states where the intracellular pH is reduced (eg
myocardial ischaemia) (Russell et al., 1999). As well as these 2 proteases, another
unidentified enzyme is capable of processing big ETs, as mice lacking both ECE-1
and ECE-2 exhibit significant concentrations of mature ET peptides (Yanagisawa et
al., 2000).
The human ECE-1 gene is located on chromosome 1. Four splice variants exist
named ECE-1a to ECE-1d in the human (Turner et al., 1998). They share a common
C terminus catalytic domain (from amino acid position 33) but differ in only a few
amino acids at the N-terminus. This determines the exact cellular location of these
isoforms (Valdenaire et al., 1999). ECE-1c, the primary isoform in humans, is found
in both the cell membrane as well as in the cytoplasm; ECE-1a is mainly found only
in the cell membrane; and ECE-2b is exclusively intracellular.
To date there have only been 2 isoforms of ECE-1 identified in the rat (Shimada et
al., 1995). These have been rather confusingly named ECE-1α, which is now known
to be analogous to ECE-1a, and ECE-1β, which was originally thought to be the
equivalent of ECE-1a but has now been shown to be the counterpart of ECE-1c.
ECEs are characterised by their sensitivity to phosphoramidon, a dual ECE and




In mammals, two ET receptors (ETA and ETB) have been identified (Arai et al., 1990;
Sakurai et al., 1990). These are both G protein coupled receptors (GPCRs) and
contain 7 transmembrane domains of 22-26 hydrophobic amino acids in their 400-
residue sequences. Each receptor activates an overlapping set of G proteins (Gs, Gi,
or Gq) each composed of three subunits (α, β and γ), leading to activation of a range
of intracellular second messengers. Evidence from G-protein inhibitors, such as
Bordatella pertussis toxin and subunit specific antisera, indicates that ET receptors
can interact with at least 3 different Gα-subunits to activate the various downstream
second messenger pathways (Douglas et al., 1997). For example, ETA and ETB
receptors, located on vascular smooth muscle, are coupled to phospholipase C (PLC)
via Gαq. Activation of this pathway results in elevated intracellular levels of inositol
triphosphate, diacylglycerol and calcium causing, amongst other effects, a long
lasting vasoconstriction (Pollock et al., 1995). VSMC ETA receptors are also coupled
to adenylate cyclase (AC) by GαS, whereas EC ETB receptors are linked to AC via
GαI (Rubanyi et al., 1994). Thus the particular second messenger pathway activated
is dependent on the cell type on which the ET receptors are expressed.
The precise signalling mechanisms utilised by ETA compared to ETB receptors, on
cells types such as vascular smooth muscle cells (VSMCs), may exhibit certain
differences but the exact nature of these has not been determined (Douglas et al.,
1997).
Activation of the EC ETB receptor, in contrast, results in increased endothelial nitric
oxide synthase (eNOS) (Hirata et al., 1993) and prostacyclin synthase (PGI2-S) (see
Figure 1-3 below).
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Figure 1-3: ET receptor intracellular signalling
Schematic illustration of the intracellular signalling pathways involved in the
response of the cell to activation of the G protein linked ET receptor. AA,
arachidonic acid; AC, adenylate cyclase; COX, cyclo-oxygenase; DAG,
diacylglycerol; eNOS, endothelial NO synthase; GC, guanylate cyclase; IP3, inositol
1,4,5-trisphosphate; LOX, lipoxygenase; LT, LX, leukotrienes; PA, phosphatidic
acid; PGE2, prostaglandin E2; PGI2, prostaglandin I2; PKA, protein kinase A; PKC,
protein kinase C; PKG, protein kinase G. (Adapted from (D'Orleans-Juste et al.,
2002).
1.1.4.1 ETA RECEPTOR
The ETA receptor has subnanomolar affinities for ET-1 and ET-2 but very much
lower affinity for ET-3 (Arai et al., 1990). ETA receptors are found on vessel and
airway smooth muscle cells, cardiomyocytes, liver stellate cells and hepatocytes,
brain neurons, osteoblasts, melanocytes and keratocyes, adipocytes and various cells
of the reproductive tract (Kedzierski et al., 2001).
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1.1.4.2 ETB RECEPTOR
1.1.4.2.1 Molecular structure of ETB receptor
The ETB receptor has a relative molecular mass of 50 kDa and exhibits remarkable
structural homology across species although the chromosomal location and number
of amino acids are species specific (D'Orleans-Juste et al., 2002). Mutations of the
gene have been identified in patients with Hirschsprung’s disease (Berthiaume et al.,
2000; Chakravarti, 1996; Edery et al., 1996; Gariepy, 2001). A mutation in the first
transmembrane domain of the human ETB receptor (Cys109 replaced by L-Arg)
impedes the translocation of the receptor to the membrane (Tanaka et al., 1998).
Furthermore, substitution in the fifth transmembrane domain of the highly conserved
Try276 by Cys does not affect the binding of the ligand to the receptor, but markedly
reduces calcium entry and mobilization of the ligand receptor complex (Puffenberger
et al., 1994). In addition, substitution of Ser390 by L-Arg in the last intracellular C-
terminal loop of the GPCR does not affect binding, but markedly reduces the
capacity of the complex to increase intracellular calcium (Tanaka et al., 1998).
1.1.4.2.2 Pharmacology of ETB receptor
In contrast to the ETA receptors, the ETB receptor binds all ETs with equal affinity
(Sakurai et al., 1990). During the 1990s, a subdivision of ETB receptors into ETB1
and ETB2 was proposed based on the much lower observed affinity of VSMC ETB
receptors compared to those of ECs. Functional studies had suggested that
PD142893, a dual ETA/B antagonist, could block the vasodilator actions of ET-1 at
EC ETB receptors, but not constrictor responses mediated by VSMC ETB (Douglas et
al., 1995; Warner et al., 1993). However, in the ETB receptor gene knockout (KO)
mouse, both the PD142893-sensitive vasodilator response and the PD142893-
resistant contractile response to the ETB agonist sarafotoxin S6c were completely
absent (Mizuguchi et al., 1997). These results indicate that the pharmacologically
heterogeneous responses to S6c are mediated by ETB receptors derived from the
same gene, providing strong evidence against a molecular basis for the sub-
classification of the ETB. Furthermore, in human tissue, both ETA- and ETB- selective
radiolabeled ligands bound with a single affinity, and Hill slopes close to unity
(Davenport et al., 1998; Davenport et al., 1994; Molenaar et al., 1992). Similarly,
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competition studies using unlabeled ligands provided no evidence to suggest any
sub-classification of the ETB receptor (Peter et al., 1996; Russell et al., 1996).
1.1.4.2.3 Expression of ETB receptor
ETB receptors are found on a wide range of tissues: vessel ECs as well as smooth
muscle cells, liver hepatocytes and Ito cells, renal collecting duct epithelial cells,
airway smooth muscle cells, osteoblasts, neurons of the CNS and PNS (Kedzierski et
al., 2001). Here they play fundamental roles in the regulation of several
physiological functions, such as modulation of vascular resistance (Strachan et al.,
1999), natriuresis (Clavell et al., 1995), hepatic function (Rockey et al., 1996), and
neuronal activities (Lysko et al., 1995).
1.1.5 Internalisation of receptors
Elegant studies have used fluorescence microscopy to track the movement of
fluorescein-conjugated ET-1 when bound to ETB receptors labeled with green
fluorescent peptide (GFP). Chinese hamster ovary cells expressing the ETB/GFP
fusion protein demonstrate strong signals at the plasma membrane. On addition of
fluorescein-conjugated ET-1, internalisation of ligand and receptor occurs within 5
minutes, via a sucrose-sensitive (i.e. clathrin-mediated) pathway (Oksche et al.,
2000). In contrast, ETA receptors are internalised via caveolae (Chun et al., 1995),
where they remain intact for up to 2 hours, until the ET-1/ ETA receptor complex
separates, most likely within acidic lysosomes. If such prolonged binding of ET-1 to
ETA receptors results in the continued activation of signal-transducing G proteins,
then this might account for the prolonged period of ET-1 induced VSMC
contraction. Whilst ETA receptors are eventually recycled back to the cell surface
(Marsault et al., 1993), ET-1 remains bound to ETB (see below) (Oksche et al.,
2000). Reappearance of ETB at the cell surface is therefore dependent on de novo
synthesis of receptors. The lack of trafficking of ETB back to the cell membrane
helps provide an explanation for the rapid tachyphylaxis of ETB modulated
vasodilatation seen in response to repeated boluses of ET-1, whilst ETA-mediated
vasoconstriction is preserved (Le Monnier de Gouville et al., 1990).
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1.1.6 Clearance of ET-1
ET-1 is removed from the plasma largely by binding to ETB receptors although it is
also degraded by neutral endopeptidases (Deng et al., 1992). Inhibition of neprilysin
(neutral endopeptidase EC 3.4.24.11) increases both urinary and plasma ET-1
concentrations, implying it plays a role in controlling ET-1 removal from the
circulation (Abassi et al., 1992). The sites of this non ETB mediated clearance are
likely to be in the kidney and liver (Burkhardt et al., 2000).
As outlined above, fluorescence microscopy has shown that ETB receptors bind ET-1
and internalise it, thereby removing the peptide from the plasma (Oksche et al.,
2000). Early work in rats has shown that exogenous radiolabelled ET-1 is rapidly
removed from the plasma and trapped mostly in the lungs, but also in the liver and
kidneys (Fukuroda et al., 1994). The lungs contain ~50% of the endothelium of the
entire vascular tree, and so unsurprisingly are extremely efficient at scavenging ET-1
from the plasma: they retain >60% of the circulating ET-1 at each pulmonary pass
(de Nucci et al., 1988; Dupuis et al., 1996b). This clearance is significantly inhibited
by the ETB antagonist BQ-788, whilst ETA blockade with BQ-123 has no such effect
(Fukuroda et al., 1994). Similar studies in isolated rat hearts showed that ETB
blockade increases plasma ET-1 concentration (Brunner et al., 1996).
ECs in culture swiftly scavenge exogenous ET-1 in an ETB dependent, ETA
independent manner (Ozaki et al., 1995). Furthermore, transgenic rats, featuring a
homozygous mutation in the ETB gene, have an increased circulating concentration
of ET-1 (Gariepy et al., 2000). Both wild type rats treated with ETB antagonists
(Burkhardt et al., 2000) as well as heterozygote ETB knockout (KO) mice
(Berthiaume et al., 2000) demonstrate impaired ET-1 scavenging whereas wild type
rats given ETA antagonists and heterozygote ETA KO mice have normal ET-1
clearance.
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Studies in humans have shown that the lungs are a major site of ET-1 extraction from
the plasma (Dupuis et al., 1996b) and that agents that block the ETB receptor cause
increases in plasma ET-1 concentrations (Cowburn et al., 2005; Dingemanse et al.,
2002; Goddard et al., 2004b; Haynes et al., 1996; Strachan et al., 1999; Sutsch et al.,
1998; Weber et al., 1996). In contrast there was no significant increase in ET-1
plasma concentration at a range of ETA selective doses of BQ-123 (Cowburn et al.,
2005; Goddard et al., 2004b; Spratt et al., 2001).
In summary, whilst there is limited evidence for degradation of ET-1 by peptidases,
most of the removal of ET-1 from the circulation is via binding to the ETB receptor
followed by internalisation.
1.2 PHYSIOLOGICAL ROLES OF ENDOTHELIN
The ET system is involved in a wide spectrum of different physiological processes
throughout the body. Here, the role of ET in embryological development, the control
of vascular tone, renal function as well as in the pulmonary vascular tone and
remodelling will be discussed.
1.2.1 Role of Endothelins in development
The discovery that the ET system is important in development was serendipitous.
Initial efforts to generate transgenic animal models featuring gene KO of different
components of the ET system were complicated by embryonic lethality. Study of the
phenotype of these models has revealed the importance of the ET system in correct
pattern formation during embryonic development.
ET-1, ETA, or ECE-1 deficient animals have craniofacial malformations including
cleft palate, small mandible, hypoplastic tongue, and abnormal fusion of the hyoid
bone to the base of the skull (Clouthier et al., 1998; Clouthier et al., 2004; Kurihara
et al., 1994; Yanagisawa et al., 1998) and so die at birth due to airway obstruction.
For normal development of the cephalic neural crest cells, ET-1 produced by the
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epithelium of the pharyngeal arches must activate ETA receptors on these neural crest
cells (Clouthier et al., 2000). Similarly, activation of ETA receptors on cardiac neural
crest cells, by ET-1 produced from overlying ECs, is required for normal
development of the great vessels and ventricular outflow tract. ET-1, ETA, or ECE-1
KO mice also feature cardiac abnormalities including interruption of the aorta,
presence of a right-sided aortic arch and ventricular septal defects (Clouthier et al.,
1998; Kurihara et al., 1995; Yanagisawa et al., 1998). ECE-2 KO mice are healthy
into adulthood, are fertile in both sexes, and live a normal life span. However, when
they are bred onto an ECE-1-null background, defects in cardiac outflow structures
become more severe than those in ECE-1 single KO embryos (Yanagisawa et al.,
2000).
ET-3 and ETB KO mice are viable until weaned at ~3 weeks of age. ECE-1 KO mice
display the additive phenotype of animals lacking ET-1/ETA and ET-3/ETB
pathways. ET-3, ETB or ECE-1 deficient mice have white spotted hair and skin
colour, but normal black eyes. They die at weaning due to intestinal obstruction
caused by aganglionic megacolon (Baynash et al., 1994; Hosoda et al., 1994;
Yanagisawa et al., 1998). Correct development of the myenteric plexus depends on
ET-3 released by mesenchymal tissue activating ETB receptors on neural crest cells
(Xie et al., 1997). It has been shown that these neural crest cells develop into
melanocytes (Shin et al., 1999). The phenotype of spotted white coat colour and
intestinal aganglionosis is also seen in naturally occurring mutations of the ET-3
(lethal spotted mice) (Baynash et al., 1994) and ETB receptor (piebald-lethal)
(Hosoda et al., 1994) genes. Furthermore ETB receptor and ET-3 mutations have
been identified in patients with Hirschsprung’s disease (Chakravarti, 1996; Edery et
al., 1996; Gariepy, 2001).
Thus ET-3, ETB and ECE-1 are necessary for normal development of neural crest
derived epidermal melanocytes and enteric neurons, whilst ET-1, ETA and ECE-1 are
necessary for the successful development of cephalic and cardiac neural crest derived
craniofacial and cardiac outflow structures.
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1.2.2 Role of Endothelins in vessels
When identified in 1988, ET-1 was first characterised as a highly potent
vasoconstrictor peptide (Yanagisawa et al., 1988), and so, not surprisingly, much
effort has been focussed on its role in the control of vascular tone and regulation of
BP. ET-1 is the only isoform of the 3 ETs produced by ECs (Inoue et al., 1989), and
of the 3 has the most marked effects on the vessel wall (Levin, 1995). Its local
concentration is ~100-fold that found in the plasma, as more than three quarters of
ET-1 is secreted abluminally from the basolateral side of ECs (Wagner et al., 1992).
Both ETA and ETB receptors are expressed by VSMCs within the blood vessel wall
(Arai et al., 1990; Batra et al., 1993), whereas only ETB receptors, are found on ECs
(Saetrum Opgaard et al., 1996). In a wide range of species, an intravenous bolus of
ET-1 results in a biphasic response (Yanagisawa et al., 1998): there is an initial fall
in vascular resistance, lasting seconds to minutes (which is not seen in mice (Giller et
al., 1997)), before a longer lasting vasoconstriction (minutes to hours). Experiments,
using selective antagonists in combination with inhibitors of NO and PGI2 synthesis,
have revealed that the initial hypotensive response is mediated by EC ETB derived
NO or PGI2 (Giardina et al., 2001). The longer lasting vasoconstriction is dependent
on VSMC ETA receptor activation (Bird et al., 1993).
1.2.2.1 CLINICAL STUDIES
Evidence of involvement of endogenous ET-1 the regulation of basal vascular tone
regulation comes from studies using selective ET antagonists. Infusion of the
selective ETA antagonist BQ123 results in vasodilatation of the forearm circulation of
healthy human volunteers (Haynes et al., 1994), demonstrating that ETA receptors
are tonically activated. In contrast, ETB receptor blockade with BQ788 causes similar
forearm vasoconstriction to NOS inhibition, suggesting that ETB receptors cause
tonic vasodilatation mediated by NO (Verhaar et al., 1998). Further work has
confirmed that such selective ET receptor blockade has a similar effect on systemic
haemodynamics (Spratt et al., 2001; Strachan et al., 1999).
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1.2.2.2 GENETIC ANIMAL MODELS
Further evidence for the direct role of ET-1 in the regulation of vascular tone comes
from experiments using rodents featuring genetic disruption of components of the ET
system.
1.2.2.2.1 Animal models deficient in ET-1
As outlined above in section 1.2.1, ET-1 null mice perish at birth, dying due to
airway obstruction caused by craniofacial malformation. However, animals
heterozygous for ET-1 KO are viable, and demonstrate mild hypertension compared
to wild type controls, despite reduced plasma and lung ET-1 concentrations
(Kurihara et al., 1994). The ET-1 +/- mice demonstrated no difference in response to
an intravenous bolus of ET-1 or nitric oxide synthase inhibitor, N-nitro-L-arginine-
methyl ester (L-NAME), compared to controls. Thus the authors conclude that whilst
ET-1 is clearly important in BP homeostasis, ET-1 +/- mice do not have significantly
impaired NO production or different patterns of ET receptor expression.
Further work involving a number of different mutants, has shown that whilst ET-1
+/- mice and ETB-/s mice (with only 1/8th of normal level of ETB expression – see
1.2.2.2.4) demonstrate hypertension, ECE +/-, ETA+/- mice are normotensive
(Kuwaki et al., 1999). Attenuation of reflex increases in respiration frequency and
minute volume, in response to hypoxia and hypercapnia, were apparent in ET-1 -/-
and ETA receptor-null mutated tracheotomised newborn mice, but not in ETB
receptor-null mutated newborn mice, strongly suggesting that the ET-1/ETA receptor
signaling system is critically involved in the reflex control of respiration. In a further
set of experiments ET-1 +/- mice demonstrate augmented renal sympathetic nerve
activity and blunted phrenic nerve activity in response to hypercapnia and hypoxia,
relative to controls (Kuwaki et al., 1999). ETB-/s animals display no such differences.
The authors conclude that endogenous ET-1 plays an important role in the central
neural control of circulation and respiration, most likely mediated by ETA receptors.
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In addition to problems of embryonic lethality, such experiments illustrate a further
drawback with using transgenic models featuring germline genetic modification of
components of the ET system in an effort to determine the role of ET in
cardiovascular homeostasis. Interpretation of the resulting phenotype can be
complicated by unexpected effects in different tissues throughout the body. By
generating conditional knockouts, where gene deletion or overexpression is limited
to a certain cell type, the role of different components of the ET system expressed by
particular tissues can be more easily determined.
The advantage of tissue specific KO mouse models, is illustrated by the generation of
an EC specific ET-1 KO mouse (Kisanuki et al., 1999). Although these mice display
similar responses to inhibitors of the angiotensin and sympathetic systems in
comparison to controls, they are hypotensive. Thus it would appear that ET-1,
generated by ECs, has a tonic effect at neighbouring VSMCs, acting to increase
vascular tone.
1.2.2.2.2 Animal models overexpressing ET-1
Adenoviral gene transfer of the prepro-ET-1 gene, whilst not resulting in a germline
mutation, caused a transient increase in hepatic ET-1 synthesis and raised plasma
ET-1 concentrations in treated rats (Niranjan et al., 1996) over a limited period.
These animals displayed significant hypertension that was reversed by treatment with
an ETA antagonist, implying that the raised BP was due to increased activation of
vasoconstrictive ETA receptors.
Somewhat surprisingly however, mice featuring germline over expression of ET-1
do not exhibit hypertension (Hocher et al., 1997) unless exposed to high salt diet
(Shindo et al., 2002). When ET-1 overexpression is restricted to the endothelium
using the Tie2 promoter to target expression of human preproET-1 to ECs, the
transgenic mice exhibit 3-fold increased vascular wall ET-1 mRNA, a 7-fold raised
ET-1 plasma concentration, but no elevation in BP (Amiri et al., 2004). The authors
used radiotelemetry to measure BP over an extended period in conscious undisturbed
17
mice, resulting in data of increased reliability compared to other studies that involved
anaesthetised preparations measured over only a limited duration, or tail cuff
sphygmomanometry (Pickering et al., 2005). These EC ET-1 overexpressing mice
exhibited marked hypertrophic remodeling and endothelial dysfunction of resistance
vessels, altered ET-1 and ET-3 vascular responses, and significant increases in ETB
expression compared with WT littermates. The authors conclude that ET-1 has a
direct non-haemodynamic effect on vessels to cause remodelling, endothelial
dysfunction perhaps through activation of NADPH oxidase.
1.2.2.2.3 Animal models deficient in ETA receptors
As described above (section 1.2.1), KO of the ETA receptor results in death due to
airway obstruction. However, by delivering ETA -/- mice by caesarean section on the
expected day of delivery and performing tracheotomies, this technical obstacle has
been overcome, allowing the survival of the mice for a limited period (Kuwaki et al.,
2002). BP, recorded under anaesthesia, was not different from that of age-matched,
similarly treated wild-type mice, demonstrating that, at least during very early life,
ETA receptors are not involved in cardiovascular regulation. There is no known
hypomorphic allele of the ETA gene, unlike that for the ETB gene (see below).
Heterozygote ETA receptor KO mice develop normally into adulthood and are
normotensive (Berthiaume et al., 2000). A VSMC ETA receptor specific KO animal,
ideally with temporal as well as spatial control of ETA receptor expression, would
allow the role of the ETA receptor in BP regulation to be fully addressed.
1.2.2.2.4 Animal models deficient in ETB receptors
As with other components of the ET system, KO of the ETB receptor results in a
lethal phenotype (Gariepy et al., 1998; Hosoda et al., 1994). The ETB receptor on
neural crest cells is required for normal epidermal melanocyte and enteric neuron
development as discussed in section 1.2.1. A naturally occurring recessive mutation,
known as piebald lethal (sl), is caused by complete deletion of the ETB receptor gene.
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A milder allele, piebald (s), which produces spotted coat colour only, expresses
around one quarter of the levels of structurally intact ETB receptor mRNA and
protein found in wild type mice (Hosoda et al., 1994). Ohuchi and colleagues crossed
such mice with heterozygote ETB KO (ETB+/-) animals, resulting in animals with one
eighth the level of normal ETB receptor expression (Ohuchi et al., 1999). Although
these mice all had a spotted coat colour, only a minority developed aganglionic
megacolon (7/37) and data from such animals were excluded. The BP of ETB-/s mice
was significantly higher than that in ETB+/s or ETB+/+ mice. Interestingly the plasma
concentration of ET-1 was not different between ETB-/s and ETB+/s mice (both ~15
pg.ml-1), although the paper does not reveal the plasma concentration of ET-1 found
in ETB+/+ mice, which one would expect to be around the normal concentration ~ 4
pg.ml-1 (see section 5.3.1; (Amiri et al., 2004; Shindo et al., 2002). Acute blockade
with the selective ETB antagonist, BQ-788, increased BP in ETB+/s and ETB+/+ but
not in ETB-/s mice. This was attenuated by pretreatment with indomethacin (a PGI2-S
inhibitor), but not with L-NAME. Thus it seems that endogenous ETB activation
elicits a depressor effect, in part through tonic production of prostaglandins, and not
by means of unimpaired clearance of circulating ET-1.
Others have also found ETB deficient mice to be hypertensive compared to controls,
but they have identified different mechanisms responsible for the raised BP
(Berthiaume et al., 2000). In this study, hypertensive ETB+/- mice demonstrated
impaired clearance of ET-1. The hypertension was normalised by treatment with the
ETA antagonist BQ-123, suggesting that the raised BP was secondary to raised
plasma ET-1 concentrations causing increased stimulation of vasoconstrictive ETA
receptors.
Similar to piebald lethal mice, the spotting lethal rat, a naturally occurring rodent
model of Hirschsprung’s disease, carries a deletion in the ETB receptor gene that
abrogates expression of functional ETB receptors. Rats homozygous for this mutation
(sl) exhibit coat color spotting and congenital intestinal aganglionosis (Gariepy et al.,
1996). An elegant approach to investigate the role of the ETB receptor in the control
of BP has involved the ‘genetic rescue’ of such sl rats that would otherwise die at
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weaning from intestinal obstruction. The human dopamine-β-hydroxylase (DβH)
promoter was used to direct transgenic expression of ETB to colonising enteric
neuronal precursors in the sl/sl rat. The DβH-ETB transgene compensates for
deficient endogenous ETB in these rats and prevents the intestinal agangliosis
(Gariepy et al., 1998). On a normal diet, these rescued ETB deficient rats demonstrate
mild hypertension, which is markedly accentuated by increasing the salt in the chow.
Intravenous L-NAME and indomethacin had a similar effect in both rescued and
control animals, suggesting that there is no difference in NO or PGI2 availability in
the vessels of these rescued ETB deficient rats compared with controls. As will be
discussed in the renal section (1.2.3.2) below, the authors conclude that the salt
sensitive hypertension is due to impaired ETB mediated natriuresis.
A similarly ‘rescued’ ETB deficient mouse has been found to demonstrate mild
hypertension on a normal sodium diet by one group (Murakoshi et al., 2002), whilst
others, have shown this same model to exhibit raised BP only when fed high salt diet
(Quaschning et al., 2005). Interestingly the ETB deficient mice exhibits endothelial
dysfunction, even when not hypertensive on a normal salt diet (Quaschning et al.,
2005).
From the studies described above, there are a number of possible mechanisms that
would explain the observed hypertension in ETB deficient animals. Firstly, reduced
NO availability caused by loss of EC ETB receptors could result in increased vascular
tone; second, elevated plasma ET-1 concentrations, due to impaired ETB mediated
clearance of ET-1, is likely to enhance vasoconstrictive ETA activity; and third, the
raised BP could be a result of the lack of ETB mediated natriuresis. The development
and phenotyping of tissue specific ETB receptor down-regulated mice will greatly
assist in the understanding of the important roles played by ETB receptors expressed
on different cell types.
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1.2.3 Role of Endothelin in the kidney
In addition to being synthesised by ECs within the kidney, ET-1, as well as, ET-3 are
produced by a number of different cells throughout the nephron including inner
medullary and cortical collecting duct epithelial cells (Karet et al., 1996; Kohan,
1991). The highest concentration of ET-1 has been localised to the renal medulla
(Kitamura et al., 1989). ET receptors are expressed on renal blood vessels, as well as
on tubular epithelial cells, where the ETB receptor is the predominant receptor
subtype, particularly in the inner medulla (Chow et al., 1995; Terada et al., 1992). As
well as influencing renal blood flow, the renal endothelin system controls water and
sodium balance, and is very important in acid-base homeostasis.
1.2.3.1 ROLE OF ETA AND ETB RECEPTORS IN CONTROL OF ACID –BASE
HOMEOSTASIS
The ET system, through the ETB receptor, plays a role in renal acid-base balance.
Wild type mice respond to an acid diet by increasing their acid excretion, by means
of a range of different mechanisms, including elevating the expression of the Na+/H+
(NHE3) cation exchanger in the luminal membrane of the proximal convoluted
tubule and thick ascending limb of the loop of Henle (Ambuhl et al., 1996). In cells
expressing NHE3, ETB activation results in increased proton excretion (Chu et al.,
1996). When ETB deficient mice are challenged with increased dietary acid, they
develop more severe metabolic acidosis than wild type controls (Laghmani et al.,
2001). Further work, using ETA/ ETB receptor chimeras and site-directed
mutagenesis, has identified the ET receptor domain(s) involved in ET-1 regulation of
NHE3 activity in isolated kidney cells. ETA receptor activation inhibits NHE3
activity, an effect for which the COOH-terminal tail is necessary and sufficient.
Activation of NHE3 by ET-1 requires the COOH-terminal tail as well as the second
intracellular loop of the ETB receptor (Laghmani et al., 2005).
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1.2.3.2 ROLE OF ETA AND ETB RECEPTORS IN CONTROL OF SODIUM
BALANCE
Intra-arterial ET-1, infused into rabbits, reduces renal blood flow, cortical perfusion,
glomerular filtration rate, urinary flow and sodium excretion (Evans et al., 1998),
most probably secondary to ETA mediated vasoconstriction (Pollock et al., 1994).
When big ET-1 is infused into the femoral artery of rats, an increase in sodium and
water excretion is observed, that cannot be blocked by the ETA antagonist BQ123
(Pollock et al., 1994), suggesting that ETB activation within the medulla causes
natriuresis and diuresis. In cultured inner medullary collecting duct (IMCD) cells,
ETB activation reduces the water permeability 6-fold in vasopressin stimulated cells
(Edwards et al., 1993), suggesting that in vivo, ET-1 acts at ETB receptors to lower
water reuptake from the nephron and increase urinary water loss.
The role of ETB in the control of water and sodium balance by the kidney has been
further investigated using genetically modified animals. As outlined in the previous
section (1.2.2.2.4), ETB deficient rodents were found to be hypertensive by several
different groups (Berthiaume et al., 2000; Gariepy et al., 2000; Murakoshi et al.,
2002; Ohuchi et al., 1999; Quaschning et al., 2005). Early studies suggested that the
raised BP was secondary to loss of ETB mediated tonic vasodilatation (Ohuchi et al.,
1999), or due to increased ETA receptor activation caused by raised plasma ET-1
concentrations (Berthiaume et al., 2000). The animals in these studies were all fed
diet of a ‘normal’ NaCl composition (usually 0.76% NaCl). The hypertension of
‘rescued’ ETB deficient rodents was found to markedly salt sensitive (Gariepy et al.,
2000; Murakoshi et al., 2002; Quaschning et al., 2005). Whilst the ETB deficient rats
exhibited elevated plasma ET-1 concentrations, an intravenous bolus of ETA receptor
antagonist failed to normalise the hypertension (although it did result in a greater
depressor response than seen in controls) (Gariepy et al., 2000). Acute inhibition of
NO and PG synthesis had a similar hypertensive effect in both controls and rescued
ETB deficient rats, and there was no difference in either the aldosterone
concentration, plasma renin activity or in response to the ACE inhibitor captopril.
Thus it seems that the salt sensitive hypertension is secondary to loss of ETB
mediated natriuresis. As the hypertension is normalised by amiloride, which inhibits
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the epithelial sodium channel ENaC, the authors propose that tonic activation of ETB
limits ENaC sodium reabsorption in the renal collecting duct.
Within the renal medulla ETB receptors are expressed on several different cell types
including ECs, IMCDs (Kohan et al., 1992) and renal interstitial cells (Wilkes et al.,
1991). Each of these is capable of generating NO (Hughes et al., 1995; Wu et al.,
1999; Zhuo, 2000). It is generally accepted that NO acts to inhibit sodium
reabsorption in the nephron (Wilcox, 2000) as well as antagonising the action of
vasopressin (Stoos et al., 1995). Both the NO synthase inhibitor, L-NAME, and the
specific ETB antagonist, A192621, independently abolish the diuretic and natriuretic
effects of big ET-1 in the kidneys of anaesthetised rats (Hoffman et al., 2000). From
the experiments using rescued ETB deficient rats (Gariepy et al., 2000), described
above, it is unclear whether IMCD-derived ET-1 targets ETB receptors on IMCD
cells (in an autocrine fashion) or neighbouring ECs/ interstitial cells (paracrine
mechanism), to release NO that inhibits sodium reabsorption (see Figure 1-4).
Figure 1-4: Autocrine versus paracrine control of ETB mediated natriuresis
adapted from (Kotelevtsev et al., 2001).
By determining whether any of a panel of cell specific ETB receptor down-regulated
mice demonstrate salt sensitive hypertension, the identity of this unknown cell type
can be determined, allowing fuller understanding of the renal ET system.
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1.2.3.3 ANIMAL MODELS FEATURING ALTERED EXPRESSION OF ET-1:
EFFECT ON RENAL SODIUM HANDLING/RENAL FUNCTION
Animals deficient in ET-1 are hypertensive (Kurihara et al., 1994), most likely
secondary to altered central sympathetic outflow (Kuwaki et al., 1999), rather than
due to abnormal sodium handling by the kidney, as heterozygote ET-/+ mice do not
demonstrate salt sensitivity (Morita et al., 1999).
Despite a reduced glomerular filtration rate, mice overexpressing human ET-1 are
not hypertensive on a normal salt diet, but develop glomerulosclerosis, interstitial
fibrosis and renal cysts (Hocher et al., 1997). A second transgenic strain of ET-1
overexpressing mice, generated by another group (Shindo et al., 2002), had normal
BP and no histological abnormalities in the visceral organs of young (8 weeks old)
animals. However, in old transgenic mice (12 months of age), renal manifestations,
including prominent interstitial fibrosis, renal cysts, glomerulosclerosis as well as
narrowing of the arterioles, were detected. These pathological changes were
accompanied by decreased creatinine clearance, elevated urinary protein excretion
and salt-dependent hypertension. It thus appears that mild, chronic overproduction of
ET-1 does not primarily cause hypertension but triggers damaging changes in the
kidney which lead to the susceptibility to salt-induced hypertension.
EC ET-1 overexpressing mice are normotensive at 10 weeks of age (Amiri et al.,
2004), and preliminary results in 10 month old mice show only a minimal elevation
of systolic BP with salt loading (Amiri et al., 2005).
By using the Cre/lox system Ahn and colleagues have investigated the role played by
IMCD derived ET-1 (Ahn et al., 2004). They developed an IMCD specific ET-1 KO
mouse and demonstrated that it too exhibited salt sensitive hypertension. This
supports the hypothesis that IMCD-derived ET-1 acts at local ETB receptors, to
stimulate the generation of NO that, in turn, reduces tubular sodium reabsorption. An
autocrine action for this IMCD-derived ET-1 was demonstrated by the finding that
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IMCD specific ETB down-regulated mice demonstrated salt sensitive hypertension
(Ge et al., 2006). However, this was more modest than that seen in IMCD ET-1 KO
animals, suggesting that IMCD-derived ET-1 also acts in a paracrine manner on ETB
on neighboring cells.
However, EC and renal interstitial cell specific ETB receptor down-regulated mice
are required before the location of these ETB receptors can be identified.
1.2.4 Role of endothelin in the lungs
The highest level of ET-1 has been identified in the healthy rat lung, where
concentrations are more than five-fold greater than in any other organ (Firth et al.,
1992). ET-1 is produced by pulmonary ECs, airway epithelial cells, and
macrophages (Ehrenreich et al., 1990; MacCumber et al., 1989). As well as being
found on blood vessels within the lung, ET receptors are present on the smooth
muscle cells of bronchioles. The ratio of ETA to ETB receptors expressed on airways
smooth muscle varies across species: in man there are ~10 times the number of ETB
receptors as ETA receptors (Goldie et al., 1995), whereas the opposite is true in sheep
(Ergul et al., 1995; Goldie et al., 1994). In rodents airways, there are approximately
equal proportions of ETA and ETB receptors (Henry, 1993). As well as being
expressed in blood vessels, ETB receptors are also found on the neurones of the
intramural autonomic nervous system (Takimoto et al., 1993).
1.2.4.1 ROLE OF ET-1 IN CONTROL OF AIRWAY RESISTANCE
1.2.4.1.1 Interstitial lung disease
In the lung, the ET system is involved in the control of both airway and vascular
tone. Intravenous administration of ET-1 increases airway resistance in a dose
dependent manner (Adamicza et al., 1999). This airway constricting effect of ET-1,
along with its proliferative effects, is likely to contribute to the pathogenesis of
interstitial lung disease and asthma. Mice overexpressing human preproET-1 have
progressive pulmonary fibrosis and accumulation of inflammatory cells in the
absence of pulmonary hypertension (Hocher et al., 2000). A model using gene
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transfer to increase ET-1 expression in alveolar macrophages and lung epithelial
cells, showed oedematous alveolar septa and hyperplastic connective tissue plaques
in a manner characteristic of that seen in human brochiolitis obliterans (Takeda et al.,
1997).
1.2.4.1.2 Asthma
Asthma is an inflammatory obstructive lung disease involving elevated airway tone,
hypersecretion of mucus, airway smooth muscle and fibroblast proliferation as well
as inflammatory cell recruitment and activation. ET-1 is an airway smooth muscle
spasmogen and mitogen, mucus secretogogue and inflammatory cell activator
(Goldie et al., 1996). ET-1 also greatly enhances cholinergic neuronal activity in
human (Fernandes et al., 1996) and animal (Henry et al., 1995) airways. This is
important, because cholinergic nerves provide the dominant constrictor innervation
in the respiratory tract and this system is overactive in some asthmatics. In a guinea
pig model of asthma, the ETB antagonist BQ788 suppressed the immediate
constrictive phase of the asthmatic response, whereas the late phase was blocked by
ETA blockade with BQ123 (Uchida et al., 1996). Asthmatic patients have increased
ET-1 concentrations in their bronchoalveolar lavage fluid (Sofia et al., 1993), and
when challenged with aerosolised ET-1 they demonstrate bronchoconstriction not
seen in healthy volunteers (Chalmers et al., 1997).
1.2.4.2 ROLE OF ET-1 IN PULMONARY CIRCULATION
In the pulmonary vasculature, the expression of ETB relative to ETA receptors
increases as one moves distally down the vascular tree (Davie et al., 2002). ET-1
induces a biphasic response: initial vasodilatation followed by vasoconstriction
(Hasunuma et al., 1990). However, blockade of VSMC ETA and ETB receptors with
mixed ET antagonists is required to inhibit this ET-1 mediated vasoconstriction (Sato
et al., 1995). Activation of both subtypes of ET receptor also results in proliferation
of vascular smooth muscle (Davie et al., 2002). Indeed, mice overexpressing ET-1
display pulmonary fibrosis (Hocher et al., 2000).
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The role of the EC ETB receptor in the control of pulmonary vascular tone is less
straightforward to define. As well as clearing ET-1 from the circulation (Dupuis et
al., 1994; Dupuis et al., 1996b) as outlined in section 1.1.6, pulmonary EC ETB
activation causes release of antiproliferative vasodilators NO and PGI2, which in turn
inhibit the synthesis of ET-1 (de Nucci et al., 1988; Lal et al., 1996). However, part
of the ET-1 induced vasoconstriction in PAs is dependent on thromboxane A2
(TXA2) (Curzen et al., 1995; Horgan et al., 1991) with studies suggesting that this is
mediated by the ETB receptor (Curzen et al., 1995; D'Orleans-Juste et al., 1994;
Noguchi et al., 1996) on the endothelium (Curzen et al., 1995). Although the
production of TXA2 within the lungs varies across species (Westcott et al., 1988), the
EC ETB receptor may have a dual role in the pulmonary vasculature, modulating both
vasoconstriction and vasodilatation.
1.2.4.3 PULMONARY ARTERIAL HYPERTENSION
Before detailing the important role of the ET system in the pathogenesis of
pulmonary arterial hypertension (PAH), the classification, pathology, genetic and
molecular basis for this debilitating condition will be discussed. PAH is a rare
disease affecting ~1-2 individuals per million per year (Morrell et al., 2001a). It is a
progressive condition, characterised by a persistent increase in pulmonary vascular
resistance that ultimately leads to right heart failure and death (median survival 2.8
years following diagnosis (Rubin, 1997)). Idiopathic PAH can be either familial or
occur as an isolated phenomenon. PAH can also develop secondary to a number of
diseases: collagen vascular diseases (such as systemic sclerosis or systemic lupus
erythematosus); congenital left to right shunts; sarcoidosis; chronic thromboembolic
disease and chronic lung disease (Braun-Moscovici et al., 2004; Galie et al., 2004)
(Table 1-1).
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Table 1-1 Classification of pulmonary hypertension
The 2003 Venice Classification (Rubin, 2004).




• Collagen vascular disease
• Congenital systemic-to-pulmonary shunts
• Portal hypertension
• HIV infection
• Drugs and toxins
• Other: HHT, haemoglobinopathies, etc.
• PAH with significant venous or capillary involvement
• Pulmonary veno-occlusive disease
• Pulmonary capillary haemangiomatosis
• Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension with left heart disease
3. Pulmonary hypertension associated with lung disease and/or hypoxaemia
• Chronic obstructive pulmonary disease
• Interstitial lung disease
• Sleep-disordered breathing
• Alveolar hypoventilation disorders
• Chronic exposure to high altitudes
• Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease
5. Miscellaneous: Sarcoidosis, histiocytosis X, etc.
1.2.4.3.1 Pathology
In both idiopathic and secondary PAH obstruction of small PAs, plexiform lesions,
medial hypertrophy, concentric laminar intimal fibrosis, fibrinoid degeneration, and
thrombotic lesions are seen in severe cases (Bjornsson et al., 1985; Palevsky et al.,
1989; Pietra et al., 1989; Wagenvoort, 1980). The term plexogenic arteriopathy is
used because of the existence of plexiform lesions (200–400mm diameter) which are
a tangle of capillary-like channels adjacent to a small pulmonary artery (PA) (Cool et
al., 1999). The ECs comprising plexiform lesions in idiopathic PAH appear to be due
to a monoclonal proliferation of cells, whereas lesions in secondary PAH are of
polyclonal origin (Lee  et al., 1998). Discussion remains as to the relative
contribution of vasoconstriction versus the structural changes associated with
remodeling to the phenotype of PAH (Stenmark et al., 2005).
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1.2.4.3.2 Genetics of PAH
The low incidence of the disease, combined with the observation that the majority of
cases appeared to be ‘sporadic’, have hampered the generation of detailed pedigrees
of patients suffering from PAH. However, following the establishment of a US
National Institutes of Health central registry of all those diagnosed with the
condition, it was determined that the condition is most likely autosomal dominant
with incomplete penetrance (Loyd et al., 1984). A genome screen using polymorphic
microsatellite markers, established linkage between idiopathic PAH and a region on
the long arm of chromosome 2 (2q33) (Morse et al., 1998; Nichols et al., 1997).
Sequencing of positional candidate genes revealed heterozygous mutations involving
the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2), a
member of the transforming growth factor-β (TGFβ) superfamily of receptors (Deng
et al., 2000; Lane et al., 2000). The heterogeneous mutations include frameshift,
nonsense and missense. The frameshift and nonsense mutations predict premature
truncation of the 1038 amino acid protein. Missense mutations occur at highly
conserved and functionally important sites that are predicted to perturb ligand
binding or disrupt the kinase domain of the receptor. Interestingly, the same
mutations underlie 26% of apparently sporadic cases of idiopathic PAH, some of
which are in fact familial, the remainder arising de novo (Thomson et al., 2000).
1.2.4.3.3 Cellular mechanisms in the pathogenesis of PAH
Originally discovered in association with bone growth, bone morphogenetic proteins
(BMPs), the major ligands for bone-morphogenetic-protein receptors, are also
important in embryogenesis, development, apoptosis, cell differentiation, and
proliferation. BMPR2s forms a heterodimer complex with BMPR1s to bind these
ligands on the cell surface. This complex then propagates signal via intra cellular
proteins known as Smad (mothers against decapentaplegic proteins) molecules
(Blobe et al., 2000; Heldin et al., 1997) eventually resulting in altered expression of
various proteins required for arresting cell growth and inducing apoptosis.
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Reduced expression of BMPR2 has been proposed as a mechanism for the
development of PAH in subjects with BMPR2 mutations (Machado et al., 2001).
Furthermore VSMC specific BMPR2 KO mice develop raised PA pressures and
display pulmonary vascular remodeling (West et al., 2004). Immunohistochemistry
demonstrates that ECs from the lungs of idiopathic PAH patients have reduced
BMPR2 expression compared to ECs from healthy controls (Atkinson et al., 2002),
the lowest expression being seen in patients with known BMPR2 mutations. It
remains unclear how different mutations in the BMPR2 gene can lead to the
development of the same PAH phenotype. Interestingly, plexiform lesions, from
BMPR2 heterozygote individuals with PAH, do not exhibit a further somatic
mutation in the second BMPR2 allele, suggesting that somatic loss of the remaining
wild type BMPR2 allele does not play a significant role in modulating the onset and
progression of PAH (Machado et al., 2005).
As the superfamily of TGFβ receptors are involved in the control of cell proliferation
and apoptosis, it is highly likely that a reduction or alteration in BMPR2 signaling
could lead to loss of antiproliferative or apoptotic mechanisms in the pulmonary
circulation. The normal growth of aortic and pulmonary VSMCs, in response to
growth factors, is suppressed by BMPs (Dorai et al., 2000; Morrell et al., 2001b). In
contrast, in lungs from patients with PAH, BMPs have a proliferative effect on
pulmonary VSMCs and exert a proapoptotic effect on ECs (Morrell et al., 2001b).
TGFβ receptors mutations have been detected in atherosclerotic lesions(McCaffrey
et al., 1997) and in cell populations isolated from patients with hereditary polyposis
colon cancer (Akiyama et al., 1997).
However, as phenotypic disease occurs in only 10-20% of individuals with BMPR2
mutations, other factors, such as modifier genes and environmental factors, must be
necessary for the development of PAH. Such a ‘multi-hit’ theory has been proposed
whereby an individual with a BMPR2 mutation (or an alternative mutation) would
require additional insults before developing clinical PAH (Rudarakanchana et al.,
2001; Runo et al., 2003) (see Figure 1-5).
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Figure 1-5: Pathogenesis of PAH
Proposed pathogenesis for the development of PAH. Pulmonary vascular
remodelling results from the effects of genetics, modifying genes, and environment.
1.2.4.3.4 Serotonin
Serotonin is associated with pulmonary vasoconstriction and VSMC proliferation
(Lee et al., 1991; MacLean et al., 2000; McGoon et al., 1984). Hypoxia stimulates
pulmonary neuroendocrine cells to release serotonin (MacLean et al., 2000) resulting
in the elevated plasma concentrations found in patients with idiopathic PAH (Herve
et al., 1990; Herve et al., 1995). Transgenic mice lacking the serotonin transporter
are protected against developing hypoxia induced PAH (Eddahibi et al., 2000)
whereas the opposite is seen in mice over expressing this transporter (MacLean et
al., 2004).
Appetite suppressing drugs can act as a substrate for serotonin transporters and so are
transported into pulmonary VSMCs (Rothman et al., 1999). The vasoconstrictive
effects of these agents are partially blocked by serotonin antagonists, indicating that
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their effects are at least partially mediated via serotonin receptors (Belohlavkova et
al., 2001). Such actions could serve as links between anorectic agents and the
development of PAH.
1.2.4.3.5 Extra cellular matrix
By breaking down the extracellular matrix, vascular serine elastases and matrix
metalloproteinases (MMPs) release matrix bound mitogens and induce tenascin C,
resulting in VSMC proliferation (Cowan et al., 2000b). In rats with experimental
PAH, pharmacological inhibition of these enzymes reduces the concentration of
tenascin C, increases VSMC apoptosis and lowers PA pressures (Cowan et al.,
2000a; Cowan et al., 2000b). NO has also been shown to limit serine elastase
activity, a further mechanism through which this mediator inhibits vascular
remodeling (Mitani et al., 2000).
1.2.4.3.6 Voltage-gated potassium channels
Increased intracellular calcium concentrations results in contraction and proliferation
of PA VSMCs (Yuan et al., 1998a). Voltage-gated potassium channels control cell
membrane potential and the release of calcium from intracellular stores within the
sarcoplasmic reticulum (Yuan et al., 1998a). PA VSMCs from patients with
idiopathic PAH, express less mRNA coding for voltage-gated potassium channels,
have a reduced channel current and increased intracellular calcium concentrations
compared with control PA VSMCs (Yuan et al., 1998a; Yuan et al., 1998b). Such
elevated intracellular calcium concentrations could be one factor responsible for the
development of clinically significant PAH. Appetite suppressant drugs may result in
PAH by blocking voltage-gated potassium channels (Belohlavkova et al., 2001; Weir
et al., 1996).
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1.2.4.3.7 Other possible modifiers
Patients with idiopathic PAH exhibit both increased fibrinogen plasma levels and a
diminished fibrinolytic response compared with healthy subjects. Such as
prothrombotic state could predispose to the development of PAH (Huber et al.,
1994).
The renin-angiotensin-aldosterone system may also be implicated in the pathogensis
of PAH. Increased expression of angiotensin converting enzyme (ACE) is found in
intimal and plexiform PAH lesions (Orte et al., 2000; Schuster et al., 1996). Hypoxia
causes increased PA VSMC angiotensin receptor expression (Chassagne et al.,
2000). Angiotensin II stimulates the growth of human PA VSMCs and may
contribute to vascular remodeling in distal PAs (Morrell et al., 1999). Administration
of ACE inhibitors to rats with monocrotaline induced PAH, results in restoration of
their endothelial function (Kanno et al., 2001), and when given to hypoxic rats
prevented medial thickening of PAs (Clozel et al., 1991; van Suylen et al., 1998).
1.2.4.3.8 Endothelial dysfunction and the ET system in PAH
The vascular endothelium and activation of various mediators and growth factors
such as the ET system are thought to play a crucial role in the development of PAH.
In the healthy lung a balance exists between vasodilators/ anti-mitogens (such as NO
and PGI2) and vasoconstrictors/ mitogens (such as TXA2 and ET-1). In PAH this
balance is shifted towards the factors causing vasoconstriction and vascular
remodeling, leading to endothelial dysfunction and widespread pulmonary vascular
obstruction (Figure 1-6).
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Figure 1-6: Endothelial dysfunction in PAH
Vasoconstriction and vasodilatation in the pulmonary circulation. In the normal
pulmonary circulation, there is a balance between the mediators of vasoconstriction
and vasodilatation, maintaining minimal resting tone. In the hypertensive pulmonary
circulation there is upregulation of vasoconstrictor pathways and reduced production
of NO and PGI2. Although there are increased circulating levels of vasodilators, such
as atrial natriuretic peptide (ANP), these are insufficient to counteract the effect of
vasoconstrictors, the net result being increased pulmonary vascular tone and vascular
remodeling.
Early work has shown that patients with idiopathic PAH demonstrate increased
production of TXA2 and reduced concentrations of PGI2 (Christman et al., 1992)
likely secondary to lowered expression of PGI2-S (Tuder et al., 1999).
Immunohistochemical staining has revealed minimal levels of NOS expression in
idiopathic PAH patients compared to healthy controls (Giaid et al., 1995). When
mice lacking key factors such as eNOS (Fagan et al., 1999) or atrial natriuretic
peptide (ANP) or its receptor, NPR-A (Zhao et al., 1999), are exposed to a hypoxic
environment for prolonged periods (>1 week) they develop more severe pulmonary
hypertension, vascular remodeling and right ventricular hypertrophy than wild type
mice. Transgenic mice that overexpress prostacyclin synthase are protected against
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developing hypoxia induced PAH (Geraci et al., 1999). Thus alterations in the level
of expression of these mediators (Figure 1-6), perhaps due to underlying genetic
polymorphisms, could conceivably alter susceptibility to hypoxia-induced pulmonary
hypertension in man.
A number of animal models have been used to investigate PAH: chronic hypoxia; the
treatment with the endothelial toxin monocrotaline; bleomycin lung injury; left to
right shunts. Such experimental models of PAH all exhibit increased plasma
concentrations of ET-1 (Frasch et al., 1999; Li et al., 1994a). The ratio of systemic
arterial to venous ET-1 concentrations is significantly increased in patients with
PAH. Whether this represents increased local ET-1 production within the lung, with
spilling over into the circulation, perhaps combined with a reduced ETB mediated
clearance, remains to be fully established (Dupuis et al., 1998; Stewart et al., 1991).
These raised ET-1 concentrations are more likely to be a marker of disease severity
rather than directly mediating the development of PAH, as neither rats chronically
infused with ET-1 (Migneault et al., 2005) nor 12 month old transgenic ET-1
overexpressing mice (Hocher et al., 2000) display PAH. Activation of the ET system
in isolation is not sufficient to cause PAH: this must be combined with an imbalance
of other endothelial factors (such as NO, PGI2, or TXA2) as well as modifications of
VSMC properties (eg voltage gated potassium channels (Archer et al., 1989) and the
BMPR2 (Lane et al., 2000)). However the most compelling evidence of activation of
the ET system in PAH, is that increased ET-1 expression is not only found in patients
suffering from the condition, but also correlates with the severity of the disease
(Giaid et al., 1993). Patients with PAH display a two-fold increase in [125I]-ET-1
binding in the media of distal PAs (Davie et al., 2002), due to increased ETB receptor
expression (Bauer et al., 2002).
1.2.4.3.9 ET antagonists in PAH
Both mixed ETA/B and ETA selective antagonists have demonstrated efficacy in the
prevention and treatment of PAH in a wide range of experimental models (Okada et
al., 1995; Oparil et al., 1995; Park et al., 1997; Prie et al., 1997; Rondelet et al.,
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2003). Reduction in pulmonary vascular tone, decreased medial hypertrophy relative
to luminal diameter and improved endothelial function are all possible mechanisms
of the beneficial effects of ET blockade (Prie et al., 1998).  In addition to ETA
receptor inhibition, antagonism of the pulmonary VSMC ETB receptor, if
significantly expressed, would offer more complete blockade of the vasoconstrictive,
proliferative, and profibrotic effects of ET-1. However, blockade of the EC ETB
receptor would inhibit the beneficial effects of NO and prostacyclin release. Thus the
net effect of ETB receptor blockade is not clear.
There has been only one direct comparison of mixed ETA/B and ETA selective
antagonists in a model of PAH (Jasmin et al., 2001). Using monocrotaline induced
PAH, both agents improved survival, but this only reached statistical significance for
the mixed ETA/B antagonist. However, similar falls in right ventricular (RV) systolic
pressure were seen with both agents. Indirect evidence in support of the use of
selective ETA receptor blockade comes from studies involving genetic disruption of
the ETB receptor. ‘Rescued’ ETB deficient rats exhibit an exaggerated pulmonary
hypertensive response to hypoxia (Ivy et al., 2001; Ivy et al., 2002), suggesting that,
at least in a rodent model of PAH, the net effect of ETB blockade is beneficial.
1.2.4.3.10 Clinical trials of ET antagonists in PAH
Clinical therapy for PAH includes anticoagulation, digoxin, diuretics and calcium
channel blockers (in the small proportion of those patients that responded favourably
to acute vasoreactivity testing) (Runo et al., 2003). Further treatment strategies
include PGI2, either as a continuous intravenous infusion or as inhaled therapy
(Iloprost) (Humbert et al., 2004). The beneficial effects of ET antagonists in animal
models provided a sound rationale for testing this form of treatment in humans. The
BREATHE-1 (Bosentan: Randomized Trial of Endothelin Receptor Antagonist
Therapy) study randomised 213 NYHA Class III/IV patients to either placebo or
bosentan 62.5 mg for 4 weeks, followed by either 125 mg or 250 mg, twice daily, for
a further 12 weeks (Rubin et al., 2002). Both doses improved NYHA class, distance
walked in 6 minutes and reduced time to clinical worsening. A dose dependent
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reversible disturbance in hepatic transaminases was observed, resulting in the lower
dose of 125 mg, twice daily, receiving approval for the treatment of Class III/IV
PAH in the US and Europe.
The clinical efficacy of selective ETA antagonists was evaluated in the STRIDE-1
(Sitaxsentan to Relieve Impaired Exercise) study (Barst et al., 2004). This trial
randomised 178 patients with NYHA II/III/IV PAH to placebo, sitaxsentan 100 mg
or sitaxsentan 300 mg given once daily for 12 weeks. Whilst the primary endpoint of
increased VO2 max (the maximum amount of O2 that can be catabolised per unit body
weight) was not reached, significant improvements in 6 minute walk distance (6MW)
and pulmonary haemodynamics were seen.
In STRIDE-2, 247 patients with PAH were randomised to placebo, sitaxsentan 50
mg, sitaxsentan 100 mg or bosentan (125 mg twice daily) for 18 weeks and their
6MW compared (Barst et al., 2006). Due to problems of cooperation with its
suppliers, the bosentan arm was ‘open label’ and included for observation purposes
only. Those patients treated with 100mg sitaxsentan had the most improved 6MW,
and had a lower incidence of hepatic toxicity than the open label bosentan group.
Following STRIDE-2, a truly blinded, fully randomised head-to-head trial between
mixed ET and selective ETA antagonism in the treatment of PAH is unlikely to be
performed, but such a study is needed to allow a direct comparison between these 2
classes of drugs.
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1.3 GENERATION OF EC-SPECIFIC ETB RECEPTOR DOWN-
REGULATED MICE
1.3.1 Gene targeting: The classical approach
Prior to the development of gene targeting techniques, the understanding of the in
vivo function of genes was dependent on their analysis by inactivation or
modification due to mutation, and the study of the consequences of this mutation in
the mutant organism. In mammals, this approach was limited to the rare spontaneous
mutations reflected in obvious phenotypes, as in the case of inheritable diseases in
man. The targeted mutagenesis of the mouse germline was thus a fundamental
breakthrough in this area of research. In its original form, gene targeting involves the
inactivation of a given gene in the genome of embryonic stem (ES) cells by
homologous recombination (Koller et al., 1992; Thomas et al., 1987). ES cells derive
from an early stage of mouse development (the inner cell mass of 4.5-day old
blastocyst) and so retain their totipotency. Thus they can participate in the generation
of all cell lineages of the mouse (including germ cells) if transferred into an early
mouse embryo. Transfer of mutant ES cells into mouse embryos thus allows the
transmission of the mutation in question into the mouse germline.
Gene inactivation is achieved by replacing a predetermined gene segment with a
mutant version of this segment, through homologous recombination. Since the latter
is infrequent in mammalian cells, the isolation of the mutant ES cells requires
stringent selection. In the original experiments, this was achieved by placing a
selectable gene (the neomycin resistance gene) into the targeted locus in a manner
that allows its expression (and hence cellular selection) while inactivating the target
gene (Thomas et al., 1987).
1.3.2 Refining classical gene targeting by the Cre-loxP recombination system
A limitation of classical gene targeting comes from the presence of a selection
marker gene in the targeted locus. Since this gene must be active in order to allow ES
cell selection, it is possible that its expression might affect the mutant phenotype in
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an unpredictable way. This potential problem can be avoided by the elimination of
the selection marker genes from the targeted locus, using the Cre-loxP recombination
system (Hoess et al., 1982; Sternberg et al., 1981). The bacteriophage enzyme, Cre
recombinase, recognizes a sequence motif of 34 bp, called loxP (Hoess et al., 1982).
If a DNA segment is flanked by two loxP, Cre excises that segment from the DNA,
leaving a single loxP site behind. Assuming this loxP site does not itself affect gene
expression, ‘clean’ deletions can thus be produced. In a gene targeting experiment, if
the selection marker gene (such as the neomycin resistance gene) on the targeting
vector (subsequently inserted into the target locus by homologous recombination) is
flanked by loxP sites, it can later be removed from the ES cell genome via transient
transfection of a Cre-expression vector into these cells (see Figure 1-7). However,
perhaps more importantly, Cre-loxP-mediated targeted mutagenesis, facilitates
conditional (rather than general) gene targeting.
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Figure 1-7: Generation of mice with loxP-flanked target genes (flox).
 (1) Gene targeting vector containing three loxP sites (filled triangles), two of them
flanking the Neomycin resistance (neo) gene. (2) Target gene in the genome of ES
cells (exons drawn as filled boxes). (3) Genomic locus modified by homologous
recombination (HR) between vector and target gene. (4) Deletion of the loxP-flanked
neo gene by transient Cre expression in ES cells. Two loxP sites remain in the target
gene. (5) Generation of a loxP-containing mouse line from modified ES cells.
(Adapted from (Rajewsky et al., 1996).
1.3.3 Conditional gene targeting: Tissue specific knockout/downregulation
Conditional (ie cell-type specific or inducible) gene targeting is useful for several
reasons. Firstly, germline mutations may result in a lethal phenotype (as seen with
ETB null animals) preventing the study of the function of that gene in the adult
animal. Second, genes may code for proteins that exert different effects when
expressed on different cell types. For example, ETB receptors on VSMCs exert the
opposite effect (vasoconstriction) to EC ETB receptors (vasodilatation).
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The strategy of conditional targeting of endogenous genes, that was used in the
generation of our EC ETB down-regulated mice, consists of flanking a target gene or
gene segment with loxP sites in ES cells by classical gene targeting and deleting the
selection marker gene by transient transfection with a Cre-encoding plasmid. This
process yields ES cell mutants in which the gene segment of interest is either flanked
by loxP sites or deleted. Either mutation can be transmitted into the germline. In the
former case, the mutant mice carry a functional, but loxP-flanked gene in their
genome (Figure 1-7). In the latter the gene is deleted in all cells of the body,
generating the situation of a classical knockout experiment, except that no selection
marker gene remains in the mutant locus.
Conditional targeting of loxP-flanked genes or gene segments can be achieved by
crossing the mutant animal with a second strain of mouse (in our case the EC
specific Tie2-Cre) in which Cre recombinase is expressed in a cell-type-specific
manner. Although all cells in the progeny contain floxed alleles, expression of Cre
recombinase only occurs in cells in which the tissue-specific promoter is active,
thereby limiting recombination exclusively to these cells. The success of such tissue
specific conditional gene targeting is entirely dependent on the precise restriction of
Cre expression to the desired target cell type. ‘Leaky’ expression of Cre will result in
recombination in other cell types, whilst a ‘patchy’ expression of Cre in target cells
will result in reduced rate of recombination and a mosaic pattern of gene knockout.
Either of these events would complicate the interpretation of any observed
phenotype.
Many other groups have established that, in principle, cell-type-specific gene
targeting can be successfully performed in this manner (Ahn et al., 2004; Gu et al.,
1994; Hirota et al., 1999; Kedzierski et al., 2003; Shohet et al., 2004). If Cre
expression could be induced specifically in any given cell type, then the gene in
question can be specifically knocked out/ knocked down in that particular cell type.
By crossing the floxed mouse with a range of such tissue specific Cre lines a panel of
tissue specific down-regulated mice can be generated.
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1.3.4 Endothelial cell specific downregulation
The Tie2 gene encodes the vascular EC tyrosine kinase angiopoietin receptor
(Loughna et al., 2001). Promoter and enhancer elements from this Tie2 gene, are
capable of directing ß-galactosidase reporter gene expression specifically into ECs of
transgenic mouse embryos (Schlaeger et al., 1997). This is maintained throughout
development and into adulthood. Tie2-Cre mice, in which the Cre recombinase gene
is expressed under the control of the Tie2 promoter, have been generated (Kisanuki
et al., 2001). Accurate assessment of the expression pattern of Tie2-Cre transgenic
mice is essential for predicting the pattern of recombination events in mice
harbouring functional loxP sites. By crossing Tie2-Cre mice with a reporter mouse
strain CAG-CAT-Z and Rosa 26 (R26R) (Kisanuki et al., 2001), the distribution of
Cre mediated recombination can be determined from the pattern of lacZ expression.
LacZ was seen in ECs, but was also found in endocardial and mesenchymal cells of
the atrioventricular canal and proximal cardiac outflow tract (Kisanuki et al., 2001).
Such work demonstrating the EC specificity of Cre expression have been repeated by
others, using the same Tie2-Cre transgenic line (Liao et al., 2001). This group,
characterising an EC specific Connexin 48 knockout mouse, went on to investigate
the efficiency of Tie2-Cre mediated gene deletion. Using tissue from their KO mice,
they showed that cultured pulmonary ECs had ~80% of the Connexin 48 gene
deleted compared to brain gray matter.
Other groups have now produced different strains of Tie2-Cre transgenic mice
(Constien et al., 2001; Theis et al., 2001) and have observed small differences in
expression pattern most likely secondary to variations in the insertion site of the
transgene. The EC ETB down-regulated mice, generated in our laboratory, utilised
the Tie2-Cre mice of Kisanuki and colleagues, a kind gift of Professor Masashi
Yanagisawa (University of Texas, USA).
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1.3.5 Generation of EC-specific ETB receptor down-regulated mice
The generation of the EC-specific ETB receptor down-regulated mouse (FF/Tie2)
was carried out by Dr A Bagnall under the supervision of Dr Yuri Kotelevtsev
(University of Edinburgh, UK) (Bagnall et al., 2006). A fragment of the ETB receptor
gene was replaced with a targeting vector, featuring loxP sites flanking exons 3 and 4
and a loxP-flanked selection marker (including a neomycin-resistance gene and
thymidine kinase gene), by homologous recombination into ES cells from 129/01a
embryos. Neomycin-resistant clones were selected and DNA extracted and analysed
by PCR. Specific recombination was detected by polymerase chain reaction (PCR)
and Southern analysis with a 3’ external probe in 6/97 colonies of ES cells analysed
(Figure 1-8).
Figure 1-8: Gene targeting of the ETB gene
Structure of the targeting vector (i) and ETB receptor gene (ii): Black rectangles,
exons; black triangles, loxP sites; MC1, Mario Cappeci-1 promoter; PGK,
Phosphoglucokinase promoter; TK, Thymidine kinase gene ; Neo, neomycin
resistance gene. The positions of internal and external probes used for Southern
analysis are illustrated. Following homologous recombination events in ES cells, the
selection marker was removed by Cre recombinase-mediated excision. The structures
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of the targeted (‘floxed’) allele (iii) and of the floxed allele following in vivo Cre-
mediated recombination in ECs (iv) are illustrated.
Three ES cell clones underwent transfection with Cre-recombinase. Of the resulting
daughter colonies, 294 were gancyclovir-resistant (hence lacked the selection
cassette containing the thymidine kinase gene). By PCR genotyping, 11 of these
were found to retain loxP sites flanking exons 3 and 4 but to lack the selection
marker. Sequence analysis confirmed no mutations within either loxP sites or coding
regions in these clones. Cells from 3 clones were injected into C57BL/6 blastocysts.
Germline transmission was achieved in one male chimeric mouse, which was mated
to BKW females. Around half of the offspring were heterozygous for the floxed ETB
receptor gene allele. Genotype was confirmed by PCR and Southern analysis using
an internal probe as detailed in section 2.3 below. Homozygous floxed mice were
bred by intercross and backcross of BKW;129/01a heterozygotes. No abnormality of
pigmentation, gut development or longevity was observed in homozygous floxed
mice, and no deviation from Mendelian distribution of alleles was seen in intercross
experiments.
Homozygous floxed ETB receptor mice (Flox/Flox; background 50% 129/01a, 50%
BKW) were crossed with Tie2-Cre transgenic mice (Kisanuki et al., 2001)
(C57BL6/SJLF1 background). Mice were genotyped by PCR and Southern as
described in the section 2.3.
1.3.6 Initial characterisation of the EC-specific ETB receptor down-regulated
mice
Having generated the EC ETB down-regulated (FF/Tie2) mouse Dr Alan Bagnall
carried out initial phenotyping experiments (Bagnall et al., 2006).
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1.3.6.1 ETB RECEPTOR-MEDIATED ET-1 BINDING IS DECREASED IN EC
OF EC-SPECIFIC ETB RECEPTOR DOWN-REGULATED MICE
To quantitatively assess the extent of ETA and ETB receptor binding in ECs,
competitive radioligand binding studies were performed. An EC-enriched cell
population was isolated from pulmonary tissue using an EC-specific lectin, and
binding of [125I]-ET-1 was measured, in the presence and absence of selective ET
receptor antagonists.
ETB-mediated binding (ET-1 binding in the presence of an ETA selective antagonist)
was significantly decreased by 82% in FF/Tie2 pulmonary ECs compared with wild
type controls (Figure 1-9). ETA receptor-mediated binding (ET-1 binding in the
presence of ETB blockade) did not differ between groups.
Figure 1-9: Reduced ET-1 binding in pulmonary ECs from FF/Tie2 mice
EC ETB–dependent binding of [125]I]-ET-1 was significantly decreased in EC-
enriched pulmonary cells from FF/Tie2 mice (p<0.001). Total and ETA mediated
binding did not differ between groups (n=3 in each group).
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1.3.6.2 ETB RECEPTOR-MEDIATED VASODILATATION IS IMPAIRED IN
EC-SPECIFIC ETB RECEPTOR DOWN-REGULATED MICE.
Functional EC ETB receptor-mediated responses were assessed in aortic rings using
wire myography. The ETB receptor selective agonist S6c produced vasodilatation of
aortic rings preconstricted with norepinephrine in all genotypes (Figure 1-10A). The
vasodilator response was significantly attenuated in FF/Tie2 mice compared to
WW/-- controls.
Thus although not abolished, EC ETB receptor mediated vasodilation is significantly
reduced in the FF/Tie2 mice.
1.3.6.3 ETB RECEPTOR-MEDIATED RESPONSES IN NON-EC ARE
MAINTAINED IN EC-SPECIFIC ETB RECEPTOR DOWN-
REGULATED MICE.
FF/Tie2 mice displayed normal gut development and pigmentation, consistent with
functional expression of ETB receptors on neuroblasts and melanoblasts, and
produced healthy offspring. S6c-induced tracheal smooth muscle cell constriction
(Figure 1-10B) was unaltered in FF/Tie2 mice, compared to controls, demonstrating
that non-EC ETB mediated responses are preserved.
Figure 1-10: Functional evidence of EC ETB down-regulation in FF/Tie2 mice
A: Endothelium-dependent relaxation in response to the ETB selective agonist S6c
(10-7M) was significantly decreased in aortic rings from FF/Tie2 compared to WW/--
mice (p<0.01; n=10); B Smooth muscle constriction in response to S6c (10-8M) in
tracheal rings was unaltered in FF/Tie2 compared to WW/-- mice (n=16).
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1.4 AIMS OF THE PROJECT
The ETB receptor mediates a wide range of effects when expressed on different cell
types. As outlined in the sections above, ETB activation plays a fundamental role in
the control of vascular tone, in both the systemic and pulmonary circulation, as well
as controlling sodium and water balance in the kidney, and scavenging ET-1 from
the plasma. The role played by the EC ETB receptor in mediating the effect of ET-1
cannot be determined using currently available pharmacological antagonists, as these
are unable to selectively block ETB receptors in one particular cell type, without also
blocking ETB receptors expressed throughout all tissues. Such difficulties might be
overcome by utilising drug delivery mechanisms that selectively release locally
active or cell type targeted concentrations of antagonists. However, in many tissues
the different ETB expressing effector cells lie in close proximity, and so selective
targeting of a single cell type is not straightforward. Alternatively, the effects of
antagonists might be studied in vitro and the results extrapolated to an in vivo model.
Such an approach has provided the majority of the data on which the current
understanding of the physiology of the ET system is based.
Genetic manipulation of receptors provides a further mechanism whereby loss of
function effects may be studied in vivo. However, as outlined previously, complete
knockout of ETB receptor function produces a lethal phenotype that precludes study
of in vivo adult physiology. Studies on young mice prior to the onset of intestinal
obstruction are possible, but the quality of the data recorded is likely to be
compromised. A great deal of insight has been gained from the study of rescued ETB
receptor-deficient animals. However, the concurrent knockout of ETB from multiple
tissues, whilst elegant, adds little advantage over experiments using pharmacological
antagonists in terms of data interpretation. The advent of technologies that permit the
spatial and temporal regulation of gene expression provides a powerful mechanism
by which the understanding of the physiological role of the ETB receptor in an
individual cell type may be more fully characterised. Cell-specific regulation of ETB
receptor expression allows the contribution of these receptors to cardiovascular
physiology to be determined without the confounding effects of receptor down-
regulation or blockade in other tissues. By characterising the phenotype of a line of
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transgenic mice in which the ETB receptor is selectively and specifically down-
regulated in ECs, the role played by EC ETB in cardiovascular homeostasis can be
determined, without the confounding effects of receptor down-regulation or blockade
of the ETB receptor in all other tissues. This work complements other studies, using
similar conditional transgenic approaches (Ahn et al., 2004; Amiri et al., 2004; Ge et
al., 2005; Ge et al., 2006; Kedzierski et al., 2003; Shohet et al., 2004), which taken
together, will allow a more complete understanding of ET-1 signalling, and thus
better inform clinical research in this area.
I have used this EC ETB receptor specific down-regulated mouse to test the following
hypotheses:
 The EC ETB receptor plays an important role in the control of gene and
protein expression of the ET system in the mouse.
 The EC ETB receptor influences the control of BP though its influence on
vascular tone.
 The EC ETB receptor influences the control of BP through its role in sodium
excretion.
 The EC ETB receptor is responsible for clearing ET-1 from the plasma.
 The EC ETB receptor is protective against the development of hypoxia-
induced pulmonary hypertension.
The following chapters detail how I have characterised the phenotype of this EC
specific ETB receptor down-regulated mouse, generated in our laboratory. Having
established a successful breeding strategy and demonstrated that the mouse exhibits
tissue specific ETB down-regulation, I have carried out a range of experiments to test
the hypotheses detailed above.
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2 CHAPTER 2: MATERIALS AND METHODS
2.1 Animals
All experiments were performed on male mice aged 2 – 4 months, weighing 25 - 40g
unless otherwise stated. Mice were given free access to tap water and standard
(0.76% NaCl) mouse chow until 21 days prior to experiments. Mice were housed
according to UK Home Office recommendations at 22ºC with 12-hour diurnal light/
dark cycles. All procedures were performed under the provisions of the Animals in
Scientific Procedures Act (1986) (http://www.archive.official-documents.co.uk/
document/hoc/321/321-xa.htm).
2.2 Breeding
2.2.1 Breeding strategy to generate ETB null animals
Male and female offspring from a single breeding pair, in which a high rate of germ
cell recombination had been identified, were deliberately intercrossed to assess
whether a recombination event within the ETB gene was sufficient to prevent
expression of functional ETB receptors (and generate piebald ETB receptor null mice)
(Figure 2-1A).
2.2.2 Analytical breeding crosses to assess sex linkage of recombination events
In order to accurately determine whether the rate of recombination varied with the
sex of germline transmission, analytical crosses were established. Reciprocal crosses
of FF/Tie2 animals paired with W0/-- (heterozygous ETB null) mice were set up. If
recombination occurred in all gametes produced by the FF/Tie2 animal, then 50% of
the progeny would be expected to be piebald (ETB receptor null mice). If
recombination occurred in only 10% of the gametes produced by the FF/Tie2 animal,
then 5% of the progeny would be expected to be piebald (Figure 2-1B).
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Figure 2-1: Breeding strategy to generate piebalds and analytical crosses
Schematic of breeding strategy used to produce (A) piebald null ETB receptor mice;
and (B) reciprocal analytical breeding pairs to determine the effect of the sex of




W0/-- Heterozygous wild type
and null ETB/
homozygous no Cre
FW/Tie2- Heterozygous floxed and
wild type/ heterozygous
Tie2-Cre
FW/-- Heterozygous floxed and
wild type/ homozygous
no Cre
F0/Tie2- Heterozygous floxed and
null ETB/ heterozygous
Tie2-Cre
0W/Tie2- Heterozygous wild type
and null ETB/
heterozygous Tie2-Cre
F0/-- Heterozygous floxed and
null ETB/ homozygous
no Cre
00/Tie2- Homozygous null ETB/
heterozygous Tie2-Cre
00/-- Homozygous null ETB/
homozygous no Cre
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2.2.3 Breeding strategy to generate experimental animals
Breeding was organised to minimise the likelihood of unrestricted recombination
(see Figure 2-2). Harems were arranged consisting of 1 FF/Tie2 male mated with 2
FF/-- female mice in order to maximise the number of mice generated. Homozygous
floxed ETB receptor mice (Flox/Flox; background 50% 129/01a, 50% BKW) were
crossed with Tie2-Cre transgenic mice (Kisanuki et al., 2001) (C57BL6/SJLF1
background).
Figure 2-2: Breeding strategy for experimental animals
Schematic of breeding strategy used to produce EC-specific ETB receptor down-
regulated mice (FF/Tie2-), and floxed (FF/-- controls). (For definition of genotypes
see key in Figure 2-1.)
2.3 Genotyping
2.3.1 Preparation of genomic DNA from tail/ ear biopsy
In the initial stages of this work, genomic DNA was prepared from tail-tip biopsies
and mice identified by numbered ear tagging. However, more recently, to reduce the
severity of this procedure suffered by the animals, in accordance with the aims of the
Animals in Scientific Procedure Act (1986) (http://www.archive.official-
documents.co.uk/document/hoc/321/321-xa.htm) ear punching was used not only to
sample DNA but as a method of animal identification. Tail biopsy was performed
under general anaesthesia (Halothane-Vet, Merial Animal Health Ltd., Harlow, UK)
in weaned pups up to 28 days old. A 0.5cm length of tail was biopsied. Ear biopsy
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did not require anaesthesia as it is not a Home Office licenced procedure. All
samples were stored at –20°C until DNA extraction.
Biopsies were incubated at 55°C in 600µl of tail buffer (200 nM Tris HCl, 400 mM
EDTA pH 8.0, 4 M NaCl, and 10% (v/v) SDS) and 35 µl of 10 mg.ml-1 Proteinase K
and rotated continuously overnight in a Techne Hybridiser HB-1D oven (Techne,
Cambridge Ltd, UK). The following day, 20 µl of 20 µg.ml-1 DNase free RNase
(Sigma-Aldrich, Steinheim, Germany) was added and tails incubated for 1 hour at
37°C.
600 µl of Tris-saturated phenol and 37.5 µl of 2 M mercaptoethanol were added to
each tube. Tubes were rotated for 15 minutes, followed by centrifugation at 12 000 g
for 2 minutes. The aqueous phase and interphase were transferred to a fresh
Eppendorff tube and extracted with 1 volume of phenol: chloroform: isoamyl alcohol
(25:24:1), and centrifuged again at 12 000 g for 2 minutes. The process was repeated
using 1 volume of chloroform: isoamyl alcohol (24:1). The DNA was precipitated
from the aqueous phase with 600 µl of room temperature isopropanol by gentle
rotation for 5 minutes. The stringy genomic DNA precipitate was pelleted by
centrifugation (12 000 g, 2 minutes) and washed in 200 µl of 70% ethanol. DNA was
air dried for 10 minutes then dissolved in 200 µl of TE, pH 8.0. Samples were then
left to dissolve completely for 30 minutes at 37°C before being mixed gently and
stored at -20°C until required.
2.3.2 Polymerase Chain Reaction of genomic DNA
Genotyping for Floxed ETB mice: Genotyping to identify floxed (F), wild type (W)
and recombined (0) alleles was performed by PCR using forward primer 454F (5’-
TCA GTT GTA ATG AGA CAC AGA C –3’) and reverse primer 681R (5’–AGC
CAT AAA GTC ACA GCC ATT C–3’). These PCR oligos flanked a ~1.1 kb
sequence spanning both loxP sites in the targeted allele, and a 2.2 kb sequence in the
W allele (Figure 2-3).
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Figure 2-3: PCR genotyping strategy
The primers 454F and 681R were used to amplify PCR products of 1136 bp, 2241
bp, and 230 bp from the floxed, wild type and recombined alleles respectively.
Genotyping for Tie2-Cre Transgene: The presence of the Tie2-Cre transgene was
detected by PCR using forward primer TIE2 98F: (5'-CGC ATA ACC AGT GAA
ACA GCA TTG C-3') and reverse primer TIE2 101R: (5'- CCC TGT GCT CAG
ACA GAA ATG AGA-3') (Kisanuki et al., 2001).
Each of the PCRs were performed in a total of volume of 25 µl containing 500 µM
of each deoxyribonucleotide (dATP; dTTP; dCTP; dGTP), 300 nM of each primer, 1
µg of genomic DNA, 2.5 µl of 10 x BiolineTM PCR buffer, 1.125µl of 50 mM MgCl2
and 0.2 units of BiolineTM Taq polymerase. Samples were amplified using a MJ
Research Peltier Thermal Cycler PT-200 with a heated lid with the following
conditions:
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Table 2-1: PCR conditions
Flox PCR Tie2 PCR
Step 1 92°C for 2 minutes 92°C for 3 minutes
Step 2 92°C for 30 seconds 92°C for 30 seconds
Step 3 60°C for 30 seconds 55°C for 30 seconds
Step 4 68°C for 2 minutes 68°C for 2 minutes
Step 5 Return to step 2, 30 times Return to step 2, 29 times
Step 6 68°C for 10 minutes 68°C for 10 minutes
2.3.3 Quantitation of nucleic acids
Optical absorbance at 260 nm (OD260) of DNA-containing solutions was measured
using a Bio-Rad SmartSpec 3000 Spectrophotometer (Bio-Rad, UK). DNA samples
were diluted 1:50 to a final volume of 200 µl. Dilutions of samples were adjusted if
the spectrophotometric readings were outside the range 0.1 – 0.8 (optimal range of
the spectrophotometer). The spectrophotometer calculated the concentration of DNA
in each sample and values of total DNA yield (µg.µl-1) in each sample were obtained
by adjusting for the dilution factor.
2.3.4 Agarose gel electrophoresis
DNA molecules were separated according to size using 1% agarose gel
electrophoresis. All gels were prepared with SeaKem LE agarose (FMC Bioproducts,
Rocklands, USA) using 1 x TAE (40 mM Tris-acetate, 1 mM EDTA) and were
stained with 0.5 µg.ml-1 of ethidium bromide (Product code E-8752, Sigma-Aldrich,
Gillingham, Dorset, UK). Samples were mixed with 6 x loading dye solution (0.09%
bromophenol blue, 0.015% xylene cyanol FF and 10% glycerol) to a final
concentration of 1 x before electrophoresis. All sizes were judged according to 100
bp ladder size markers run concurrently on the same gel (GeneRulerTM: 1000, 900,
800, 700, 600, 500, 400, 300, 200, 100, 80 bp; MBI Fermentas, St Leon-Rot,
Germany). DNA was visualised on the gel using a transilluminator and digital
acquisition system (Ultra-Violet Products Ltd, Cambridge, UK).
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2.4 GENOTYPING APPROACHES
2.4.1 ‘Comparative’ PCR of tail biopsies
This involved using identical quantities of tail derived DNA in each PCR, and then
comparing band intensity on the resulting gels.
Tails were biopsied and DNA extracted as outlined above (see section 2.3.1). The
concentration of DNA in each sample was determined using spectrometry to
determine the OD260 (see section 2.3.3). 50 ng of sample was used in each PCR mix,
which was otherwise performed as outlined above (see section 2.3.2). 17 µl of the
products of the PCR were loaded onto a 1% agarose gel. Attempts were then made to
compare the intensity of the 0 band and F band amongst samples and with those of
control of known genotype.
2.4.2 PCR of ‘EC free’ tissue
Hair: Hair sampling offers a potential source of genomic DNA for genotyping
involving minimal distress to the animals (Schmitteckert et al., 1999). Hair was
plucked from mice using forceps and the hair bulbs collected. The shaft of the hair
filament was discarded. DNA was then extracted from the hair samples using the
same protocol as for the tail/ ear biopsies (see section 2.3.1) and the PCR performed
as described previously (see section 2.3.2).
Testes: Testes were removed post mortem from experimental animals and frozen in
liquid nitrogen until DNA extraction. Using a fresh scalpel blade for each sample,
approximately one third of the testis was cut up and minced before DNA was
extracted using the same protocol as for the tail/ ear biopsies (see section 2.3.1) and
the PCR performed as described previously (see section 2.3.2).
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Hearts: Using collagenase digestion followed by centrifugation, we aimed to
crudely separate the larger and heavier cardiomyocytes from other less dense cells
such as ECs.
Hearts were removed from a selection of freshly culled experimental animals and
rinsed in PBS, before being cut into halves. One portion of the whole heart was put
on ice for later extraction. Crude isolation of cardiomyocytes was performed on the
other half of the heart, using collagenase digestion followed by centrifugation. We
intended to separate the larger and heavier cardiomyocytes from other less dense
cells such as ECs. This involved mincing the cardiac tissue in a Petri dish using small
scissors, in ~1 ml of phosphate buffered saline (PBS). After adding 1 ml of
collagenase (10mg.ml-1; Sigma-Aldrich, Steinheim, Germany) the mixture was
incubated for 60 minutes at 37°C. The mixture was then poured through a filter
basket (VWR International Ltd., Poole, UK) into a 50 ml Falcon tube. The filter
basket was then rinsed with 20 ml PBS. The Falcon tube and its contents were
centrifuged for 5 min at 1000 rpm. The supernatant was discarded, and the pellet
resuspended in 15 ml PBS. The mixture was centrifuged for 3 minutes at 800 rpm,
the supernatant discarded, and the pellet resuspended in the minimum volume of
PBS required.
DNA was then extracted from both the crude isolate of cardiomyocytes and the
undigested half of heart tissue, using the same protocol as for the tail/ ear biopsies
(see section 2.3.1) and the PCR performed as described previously (see section
2.3.2).
2.4.3 Southern blot
Southern analysis involves digestion of genomic DNA using a restriction
endonuclease, cutting it into sequences of certain lengths. Fragments of interest can
be labelled using a radiolabelled [32P]-homologous internal probe.
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2.4.3.1 PRODUCTION OF INTERNAL PROBE FOR SOUTHERN BLOT
ANALYSIS
Dr Yuri Kotelevtsev (University of Edinburgh, UK) produced the internal probe.
This involved locating EcoR I restriction sites in the gene sequence with the insertion
cassette, allowing an internal probe to be identified.
Figure 2-4: Southern blot strategy
The the probe, used in Southern Blot to genotype FF/Tie2 from F0/Tie2 mice, was
located between exons 4 and 5.
The probe was amplified by PCR with primers homologous to either end of this
sequence (forward primer: 5’-TAG ATA GAA GTT GCC TAA CCT TAG-3’; and
reverse primer 5’CTT CTT CCA TTC TAC CTG CTT-3’) using a fragment of the
pλP ETB plasmid (kind gift by Dr A Bagnall, University of Edinburgh, UK) as the
template. The probe was then purified by gel electrophoresis.
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The probe was labeled using a modified protocol developed by Feinberg and
colleagues (Feinberg et al., 1983). This involved mixing 50 ng of template DNA, 2.5
µl of 1 x hexanucleotide solution with sufficient dH2O to make a final volume of 14
µl. The mixture was boiled for 5 minutes before immediate cooling to -20°C. After
brief centrifuging 5 µl of 5 x oligodeoxynucleotide labeling buffer (250 nM Tris-HCl
pH 8.0; 25 mM MgCl2; 5 mM β-merceptoethanol; 2.0 mM dCTP; 2.0 mM dATP; 2.0
mM dGTP; 2.0 mM dTTP; 1 M HEPES pH 6.6 and 1 mg.ml-1 oligonucleotides), 5 µl
α32P-dCTP(3000 Ci.mmol-1; 10 Ci.µl-1) and 1 µl of Klenow enzyme (2.0 units.µl-1).
The probe was labeled for 2 hours at 37ºC before removal of incorporated
nucleotides using a NAP-5 column (Pharmacia Biotech). The reaction mixture was
diluted to a final volume of 400 µl with TE (pH 8.0) and loaded onto an equilibrated
column. The sample was eluted in 600 µl of TE and denatured by boiling for 5
minutes.
2.4.3.2 RESTRICTION OF GENOMIC DNA, SEPARATION OF DNA
FRAGMENTS, SOUTHERN BLOTTING AND HYBRIDISATION
The Southern blot analysis was carried out both by myself and Dr Markus Schneider
(University of Edinburgh, UK), under the close supervision of Dr Yuri Kotelevtsev
(University of Edinburgh, UK). Approximately 10 µg of genomic DNA were
digested overnight at -20°C with 20 units of restriction enzyme (EcoRI). Reactions
were terminated by heat inactivation of the enzyme at 65°C for 15 minutes. The
entire sample was loaded on a 1% agarose gel and DNA fragments separated by
electrophoresis. A photograph of the gel was taken alongside a transparent ruler. The
DNA fragments were transferred by capillary action onto a positively charged nylon
membrane (Boehringer Mannheim, Germany). Capillary transfer was performed by a
rapid alkaline (0.4 M NaOH, 1 M NaCl) transfer procedure as described previously
(Chomczynski et al., 1984; Reed et al., 1985). Nylon membranes were then
neutralised with 2 x SSC (3 M NaCl, 0.3 M trisodium citrate, pH 7.4) for 15 minutes
and DNA fixed to the membrane by ultra-violet cross-linking at 254 nm followed by
baking at 80°C for 40 minutes. Membranes were washed in 25 ml of pre-
hybridisation solution (0.25 M Na2HPO4 [pH7.2], 7% [w/v] SDS, 1.0 mM EDTA and
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50 – 200 µg.ml-1 of sheared and denatured salmon sperm DNA) in a pre-warmed
hybridisation bottle at 68°C for 1 hour. The bottle was continuously rotated using a
Techne hybridisation oven (Techne (Cambridge) Ltd, Cambridge, UK). This first
wash was discarded and replaced with a further 25 ml of pre-hybridisation solution
pre-warmed to 68°C, containing the heat denatured radiolabelled probe (1 x 106 - 2.5
x 105 cpm.ml-1).
Membranes were washed for 16 hours by continuous rotation at 68°C before the
hybridisation solution was discarded. Membranes were then washed twice, each for
10 minutes, in 25 ml of washing solution A (20 mM Na2HPO4 [pH7.2], 1.0 mM
EDTA [pH 8.0], 5% (w/v) SDS) followed by a further 2 washes of 10 minutes in
washing solution B (20 mM Na2HPO4 [pH7.2], 1.0 mM EDTA [ pH 8.0], 1% (w/v)
SDS). When dry, the membranes were covered in Saran Wrap and placed in an
autoradiography cassette with 2 enhancement screens and Kodak X-Omat film.
Autoradiographs were exposed for a minimum of 16 hrs at -70°C prior to
development.
2.5 EC specific Cre expression in Tie2-Cre mice
2.5.1 LacZ staining and histology
LacZ gene expression can be visualised by the formation of a blue precipitate
resulting from the hydrolysis of substrate 5-bromo-4-chloro-indolyl-B-D-
galactosidase (X-gal) (Pearson et al., 1961). X-gal can therefore be utilised to
analyse β-galactosidase activity in tissues from transgenic animals (Fire, 1992).
2.5.2 Staining for β-galactosidase activity
Mice were asphyxiated with CO2 and organs perfused via the heart with 15 ml of
PBS (phosphate buffered saline) (pH 7.4) followed by 15 ml of 0.2% glutaraldehyde
solution (5 mM EGTA, 100 mM MgCl2, 0.1 M NaPO4, 0.2% glutaraldehyde in
PBS). Kidneys were removed and fixed in glutaraldehyde solution for 2 hours at 40C,
equilibrated with 15% sucrose for 4 hours and then in 30% sucrose overnight. The
tissue was then frozen in liquid nitrogen and stored at –70ºC. Prior to sectioning, the
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kidneys were left for at least 30 minutes in the cryostat (Model OFT, Bright
Instrument Company Ltd., Huntingdon, Cambdridgeshire, UK) to allow the
specimens to reach the chamber temperature of –20ºC. After mounting onto a
sectioning chuck with ‘cryo-M-bed’ embedding compound (Bright Instrument
Company Ltd., Huntingdon, Cambridgeshire, UK), 10 µm sections were cut in the
sagittal plane. The sections were thaw-mounted onto Superfrost Plus slides (VWR
International).
For staining, the sections were briefly rinsed in PBS (pH 7.4) before being
transferred to X-gal solution (1 mg.ml-1 X-gal [from stock solution of 25 mg.ml-1 in
DMSO]; 4 mM potassium ferricyanide (K6[CN]12Fe); 4 mM potassium ferrocyanide
(K4Fe[CN]6.3H2O); 2 mM MgCl2; 0.02% (v/v) Igepal Ca-630 prepared in PBS pH
7.4). Tissues were stained overnight at 37ºC. Following a final rinse in PBS for 20
minutes, the sections were counterstained with eosin to allow visualisation of the
individual cells. This involved immersion of the slides in eosin for 3 minutes
followed by washing in tap water for 20 – 60 seconds.
2.5.3 Immunohistological staining of ECs
Following quenching of endogenous peroxidase activity, sections were blocked with
1% BSA and avidin/biotin blocking reagents (Vector Labs, UK). Sections were then
exposed to biotinylated rabbit-anti-mouse CD31 primary antibodies (BD
Pharmingen; 553371, 1:100) at 4 0C overnight. Bound primary antibodies were
conjugated to streptavidin-biotin peroxidase (Vector Labs, UK) (1:200 dilution) and
stained with DAB (Vector Labs, UK). In control sections the primary antibody was
substituted for 1% BSA. Following my unsuccessful initial attempts at satisfactory
LacZ and EC immunohistological staining, the results presented here were produced
in further studies performed in our laboratory by Danielle Armour (University of
Edinburgh).
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2.5.4 GFP reporter mice
WW/Tie2 mice were mated with enhanced green fluorescent peptide (EGFP)
reporter mice (kind gift of Dr Alexander Medvinsky, University of Edinburgh, UK)
(Gilchrist et al., 2003).
The embryos were harvested at day 11, fixed in 4% paraformaldehyde (PFA)/PBS
for 60 min at 4°C. They were then washed several times in PBS. The embryos were
analysed on day of isolation. Whole embryos were screened for expression of EGFP
under an MZ FLIII fluorescent dissecting microscope (Leica).
2.6 Expression studies in EC ETB down-regulated mice
2.6.1 Quantitative autoradiography
Following euthanasia by CO2 asphyxiation, mice were rapidly frozen at -70°C. The
torsos were mounted in a cryostat and consecutive 30 µm thick longitudinal sections
were cut at a plane to encompass the heart. Sections were then thaw mounting onto
gelatin-coated slides. These were prepared by washing the slides in a detergent
solution, rinsing them in deionised water, before dipping them into a gelatin solution
(5 g gelatin, 0.25 g chromium potassium sulphate, dissolved by heating to 45°C in
500 ml deionised water) air drying and then storing at room temperature (Davenport
et al., 2002). Ligand binding assays were carried out by incubating consecutive
sections with 0.25 nmol of the ETB selective ligand, [125I]-BQ-3020 (KD ~ 0.1nM
(Molenaar et al., 1992)) or with 0.25 nmol of the ETA-selective ligand [125I]-PD-
151242 (KD ~ 0.1nM (Davenport et al., 1994)) (Amersham Bioscience, GE
Healthcare, UK) for 2 hours at room temperature. Non-specific binding was
determined by co-incubating adjacent sections in the presence of the ligand and an
excess of corresponding unlabelled peptide. Slides with calibrated standards were
exposed to Kodak MR-1 autoradiography film for four days before being developed.
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2.6.2 Image analysis
Autoradiograms were analysed by measuring the diffuse integrated OD using a
computer-assisted image analysis system (Quantimet 970, Leica, Milton Keynes,
U.K.) equipped with a shading corrector (with the correction performed in real time
before each scan) compensating for any variation in illumination. The white level
(100% transmission) was set and the scanner dark current (the current flowing in the
scanner in the absence of a signal), which would otherwise contribute to the grey
image, is eliminated.
The density of ETA or ETB receptors was measured by digitising each
autoradiographical image of the mouse torsos into an array of 630 000 image points
each with a grey value in the range 0-255. A measuring box was used to measure the
integrated OD within discrete anatomical regions. Within individual organs, regions
rich in ECs, such as lung parenchyma, renal medulla and liver sinusoids, were
compared with more EC deplete anatomical regions such as lung briochioles and
liver sinusoids. When all measurements had been made for a particular section, the
threshold for detecting the autoradiogram was increased to produce a template that
was used to align the autoradiographical image of an adjacent section used to define
the non-specific binding. The second image was digitally subtracted from the first to
measure the amount of specific binding. The resulting ODs were converted to the
amount of specifically bound radioligand in amol.mm-2 by interpolation from the 125I
standards curve. Corrections were made for decay of the radioligand from the time at
which these measurements were made to the midpoint between apposing and
developing the film. The inter-assay coefficients of variation was <3%.
2.6.3 Semi quantitative RT–PCR of the ET system
2.6.3.1 GENERAL LABORATORY PRACTICE
All work was performed using RNAse-free techniques to prevent contamination of
environmental RNAses. Gloves were worn at all times and work surfaces and
equipment were regularly and thoroughly cleaned with RNAseZap solution
(Ambion, Huntingdon, Cambridgeshire, UK). All solutions were made using 0.1%
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DEPC distilled water (0.1% w/v diethyl diethylpyrocarbonate, shaken vigorously,
left to stand overnight, before autoclaving to destroy the DEPC; Sigma-Aldrich,
Poole, Dorset, UK). At all times, samples were kept on ice to minimise any
degradation.
2.6.3.2 RNA EXTRACTION
Following CO2 euthanasia, kidneys were harvested from mice and frozen at –70ºC.
Total mRNA was isolated from mouse kidneys using a modified version of the acid
guanidinium thiocyanate-phenol-chloroform method previously described
(Chomczynski et al., 1987). Each sample (~150 mg) was removed from the freezer (-
80 oC), weighed and cut into halves, and immersed in 3 ml of denaturing solution (4
M guanidinium thiocyanate; 25 mM sodium citrate; 0.5% sarcosyl; 0.1 M β-
mercaptoethanol; all dissolved in DEPC H2O) where it was homogenised at room
temperature (Ultra-Turrax T8 Rotor-Stator homogeniser) before being disrupted by
being drawn through a green (21 Gauge) then an orange needle (25 Gauge). An equal
volume of water-saturated phenol (Fisher Scientific, Loughborough, UK) was then
added, followed by 50 µl per ml of RNA solution (150 µl total) of 2 M sodium
acetate (pH 4). The homogenate was then mixed thoroughly by inversion and the
addition of 100 µl per ml (300 µl total) of chloroform: isoamyl alcohol (24:1)
produced the final suspension which was shaken vigorously for 15 seconds and left
on ice for 15 minutes.  Subsequently, the samples were centrifuged at 10 000 G for
15 minutes and the upper aqueous phase, containing the RNA, was pipetted off into a
fresh microfuge tube. Care was taken not to disturb the interphase and phenol phase,
containing the DNA and protein residue. An equal volume of isopropanol (500 µl)
was added to the lysate and the contents were mixed by inversion before being
placed at –20 0C for at least 1 hour to precipitate the RNA. The samples were then
centrifuged (micromax RF, IEC) at 10 000 G at 4 0C for 10 minutes to pellet the
RNA. The supernatant was removed and the pellet washed twice with 1 ml of 75%
ethanol. The pellets were then air dried at room temperature, before being dissolved
in 30 µl of DEPC H2O at 60 0C and stored at –20 0C.
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2.6.3.3 RNA QUANTIFICATION AND INTEGRITY
The concentration of total RNA was determined by measuring OD260 (Bio-Rad
SmartSpec 3000 Spectrophotometer, Bio-Rad UK) (see section 2.3.3). RNA samples
were diluted 100-fold with DEPC H2O and placed in an RNase-free quartz cuvette
(200 µl, UV transparent cuvette, Bio-Rad UK). The spectrophotometer calculated the
concentration of RNA in each sample and values of total RNA yield (µg.µl-1) were
obtained by adjusting for the dilution factor. The purity of the RNA in each sample
was determined by measuring the ratio between the absorbance values at 260 and
280 nm.
A denaturing agarose gel (1.2%) was used to verify the integrity of the RNA
extracted. This was made using 0.6g of agarose, 5ml of 10x FA gel buffer (200 mM
3-[N-morpholino]propanesulfonic acid (MOPS) (free acid), 50 mM sodium acetate,
10 mM EDTA [pH to 7.0]) and 45 ml of DEPC H2O. Subsequently, 0.9ml of 37%
formaldehyde (Sigma) and 0.5 µl of ethidium bromide were mixed to the melted
agarose solution. The gel was allowed to equilibrate in 1x FA gel running buffer
(100 ml of 10x FA gel buffer, 20 ml formaldehyde (37%) and 880 ml DEPC H2O)
for 30 minutes prior to running the gel. Three µl of 5x loading buffer (16 µl saturated
aqueous bromophenol blue solution, 80 µ l 0.5 M EDTA [pH 8.0], 720 µ l
formaldehyde [37%], 2 ml glycerol [100%], 3.08 ml formamide, 4 ml 10x FA gel
buffer and DEPC H2O to 10 ml) was added to 12µl of RNA sample and this mixture
was heated at 650C for 3-5 minutes, chilled on ice, and then 10µl were loaded onto
the gel. The gel was run (5-7 V/cm) and the integrity of the RNA assessed by the
presence of well-defined bands corresponding to 28S (4.7 kbp) and 18S (1.9 kbp)
ribosomal RNA.
2.6.4 RT-PCR
The reverse transcription was performed using 6 µg of RNA, with 50 pM random
hexanucleotides (Promega) and 200 U Moloney-murine leukaemia virus reverse
transcriptase (M-MLV RT, Promega), 0.5 mM dNTPs and 5x RT buffer (final
concentration; 50 mM Tris-HCl, pH 8.3; 75mM KCl; 3mM MgCl2) in 58 µl. The
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reaction was performed at 370C for 45 minutes, then at 950C for 5 minutes to
denature the reverse transcriptase (PTC-200 Peltier thermal cycler, MJ Research Inc,
USA).
Specific primers for the PCR step were designed, using GeneJockey II software
(Biosoft, Cambridge, UK), for ETA, ETB and ECE-1 and were synthesised by MWG-
Biotech (http://www.mwg-biotech.com). These primers were designed to span
introns of the genes concerned to avoid false positive results arising from
amplification of any contaminating genomic DNA. Primer optimisation was carried
out for each gene by empirical adjustment of annealing temperature, magnesium
concentration, dNTP concentration and cycle number. Once the optimal conditions
had been determined, a control sample of cDNA was serially diluted, and the PCR
for each component of the ET system performed. By plotting the OD of the PCR
products against the dilution factor, the semiquantitative nature of the PCR was
confirmed. The primer sequences, their sizes and their specific PCR conditions are
summarised in Table 3-2.
PCR was then performed for each component of the ET system using cDNA
prepared from mouse kidneys.  Each PCR contained 1µl of cDNA, 5U Taq DNA
polymerase (Promega), 200/300 µM dNTPs, 100 pM specific primers (MWG-
Biotech), 10x PCR buffer (final concentration, 10 mM Tris-HCl, pH 9, 50 mM KCl
and 0.1% triton, Promega) and MgCl2 at a concentration specific to each primer
(Table 3-2). Samples were placed in the thermocycler and the DNA was denatured
for 4 minutes at 940C.  Subsequently, n cycles (Table 3-2) of amplification were
performed, denaturation (1 min at 940C), annealing (1 min at TA [specific
temperature - Table 3-2) and elongation (2 mins at 720C). After the last cycle, the
720C elongation step was extended to 10 minutes.
2.6.5 Agarose gel electrophoresis and densitometry
The PCR products were run on a 2% agarose gel as described in section 2.3.4. Using
a computer base image analysis system (SynGene software, GeneTools – File
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version: 3.06.02, SynGene Laboratories), the OD of each band on the gel was
measured, relative to the 500 bp marker of the 100 bp sizing ladder (Helena
Biosciences Eurpoe, Sunderland, UK). Final expression values of gene of interest
relative to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were
calculated to control for the variable efficiency of the reverse transcriptase step.
2.7 BP measurement in unconscious animals
Mean arterial blood pressure (MABP) was measured by direct cannulation of the left
common carotid artery in adult male mice (8 – 12 weeks old; 25 - 35g) as previously
described by Davisson and colleagues (Davisson et al., 1998). Anaesthesia was
induced with 5% isoflurane and maintained with 1.0 – 1.5% isoflurane (Merial
Animal Health, Harlow, Essex) using a standard small animal Boyle’s Machine
anaesthetic apparatus with high flow oxygen. A small murine anaesthetic nose cone
was used (VetTech Solutions Ltd, Congleton, Cheshire) to allow improved access to
the cervical area of the mouse. The left common carotid artery was exposed and tied
off distally, with care taken to prevent damage to the overlying submandibular
salivary glands. The proximal end of the artery was briefly occluded to allow the
vessel to be cannulated with a saline-filled Micro-Renathane® tubing catheter
(MRE-040; 0.040 inches [= 1016 µm] O.D. x 0.025 inches [= 635 µm] I.D.;
Braintree Laboratories Inc., MA, USA). Once inserted, the catheter was secured in
place with sutures. Measurements were performed in a quiet procedure room of the
MFAA (Medical Faculty Animal Area) Facility (University of Edinburgh, UK)
where the temperature was 21 – 23°C. Anaesthesia was maintained at the lowest
level possible (1-3 % isoflurane) so that the animal gave no response to painful
stimuli (such as paw pinching) yet had a respiratory rate greater than 90 respirations/
minute. Following cannulation of the carotid artery, the preparation was allowed to
stabilise for 5 minutes before the MABP was recorded over a 10-minute period.
Some of the experimental protocols required venous access. For these experiments
the right external jugular vein was exposed by careful dissection. The proximal end
was occluded with a loose ligature, before the distal end was ligated. The vessel was
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then cannulated with a saline filled catheter (MR-025; 0.025 inches [= 635 µm] O.D.
x 0.012 inches [= 305 µm] I.D., Braintree Scientific, Inc, MA, USA), and secured
with sutures, before the loose proximal ligature was released.
Catheters were produced in house by stretching the tip of a length of Micro-
Renathane® tubing in hot sesame oil as recommended in the manufacturers’
instructions (Sherer et al., 1995). Catheters were filled with heparinised 0.9% saline
(100 IU.ml-1) (Multiparin, CP Pharmaeceuticals Ltd, Wrexham, UK), to minimise the
risk of clot formation at the catheter tip. Catheter patency and position within the
lumen of the artery was verified by observing pulsatile flow within the Micro-
Renathane® tubing. BP measurements were performed after a period of stabilisation
at a steady level of anaesthesia (respiratory rates maintained between 90 and 120
breaths.min-1). The catheter was connected via a MLT844 transducer
(ADInstruments Ltd, Chalgrove, Oxfordshire, UK) to a PowerLab/4SP data
acquisition system (Model No. ML750; ADInstruments Ltd) and displayed on a
Powerbook G4 Laptop (Apple MacIntosh) using Chart 5.1 software (ADInstruments
Ltd). The BP trace was recorded at 100 samples/ second. System damping, due to the
long length of tubing required to connect to the tranducer, resulted in a low pulse
pressure, preventing the measurment of true systolic and diastolic BP. Thus MABP
only was calculated from the traces obtained.
2.8 BP measurement in conscious animals
2.8.1 Salt diet
During initial studies, mice were fed either 0.8% NaCl or 8% NaCl powdered diet
(Special Diet Service, Sussex, UK) offered in small glass hoppers. Mice were
weighed weekly and given access to tap water ad libitum. However as the animals
dispersed the powder both throughout the cage as well as all over themselves, it was
impossible to determine their food consumption.
Therefore, for the telemetry studies, gel diet of varying salt content was made up
following a similar method to that described by Ahn and colleagues (Ahn et al.,
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2004). The mice did not disperse this gel diet around the cage. One hundred grams of
diet consisted of 36 g of powder diet (Special Diet Service, Sussex, UK); 60.2 ml of
distilled water; 3.8 g of beef gelatin (SuperCook, Sherburn-in-Elmet, Leeds, UK) and
a varying amount of NaCl (Sigma-Aldrich, Gillingham, Dorset, UK) to give a final
concentration of either 0.08%, 0.8%, 2.5% or 8% NaCl gel diet. The powder was
mixed with NaCl, before boiling water was added and beef gelatin mixed in. The
mixture was ladled into ice cube trays (J Sainsburys, Edinburgh, UK) and frozen at
–20°C until at least 45 minutes before use. Each cube weighed ~15 g and therefore 1
cube/ day provided the mice (max weight 35 g) with adequate food intake (daily
mouse powdered food requirements = 15g/ 100gms/ day (Baumans, 1999)). The
animals were given access to either water or normal saline (0.9% NaCl) ad libitum.
Mice, as well their water and gel consumption, were weighed daily whilst on the gel
diet.
During certain phases of the experimental protocol selective ET antagonists were
administered orally to the animals. Having determined the minimum daily gel
consumption, and weight of each mouse, enough powdered ABT627 (ETA
antagonist) or A192621 (ETB antagonist) was added to the food mix to ensure
minimum doses of 5 mg.kg-1 and 30 mg.kg-1 respectively. These doses are known to
exert maximum selective ET receptor blockade in rodents as discussed with Dr
David Pollock (Medical College of Georgia, Alberta, USA) (Pollock et al., 2001)
and further demonstrated by my clearance studies (see section 5.3.4). The ABT627
and A192621 were kind donations from Abbott Pharmaceuticals (Il, USA).
2.8.2 Indwelling carotid artery catheters
Aseptic techniques were used for all recovery surgical procedures. The procedure for
cannulation of the left common carotid was followed as outlined above (section 2.7).
Once the tapered tip of the catheter was located into the artery, it was secured in
place with sutures and tissue glue (VetBondTM Tissue Adhesive, 3MTM, Bracknell,
UK). The other end was tunnelled beneath the skin using a large bore trochar needle,
to emerge in the inter-scapula area. Here it was secured, using VetBond tissue glue,
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within a short (5 mm) section of more rigid supportive tubing, cut from a 4 French
PortexTM catheter (Harvard Apparatus, Ltd, Edenbridge, UK), which was in turn
fastened to the skin with glue. This stiffer tubing formed a “chimney” around the
Micro-Renathane® tubing, making a firm attachment where the catheter left the skin.
After flushing with heparinised hyperosmotic (10%) saline (see below) the catheter
was sealed with a section of blunted dress-making pin (John-Lewis, UK).
Micro-Renathane® tubing has a small but finite permeability to water, which allows
water to move across the wall of the tubing in the setting of a hydrostatic pressure
pressure gradient. Thus when a Micro-Renathane® catheter is inserted into the
lumen of a high pressure vessel, such as a carotid artery, water will be lost from the
catheter lumen, allowing a small amount of blood to enter the lumen. This is likely to
clot and therefore block the catheter. To reduce the risk of this occurring, catheters
were soaked in sterile saline for 24 hours prior to implantation and filled (between
BP measurements) with hyper-osmotic solutions (10% saline - see above) to
counteract hydrostatic gradients, as per the manufacturers’ instructions (Sherer et al.,
1995).
Post operatively the mice were given subcutaneous buprenorphine (0.3mg.ml-1)
(Alstoe Animal Health, Melton Mowbray, Leicestershire, UK), 0.9% saline (0.5 –
1.0 ml/mouse) and warmed on a thermostatically controlled heat pad in singly
housed cages until fully ambulant. Twenty-four hours post procedure, the mice were
gently but firmly restrained, the dress-maker pin removed and the catheter flushed
with heparinised saline. Forty-eight hours post-operation, the mice were again
restrained, the dress-pin removed, and after flushing, the catheter was connected to
the ADInstruments transducer (sample rate: 100/second) by means of a 20 cm length
of saline-filled MicroRenathane® tubing to allow measurement of BP. The mice
were returned to their cages, and after 30 minutes of acclimatisation, the BP was
recorded for 30 minutes. Measurements were taken under unrestrained conscious
conditions, in a quiet temperature controlled room (21 – 23°C) within the MFAA
Facility (University of Edinburgh, UK). The heart rate was determined from analysis
of the arterial BP trace. The mice were than culled by cervical dislocation.
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2.8.3 Surgical implantation of telemetry devices
In the 7 days prior to radiotelemetry device insertion, the mice were fed normal salt
(0.76% NaCl) gel diet and housed in single cages to allow them to fully habituate to
these changes in their environment before surgery. Each mouse was then
anaesthetised with 6.7 ml.kg-1 IP of a mixture of ketamine (100mg.ml-1) (Pfizer,
Sandwich, UK) and metomidine (1mg.ml-1) (Pfizer, Sandwich, UK) to allow surgical
implantation of BP telemetry transmitter devices (PA-C20; Data Science
International Inc, St. Paul, MN, USA) using a similar protocol as that used for
catheter insertion (section 2.7). In brief, the left common carotid artery was exposed
and tied off distally. The proximal end of the artery was briefly occluded to allow the
vessel to be cannulated with the transmitter catheter. Once inserted, the catheter was
secured in place with sutures and VetBondTM tissue glue. The fidelity of the signal
from the transmitter was checked with an FM radio – a fluctuating signal indicating
pulsatile blood flow at the catheter tip. Once the catheter had been inserted a
subcutaneous pocket was fashioned using blunt dissection down into the left
hypochrondrium of the mouse’s abdomen. The body of the transmitter was carefully
inserted into this pocket before the skin was closed with interrupted sutures. All
telemetry surgery was performed by Mr Peter Hodgson (BHF Technician, University
of Edinburgh, UK).
Post operatively the animals were treated with subcutaneous saline and
buprenorphine (0.3mg.ml-1) (Alstoe Animal Health, Leicester) before being given
atipamazole (25 mg.kg-1) (Pfizer, Sandwich, Kent) to reverse the effects of the
anaesthetic. Until fully conscious and ambulant the mice were warmed at 35°C in a
thermostatically controlled recovery chamber (VetTech Solutions Ltd, Congleton,
Cheshire). The mice were housed singly in a specially adapted rack to allow signals
from the telemetry devices to be recorded as required. The telemeter signals were
processed using the following D.S.I. equipment: RLA1020 receiving pads, a 20
channel data exchange matrix, an APR-1 ambient pressure monitor and a DataQuest
ART Silver 2.1 acquisition system. This arrangement allowed a carotid BP signal to
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be recorded for 10 seconds on each hour for the duration of the study (200
samples/sec). BP data were excluded if the trace was clearly artefactual and not
pulsatile. The undamped signal recorded with the radiotelemetry system allowed for
SBP, DBP, MBP and HR to be determined. As in similar radiotelemetry work
(Paterson et al., 2004), the 6 hour rolling average was calculated for each of these
parameters for each individual animal to reduce signal noise (e.g. value at 0900hr
was the average of BP from 0600hr to 1100hr; the value at 1000hr was the average
from 0700hr to 1200hr). Using these rolling averages, data was compared between
genotypes in three different ways:
i) ‘Last 72hrs’: the average of all values for the last 3 days of each treatment
period.
ii) ‘Day’: the average for values at 1100hr, 1200hr and 1300hr on the
last 3 days of each treatment period. As mice are nocturnal this appeared to
correspond to the period of minimal activity in their circadian rhythm.
iii) ‘Night’: the average for values at 2300hr, 2400hr and 0100hr on the
last 3 days of each treatment period. This period appeared to correspond with
maximal activity in the circadian rhythm.
The mice, their water bottles and diet were weighed daily.
At the completion of the study, the mice were culled by cervical dislocation, and
blood was collected by direct cardiac puncture for haematocrit measurement.
2.8.4 Haematocrit measurements
Whole blood was transported as swiftly as possible on ice from the Animal Unit to
the laboratory. Capillary tubes (Micro-Haematocrit Tubes, Hawksley and Sons Ltd.,
Sussex, England) were filled with blood before being spun for 5 minutes at 160G
(Centurion Centrifuge, DJB Labcare, Buckinghamshire, UK). The haematocrit was
determined by reading the percentage of erythrocyte sedimentation, within the
plasma, using a Hawksley micro-haematocrit reader.
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2.9 ET-1 clearance studies
2.9.1 Measurement of plasma ET-1 and big ET-1 concentrations
The low plasma concentration of ET-1 and big ET-1 prevents direct measurement by
radioimmunoassay (RIA). Both peptides were therefore extracted from the plasma
using the previously described acetic acid extraction (Rolinski et al., 1994). Briefly,
1 ml of mouse plasma (pooled from 2 individual animals of identical genotype/
experimental group) was mixed with 1 ml 20% acetic acid and applied to a Varian
C18 Bond Elut column (Varian Inc., Lexington, USA). Columns were washed with
10% acetic acid and ethyl acetate. ET-1/ big ET-1 was eluted in 1.5 ml of elution
buffer (1 volume 0.05 M NH4HCO3: 4 volumes methanol) and the sample
concentrated by evaporating to dryness under nitrogen followed by resuspension in
100 µl of RIA buffer (3.85 g NaH2PO4; 18.1 g Na2HPO4; 2.93g NaCl; 1 g BSA; 1ml
Triton X-100 and 100 mg sodium azide in 100 ml deionised H2O; pH 7.4). RIA was
performed on the concentrated sample using a Peninsula Laboratory kit for
determination of plasma ET-1/big ET-1 (Peninsula Europe Laboratories Ltd., St
Helens, UK). Either 100 µl of standard, sample or control was incubated for 4 hours
with either rabbit anti-mouse ET-1 or rabbit anti-mouse big ET-1 antibody. A known
concentration of either [125I]-ET-1 or big [125I]-ET-1 was then added and the tubes
incubated for a further 16 hours. On day 2, the immune complexes were precipitated
with AmerlexTM donkey anti-rabbit antibody. The precipitates were counted in a
gamma counter, a standard curve constructed and the unknown values read from the
curve. All measurements of plasma ET-1 and big ET-1 concentration were
performed by Neil Johnston (Clinical Pharmacology Unit, University of Edinburgh,
UK).
2.9.2 Clearance studies
Mice were housed individually and fed either standard powdered chow (0.8% NaCl)
or chow mixed with the orally active ETB antagonist A192621 (Abbott, IL, USA)
(von Geldern et al., 1999) to give a dose of either 30mg.kg-1.day-1 or
100mg.kg-1.day-1, for the 7 days preceding surgery, as performed in previous studies
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(Pollock et al., 2001). Animals were weighed daily to ensure adequate nutrition.
Under isoflurane anaesthesia, the right internal jugular and left common carotid
artery were cannulated with Micro-Renathane®  tubing (MR-025 ID, Braintree
Scientific, Inc, MA, USA) as outlined above (see section 2.7). Following an
intravenous bolus of radiolabelled [125I]-ET-1 (0.37 pmol/mouse; 28 kBq/mouse
[Amersham Bioscience, GE Healthcare]), drops (~10 µl) of arterial blood were
collected over the subsequent 120 seconds as previously described (Berthiaume et
al., 2000). The length of the arterial line was minimised, to limit the dead-space of
the system (~10-15 µl) as much as possible. The activity of these samples was
measured using a gamma scintillation counter.
All carcasses of animals used in this study were disposed off in accordance with the
University of Edinburgh Hazardous and Radioactive Substances Policy.
The results were analysed and processed with the assistance of Dr Ruth Andrew
(University of Edinburgh) using the Kinetica (version 4.2) software program
(Thermo Electron Corporation, http://www.thermo.com/).
2.10 Pulmonary Arterial Hypertension Study
2.10.1 Hypobaric chamber
Mice were exposed to hypoxic conditions, by housing them in a specially designed
hypobaric chamber. This was depressurised over the course of 2 days to 550 mbar
(55 kPa or 413 mmHg [equivalent to FiO2 (percentage oxygen in inspired air) =
10%]). Temperature was maintained at 21 to 22°C, and the chamber was ventilated
with air at ~45 l.min-1. At the end of each week, the chamber was repressurised back
to atmospheric pressure over 1 hour. The bedding, diet and water were then changed
and replenished, before the chamber was again depressurised over 1 hour back to 550
mbar.  The duration of hypoxia was 14 days. Aged-matched control mice were
maintained in room air under atmospheric pressure (FiO2 = 21%) in the same room
that contained the hypobaric chamber. Thus the controls were subjected to identical
environmental conditions save for hypoxia.
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2.10.2 Haemodynamic studies
For the PAH haemodynamic studies, anaesthesia was induced with 2 - 4% halothane
and maintained with 1.5% halothane using a standard small animal Boyle’s Machine
anaesthetic apparatus with a (1 part :3 parts) mix of NO2 and high flow O2. The left
carotid artery was cannulated in a similar method to that described above (section
2.7), using a stiffer catheter (Portex 0.75 mm O.D). The catheter was connected to an
Elcomatic E751A and MP100 data acquisition system (BioPac Systems Inc, Santa
Barbara, California, USA) to give systemic pressure readings (sample rate: 100/sec).
Results were analysed off line using AcqKnowledge software package (version 3.5).
A 25-gauge needle, mounted in a stereotactic retort stand with micrometer gauge
advance, was inserted into the RV using a transdiaphragmatic approach for
measurement of RV pressure (RVP). The skin was removed from the thorax and
upper abdomen of the mouse, and the needle orientated in the long axis of the
animal, just to the right of the xiphisternum. The RVP needle was connected to a
separate channel of the MP100 data acquisition system (sample rate: 100/sec). By
comparing the trace from this needle with the systemic pressure trace (carotid
catheter) it was possible to determine when the diaphragm had been crossed
(negative pressure) before the RV was punctured (RVP systolic pressure < systemic
systolic pressure; diastolic pressure ~ 0 – 4 mmHg). Systemic and RV pressures were
recorded for ~10 minutes. The needle was then advanced further with the aim of
recording a LV (left ventricular) trace (systolic LV pressure ~ systolic systemic
carotid catheter pressure).
Once this had been achieved, the halothane anaesthesia was increased to maximum
(5%) and the mouse euthanased.
The heart was removed, blotted dry of blood, and weighed. The right lung was taken
for histology (fixed in formal saline (1 part of formaline 37%: 9 parts of saline 0.9%
solution) and the left lung put on ice for later dissection to isolate the left PA used for
wire myography.
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2.10.3 Measurement of RV hypertrophy
Having been rinsed in saline, hearts were dissected clean of all pericardial and
thymus tissue. The atria and great vessels were removed to the plane of the
atrioventricular valves. The RV free wall was dissected free from the LV together
with the septum (LV + S), and blotted dry. These were weighed separately. The
ratios of RV/LV + S; RV/Total Ventricles (TV); and RV/Body Weight (BW) were
calculated.
2.10.4 Wire myography
As the PA myography had to be performed swiftly following the euthanasia of each
mouse (within 24 hours), these experiments were performed concurrently with the
ongoing haemodynamic studies, by Dr Yvonne Dempsie (University of Glasgow
UK). Following the culling of each mouse at the end of the haemodynamic study, the
left lung was cut free from the heart and put on ice for transportation from the animal
facility to the myography laboratory. Here, each PA was gently dissected from the
neighbouring bronchiole and all adventitial tissue was carefully removed. Third
order (first interlobar) PAs were cut to yield two 2mm long segments (~300 µm
internal diameter). These segments were threaded onto 40 µm stainless steel wire and
mounted on isometric wire-myographs. The mounting procedure is illustrated in
Figure 2-5. Vessel rings were suspended between two intra-luminal mounting wires
(40 µm diameter, ∼2.2 cm in length) in a 10 ml myograph organ bath (Multi-
myograph model 610M; JP Trading, Aarhus, Denmark). One wire was attached to
the stationary support driven by a micrometer whilst the second wire was attached to
an isometric force transducer. Care was taken not to damage the endothelium during
the mounting procedure.
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Figure 2-5: Procedure for mounting of pulmonary artery rings onto the wire
myograph
Vessels were bathed in Krebs-buffer solution (118.4 mM NaCl; 25 mM NaHCO3;
4.7 mM KCl; 1.2 mM KH2PO4; 0.6 mM MgSO4; 2.5 mM CaCl2; 11 mM glucose;
[pH 7.4]) at 37°C with a constant supply of 16% O2/5% CO2. During this
normalisation period, tension was applied to give transmural pressures equivalent to
those experienced by PAs in vivo, as originally described by Mulvany and Halpern
(Mulvany et al., 1977). This procedure allows vessels to be stretched to a required
resting transmural pressure, based on the Laplace relationship for a cylindrical
vessel:
P (transmural pressure) = T (wall tension) / R (radius of the vessel)
where,
Wall tension is the force (F) divided by twice the vessel length (L):
Wall tension = F/ 2L
the radius of the vessel can be calculated from the internal circumference (IC) of the
PA ring. IC can be determined from the distance between the myography wires
multiplied by 2 (see Figure 2-5 panel 6):
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R = IC / 2π
therefore, rearranging substituting these values into the formula:
P = 2π x F / 2 x L(IC)
Thus by adjusting the tension on a given PA ring, and by measuring its length and
internal circumference, the required transmural pressure can be generated.
PAs from normoxic mice were tensioned to an equivalent pressure of 12 to 14 mm
Hg and PAs from hypoxic mice were tensioned to 30 to 33 mm Hg. These pressures
are similar to those experienced by pulmonary vessels in vivo in rodents (Herget et
al., 1978; MacLean et al., 2004). This contrasts with studies using systemic arteries,
where the tension is usually adjusted to be equivalent to in vivo pressures of more
than 60 mmHg (Mickley et al., 1997). As the pulmonary circulation has a high flow
but a low resistance, it is more suitable for PAs to be set up under equivalent
conditions to those experienced by the vessels in vivo (MacLean et al., 1998;
McCulloch et al., 1996). Periodic adjustments were made to maintain this tension
over the subsequent equilibration period. This tension was defined as zero for all
following measurements. Signals from the myograph were processed by a
MacLab/4e analogue-digital converter and displayed through Chart  software
(ADInstruments; Chalgrove, Oxfordshire, UK).
2.10.4.1 PULMONARY ARTERY WAKE UP PROTOCOL
Following a 20 minute equilibration period, PA rings were contracted twice to obtain
the maximum contraction to 50 mM KCl solution. KCl was washed out 5 times with
Krebs-buffer solution and rings were allowed to return to baseline tension prior to
further experiments. For details of the full myography protocol see section 6.2.1.
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2.10.5 Lung histology
Right lungs, harvested at the end of the in vivo haemodynamic study, were
dehydrated in 100% ethanol for between 5-7 days. The tissue was then embedded in
paraffin wax and cut into 10 µm sections. These were stained for collagen with
Miller’s Elastin Stain (Miller, 1971) and for collagen with Picro-Sirius Red
(Junqueira et al., 1979) according to the following protocol (all solutions and
chemicals were sourced from Sigma-Aldrich, Steinheim, Germany unless otherwise
stated). The sections were de-waxed by immersing in ‘Tissue Clear’ (Bayer Plc,
Newbury, Berkshire, UK) for 30 min, before being washed in a range of decreasingly
concentrated ethanol baths (100% ethanol for 2 mins; 90% ethanol for 2 mins; 70%
ethanol for 2 mins). Next, the sections were washed in running tap water for 10 mins,
and then immersed in 0.5% (w/v) potassium permanganate for 5 mins. After rinsing
in water the sections were put into 1% (w/v) oxalic acid for 2 – 3 minutes to
decolourise them. The sections were rinsed in water, then 95% ethanol, before being
immersed in Miller’s Elastin stain for 3 hours.
The Miller’s Elastin stain was made up prior to the staining: 1 g Victoria Blue 4R, 1
g New Fuschin, 1 g Crystal Violet were all dissolved in warmed 200 ml distilled
water. Resoucin (4 g), then 1 g dextrin, then freshly prepared 30% ferric chloride
was added to the mixture. After boiling for 5 minutes, the mixture was filtered whilst
still hot. The precipitate plus filter paper was redissolved in 200 ml of 95% ethanol,
boiled for 20 mins, the filtered and made up to 200 ml with 95% ethanol. Finally 2
ml of concentrated hydrochloric acid was added.
After washing in 95% ethanol, to remove excess stain, the sections were washed in
running water and immersed in Picro-Sirius Red stain (0.5 g Sirius Red F3B in 500
ml saturated picric acid) for 1 hour. Following staining the sections were washed in 2
changes of acidified water (0.5% v/v acetic acid), and then dehydrated in 3 changes
of 100% ethanol and mounted.
The sections were microscopically assessed for muscularisation of small PAs (25 to
100 µm external diameter), associated with an airway distal to the respiratory
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bronchiole. The arteries were considered muscularised if they possessed a distinct
double-elastic lamina visible for at least half the diameter in the vessel cross-section.
The percentage of vessels containing double-elastic lamina was calculated as number
of muscularised vessels/total number of vessels counted per section x 100. Three
sections from each right lung of 6 mice per group were assessed in this way. These
assessments were each performed by two investigators working independently.
2.11 STATISTICAL ANALYSIS OF RESULTS
Where only two data sets were compared, unpaired student’s t tests were performed.
All other data were analysed using repeated measures ANOVA with Newman-Keuls
multiple comparison post-test analysis. P-values quoted in the text were accepted as
statistically significant when p<0.05
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3  CHAPTER 3: CHARACTERISATION OF THE MURINE
MODEL OF EC-ETB DOWN-REGULATION
3.1 INTRODUCTION
With any conditional knockout/knockdown animal, the initial step in characterising
its phenotype is to determine that the targeted allele has been significantly down-
regulated from the cell type of interest. I have employed a 3-stage approach to this
process.
3.1.1 Deletion of exons 3 and 4 prevents ETB expression
Firstly, it was necessary to demonstrate that floxing exons 3 and 4 of the ETB gene
was sufficient to knock it out in tissues expressing the bacteriophage enzyme Cre-
recombinase. Other groups, using tissue specific Cre lines, have demonstrated that
recombination events have been noted in the germ cells of female mice featuring a
floxed allele and the Tie2-Cre transgene (Constien et al., 2001; Koni et al., 2001).
We took advantage of this phenomenon, to organise a breeding strategy that
generated mice exhibiting such germ line recombination. These mice had a piebald
appearance and died at weaning from aganglionic megacolon. Genotyping later
revealed them to be null ETB mice.
Analytical breeding crosses were then performed to empirically determine the rate of
this germ line recombination in our colony, and to verify whether there was an
increased incidence of germline recombination if the Cre transgene was expressed by
the mother rather than the father.
Having demonstrated that male germline transmission resulted in substantially
reduced rates of recombination, efforts were directed towards perfecting a swift and
reliable method of identifying animals in which this germline recombination had
occurred in one of its 2 alleles. Several different strategies were employed until a
Southern Blot was successfully developed.
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3.1.2 Tie2-Cre restricts expression of Cre recombinase to the endothelium
Second, having demonstrated that Cre mediated recombination can prevent the
expression of a functional ETB receptor in floxed ETB mice, the next step was to
demonstrate that, as long as the Tie2-Cre transgene is transmitted in the male
germline, it restricts Cre expression to ECs. Ideally, Cre-mediated recombination
occurs in both alleles of the gene of interest, resulting in complete knockout of target
gene expression in the desired cell-type. Conversely, expression in all other cells
should be unchanged from the wild-type pattern. Leaky or deregulated transcription
of the Cre recombinase transgene will result in unwanted recombination events in
other cell types. Either of these will complicate phenotype interpretation. Therefore it
is necessary to determine the expression of Cre recombinase in the Tie2-Cre mice. At
present, it is difficult to examine the distribution of the Cre protein directly, because
no satisfactory Cre antibody has been produced which functions adequately in mouse
tissues. Therefore other strategies to determine Cre expression were used. It has been
shown that the expression of the indicator protein, enhanced green fluorescent
protein (EGFP), under control of the Tie2 promoter, is restricted to the endothelium
(Motoike et al., 2000) and Tie2-lacZ mice demonstrate a panendothelial specific
pattern of lacZ expression throughout embryogenesis and into adulthood (Schlaeger
et al., 1997). Furthermore, Tie2-Cre expression is limited to endothelial and
endocardial tissue (Kisanuki et al., 2001). To demonstrate that such EC-specific
expression of Tie2-Cre was maintained in our colony, we crossed our Tie2-Cre mice
with 2 different reporter strains: a lacZ Rosa26 reporter (R26R) mouse line and a
GFP reporter strain.
3.1.2.1 BREEDING WITH LACZ ROSA 26 REPORTER STRAIN
The tissues in which the bacteriophage enzyme Cre recombinase is expressed can be
assessed using reporter mice that permit in vivo monitoring of Cre-mediated excision
events in all tissues. Such a strain of mice was generated by the targeted insertion of
a lacZ gene (which codes for the Escherichia coli enzyme β-galactosidase), preceded
by a floxed strong transcriptional termination sequence (a STOP codon), into the
ubiquitously expressed Rosa26 locus (R26R mice) (Mao et al., 1999; Soriano, 1999).
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The R26R allele terminates transcription of the lacZ gene prematurely, but when the
mice are crossed with Cre-expressing transgenic mice, the Cre-mediated excision of
the floxed termination sequence leads to constitutive lacZ expression. Thus, these
doubly transgenic animals express lacZ only in the cells that express Cre. In tissues
harvested from such animals, Cre expression is therefore mirrored by β-galactosidase
activity.
Figure 3-1: Cre mediated recombination
Cre mediated excision of the stop cassette results in expression of β galactosidase
when R26R mice are crossed with mice expressing Cre in a tissue specific manner.
3.1.2.2 BREEDING WITH GFP REPORTER STRAIN
An alternative approach to using lacZ reporter mice to monitor the pattern of Cre
expression within a particular mouse line, is to use a similar Cre reporter mouse that
expresses EGFP in place of β-galactosidase. GFPs are autofluorescent proteins that
can be visualised in living cells, and are therefore particularly useful for monitoring
gene expression in whole embryos, animals or cultured cells and organs (Chalfie et
al., 1994). The EGFP reporter mice generously supplied by Dr Alexander Medvinsky
(University of Edinburgh, UK)(Gilchrist et al., 2003) contain the ubiquitously
expressed phosphoglycerate kinase promoter, rather than the Rosa 26 promoter used
in the LacZ mice.
3.1.3 EC-specific ETB down-regulation in FF/Tie2 mice
The third and final step was to demonstrate that in our FF/Tie2 mice, there was EC-
specific ETB down-regulation. Supporting evidence of EC specific knockdown was
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provided by Dr Alan Bagnall’s (University of Edinburgh, UK) work. He provided
binding data in pulmonary ECs demonstrating ~82% reduction in ETB receptor
mediated binding and functional wire myography studies in which aortic rings from
FF/Tie2 mice demonstrated reduced endothelial dependent ETB mediated dilatation,
but preserved non endothelial dependent tracheal ETB mediated constriction (Bagnall
et al., 2006) (see section 1.3.6).
We went on to use quantitative autoradiography to demonstrate reduced ETB
expression in EC rich tissues such as the lung and renal medulla. We also used this
technique to investigate the effect of EC-ETB receptor down-regulation on ETA
receptor expression in different organs. Finally, semi quantitative RT-PCR was
performed on kidneys from the FF/Tie2 mice to investigate the effect of EC-ETB
receptor down-regulation on the gene expression of all components of the renal ET
system.
3.1.3.1 SEMI-QUANTITATIVE RT-PCR
Reverse transcription polymerase chain reaction (RT-PCR) is a highly sensitive
method for the detection of low-abundance mRNA, obtained from small tissue
samples. In RT-PCR, an RNA template is copied into a complementary DNA
transcript (a cDNA) using a retroviral reverse transcriptase. The cDNA sequence of
interest is then amplified exponentially using PCR. Real time PCR quantifies the
amount of product at the end of each cycle, whereas end-point PCR requires
optimisation of each PCR to ensure that the reaction is terminated during the
exponential phase of amplification (since it is only during this phase that
amplification is extremely reproducible). Such end-point RT-PCR can be used to
measure changes in expression levels using either semi-quantitative, or fully
quantitative competitive methods. Determination of the amount of PCR product is
performed by agarose gel electrophoresis and by measuring the intensity of a
fluorescent dye, such as ethidium bromide, that binds to it.
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Semi-quantitative RT-PCR compares transcript abundance across multiple samples,
using a co-amplified internal control, in order to normalize for differences in sample
concentration and loading. Results are expressed as ratios of the gene-specific signal
to the internal control signal. This yields a corrected relative value for the gene-
specific product in each sample. These values may be compared between samples for
an estimate of the relative expression of target RNA in the samples, eg sample 1 has
2.4-fold the ETB expression of sample 2. Ideally, the internal control should be a
gene expressed at a constant level across the sample set. Commonly used internal
samples are the ‘housekeeping genes’, glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH), ß-actin mRNA, and 18S and 28S rRNAs. GAPDH was chosen for our
study as it is commonly used (Carrell et al., 2002; Haase et al., 2002; Yalcintepe et
al., 2006) and the optimisation of the PCR conditions had already been established in
our laboratory for RT-PCR of the ET system in the rat (Wallace, 2003; Wallace et
al., 2002). Although GAPDH expression has been shown to vary with age and across
different organs (Oikarinen et al., 1991), such effects were limited in our study as we
compared gene expression in renal tissue from mice of the same age.
Fully quantitative RT-PCR, a competitive reaction, measures the absolute amount
(e.g. 5.3 x 105 copies) of a specific mRNA sequence in a sample. Dilutions of an
external control, a synthetic RNA (identical in sequence, but slightly shorter than the
endogenous target) are added to sample RNA replicates and are co-amplified with
the endogenous target. The PCR product from the endogenous transcript is then
compared to the concentration curve created by the external control, the synthetic
‘competitor RNA’. The major disadvantage of this last method is that for each
component of the ET system a different external control, a different synthetic RNA,
must be generated. Semi-quantitative PCR, as we performed allows comparison of
all ET components relative to the same internal control: GAPDH.
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3.2 RESULTS
3.2.1 Genotyping of experimental animals
A representative agarose gel used to genotype mice for the floxed ETB receptor allele
is shown in Figure 3-2. Floxed/ Wild type heterozygous animals (FW/Tie2)
demonstrated 3 bands: a 2241 bp band corresponding to the wild type (W) allele, a
1136 bp band amplified from the non-recombined floxed (F) allele, and a 230 bp
band amplified from the recombined floxed (0) alleles present within the EC of the
tail biopsy. FF/Tie2 mice exhibited bands of 1136 and 230 bp (F and 0 bands), whilst
FF/-- mice exhibited only the 1136 bp band. A single 2241 bp band was amplified
from the WW/-- and WW/Tie2 mice.
Figure 3-2: Flox PCR
An example of agarose gel used to genotype for the floxed ETB receptor allele using
primers 454F and 681R and tail/ ear punch biopsy DNA. Lane 1: WW/--; Lane 2:
FW/Tie2; Lane 3: FF/--; Lane 4: FW/Tie2; Lane 5: FF/Tie2; Lane 6: 100 bp size
marker ladder.
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The presence of the Tie2-Cre transgene was detected by the amplification of a ~ 550
bp band in a separate PCR (see Figure 3-3).
Thus both the flox and the Tie2-Cre PCR were performed on all samples. As the
exact insertion site Tie2-Cre transgene is not known (Kisanuki et al., 2001), a
conventional positive control for the Tie2-Cre PCR was not possible. Therefore, in
the absence of a band amplified by the Tie2-Cre PCR, the integrity of the DNA
sample was demonstrated by the presence of bands in the flox PCR. If no result was
seen in either the Tie2-Cre or flox PCRs, then the sample was re-extracted and the
PCRs repeated.
Figure 3-3: Tie2 PCR
An example of agarose gel used to genotype animals for the Tie2-Cre transgene.
Lanes: 3, 8, and 9 transgene absent; Lanes: 1, 2, 4, 5, 6 and 7 transgene present. Lane
10: 100 bp size marker ladder.
3.2.2 Generation of null ETB mice
We took advantage of the higher frequency of recombination events in germ cells of
female FW/Tie2 and FF/Tie2 mice to produce offspring homozygous for the
recombined allele. These pups were of piebald appearance and died shortly after
weaning from intestinal obstruction, consistent with functional ETB receptor
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deficiency (Figure 3-4C, D). When genotyped by PCR, using the primers 454F and
681R, these piebald mice exhibited only the 230 bp recombined (0) allele, indicating
that this recombined allele was unable to encode functional ETB receptor transcripts
(Figure 3-4E).
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Figure 3-4: Piebald mice
Intercross of FF/Tie2 mice results in progeny with the phenotype of ETB receptor
null mice: spotted or piebald coat appearance (D) and intestinal obstruction (C –
obstructed colon labelled c). A male 3 week old FF/Tie2 mouse (A) with normal
colon (B) shown for comparison. PCR genotyping indicates only the recombined (0)












Analytical breeding was performed over a period of ~4 months as outlined in the
scheme above (see Figure 2-1). Only one W0/-- male could be mated with each
FF/Tie2 female, whereas 2 W0/-- females could be established in a harem with each
FF/Tie2 male. Thus many more pups were born to the analytical pairs in which
FF/Tie2 males were tested compared with the pairs testing female FF/Tie2 mice. The
total number of live births and piebald animals arising from each analytical cross is
recorded in Table 3-1 below:
Table 3-1: Results of analytical breeding pairs
Sex of FF/Tie2 animal Male Female
Total number of analytical pairs 9 5
Total number of live births 214 37
Total number of piebalds born 16 6
% Piebalds overall 7.48% 16.22%
Range of % Piebald in each individual breeding pair 0 – 19% 0 – 35%
Likely proportion of ‘0’ allele gametes generated by each parent 0 – 38% 0-70%
Piebald offspring were generated by pairings where the Tie2-Cre transgene was
carried by either the male or the female parent, although the proportion of piebald
mice was greater in the latter. As each FF/Tie2 animal was paired with a W0/--
mouse, the actual rate of germ line recombination during gametogenesis would have
been double the proportion of observed piebald animals.
3.2.4 Genotyping strategies
As analytical breeding is costly and time consuming, different approaches were
developed in order to identify the frequency of germline recombination with any
individual breeding pair, swiftly and easily. Any such technique had to differentiate
mice heterozygous for the recombined floxed ETB allele and carrying the Tie2
transgene (F0/Tie2) from mice homozygous for the floxed allele and carrying the
Tie2 transgene (FF/Tie2), in which recombination only occurs in ECs. With the
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standard genotyping strategy of tail/ear biopsies (see section 2.3.2) both of these
genotypes will exhibit a ‘0’ band of 230 bp as well as an ‘F’ band of 1136 bp.
A number of different approaches were attempted, before the Southern blot analysis
was developed.
3.2.4.1 ‘COMPARATIVE’ PCR OF TAIL BIOPSIES
Initial attempts at solving this problem involved using identical quantities of tail
derived DNA in each PCR, and then comparing band intensity on the resulting gels.
Figure 3-5: Semi-quantitative PCR.
An example of an agarose gel from ‘semi-quantitative’ PCR experiment. Lane 1: 100
bp size marker ladder; Lane 2: 00/-- (piebald animal); Lane 3: FW/Tie2; Lane 4: FF/-
-; Lane 5: FW/Tie2; Lane 6: F?/Tie2; Lane 7: F?/Tie2; Lane 8: FF/Tie2; Lane 9:
FF/Tie2; Lane 10: FF/Tie2; Lane 11: 100 bp size marker ladder.
This did not give a reliable result – we were unable to differentiate the ‘0’ band from
FF/Tie2 mice (identified as highly likely to be FF/Tie2 by analytical breeding [no PB
after >50 pups]) from the ‘0’ band from F0/Tie2 mice.
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3.2.4.2 PCR OF ‘EC FREE’ TISSUE
An alternative approach was then used to differentiate FF/Tie2 from F0/Tie2 mice. If
an ‘EC free’ tissue could be isolated, DNA could be extracted and PCR performed.
Approximately 50% of cells from such F0/Tie2 ‘EC free’ tissue should exhibit a ‘0’
band of 230 bp. However, such tissue from FF/Tie2 mice should not exhibit a ‘0’
band, as it would contain no cells in which recombination of the ETB gene had
occurred. A number of potential ‘EC free’ tissues were tried:
Hair: DNA extracted from hair samples was analysed and compared with samples
extracted from the tail biopsies of the same individual animals (see Figure 3-6). Even
hair samples from animals identified as highly likely to be FF/Tie2 by analytical
breeding (no PB after >50 pups) amplified a very bright 0 band. Further gels (not
shown) revealed that hair DNA samples consistently exhibited faint 0 bands only,
even when the mice involved were of FW/Tie2 genotype. Thus hair analysis was not
a satisfactory method of genotyping our animals.
91
Figure 3-6: Hair DNA PCR
Lanes 1 - 6 DNA extracted from tail biopsies; Lane 7: 100 bp size marker ladder;
Lanes 8 – 13 DNA extracted from hair. Lanes 1 and 8: FF/Tie2; Lanes 2 and 9:
FF/Tie2; Lanes 3 and 10: FF/Tie2; Lanes 4 and 11: FF/--; Lanes 5 and 12: FW/Tie2;
Lanes 6 and 13: WW/Tie2.
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Testes: DNA was extracted from testes and tail biopsies of each individual mouse.
Following PCR, the DNA from the testes of mice known to be FF/Tie2 or FW/Tie2,
amplified a 0 band, often with no other bands being observed (Figure 3-7). No
reliable pattern of results was seen and so the technique was abandoned as a method
of distinguishing FF/Tie2 from F0/Tie2 mice.
Figure 3-7: Testes DNA PCR
An example of a genotyping gel from 3 FF/Tie2 mice showing result of PCR of
DNA extracted from both testes and tail tip biopsies.
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Heart: Following genotyping PCR, DNA extracted from whole heart tissue was
compared with DNA extracted from isolated cardiomyocytes. Although the amount
of DNA was standardised according to OD260, the agarose gel for the isolated
cardiomyocytes PCR are very faint (Figure 3-8). However, the ratio of 0 band/ F
band appeared similar for the isolated cells and whole heart tissue. Therefore this
method could not differentiate between F0 and FF/Tie2 mice.
Figure 3-8: Cardiomyocyte DNA PCR
Lanes 1 - 7 DNA extracted from intact cardiac tissue; Lane 8: 100 bp size marker
ladder; Lanes 9 – 15: DNA extracted from crudely isolated cardiomyocytes. Lanes 1
and 9: FF/Tie2; Lanes 2 and 10: FF/Tie2; Lanes 3 and 11: FF/Tie2; Lanes 4 and 12:
FF/Tie2; Lanes 5 and 13: WW/--; Lanes 6 and 14: W0/Tie2; Lanes 7 and 15:
W0/Tie2.
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3.2.4.3 SOUTHERN ANALYSIS OF TAIL BIOPSY DNA
In contrast to FF/Tie2 mice, Southern analysis (as described in section 2.4.3) of
F0/Tie2 tail tissue detected the presence of the recombined allele. Southern analysis
detected only the recombined allele in piebalds, indicating that the recombined allele
was unable to encode functional ETB receptor transcripts (see Figure 3-9).
Figure 3-9: Southern blot genotyping
Southern blot hybridisation analysis of EcoR I-digested genomic DNA from WW/--
(Lane 1), FF/Tie2 (Lane 2) and piebald (Lane 3) mice. Southern analysis only
detected the recombined allele in piebald mice (homozygous for the recombined
allele.
3.2.5 Tie2-Cre restricts Cre expression to ECs
3.2.5.1 LAC Z STAINING AND ENDOTHELIAL CELL STAINING
WW/Tie2 mice were mated in reciprocal crosses with R26R mice (kind gift of Dr Ian
Simpson, University of Edinburgh). Mice (aged 8 weeks) were culled by CO2
asphyxiation, their kidneys removed and stained for β -galactos idase .
Immunohistochemisty was also performed to visualise EC using antibodies against
CD31. Consistent with the results of previous studies (Kisanuki et al., 2001), we
observed EC-restricted LacZ staining in kidneys harvested from F1 offspring
following Flox/Flox Tie2-Cre and R26R intercross. Intense staining for both LacZ
and CD31 was seen in the glomeruli and adjoining capillaries and arterioles and in





Figure 3-10). No LacZ staining was seen in control R26R mice lacking the Tie2-Cre
transgene.
Figure 3-10: LacZ and CD31 antibody staining in kidneys from WW/Tie2-Cre
and WW/Tie2-Cre/R26R mice.
EC stained brown using antibodies to CD31 in medullary rays (A), glomerular
capillaries and arterioles (D and G). An identical pattern of LacZ staining (blue),
indicating Tie2-Cre expression, is observed in F1 mice following intercross of
FF/Tie2-Cre and R26R reporter mice (B, E and H), confirming EC-restricted
transgene expression. Control R26R mice lacking the Tie2-Cre transgene





= medullary rays; Scale bar = 100 µm. (Data from Danielle Armour, University of
Edinburgh).
3.2.5.2 GFP STAINING
WW/Tie2 mice were also mated in reciprocal crosses with a second reporter strain
(EGFP reporter mouse line – generous gift of Dr Alexander Medvinsky, University
of Edinburgh, UK).
Figure 3-11: GFP autofluorescence in day 11 FF/Tie2-Cre/GFP embryos
Micrographs showing expression of GFP in F1 Tie2-Cre/GFP embryos, following
intercross of FF/Tie2-Cre and EGFP reporter mice. Somatic arteries arising from the
developing dorsal aorta are clearly seen, indicating EC specific distribution of Tie2-
Cre.
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In Tie2-Cre/GFP F1 offspring, the blood vessels autofluoresced markedly, in contrast
to other epithelial surfaces such as the gut or bladder, offering further evidence of EC
specific Tie2-Cre expression (see Figure 3-11). No autofluorescence was seen in the
control NoCre/GFP sibling controls. These studies were all performed by members
of Dr Alexander Medvinsky’s laboratory.
3.2.6 Autoradiography to demonstrate ET receptor expression
3.2.6.1 WW/-- CONTROL MICE
Autoradiographical images of longitudinal whole torso sections from control mice,
cut at the level of the heart, revealed as expected, high densities of specific ETB
binding to the liver, lungs, medulla of the kidney and gut epithelium with lower
densities present in the heart and kidney cortex (Figure 3-12). Specific ETA binding
was highest in the heart and smooth muscle of the gut with lower densities seen in
the vasculature of organs including the kidney, liver and lungs.
3.2.6.2 COMPARISON OF WW/-- AND FF/-- MICE
I next tested whether FF/-- demonstrate altered ETB receptor expression. High levels
of binding were found as expected in ETB rich organs including the kidney and
lungs. The density of binding of ETB selective ligand to the longitudinal sections
from WW/-- animals was not significantly different in the lungs, liver, renal cortex
and medulla to those from FF/-- mice (Figure 3-12).
3.2.6.3 FF/TIE2 MICE DEMONSTRATE REDUCED EC ETB EXPRESSION
In autoradiographical images of longitudinal sections of FF/Tie2 mice, binding of
ETB selective ligand in EC-rich tissue such as lung parenchyma (Figure 3-12C,
Figure 3-13A) and renal cortex and medulla (Figure 3-12C, Figure 3-13C) was not
distinguishable from the level of non-specific binding in these tissue regions.
However, binding to other cell types known to express ETB receptors, such as




Figure 3-12: Total ETB binding in FF/Tie2 and control mice
(Previous page) Autoradiographs of total binding of the radiolabelled ETB selective
ligand [125I]-BQ3020 in WW/-- (A) FF/-- (B) and FF/Tie2 (C) mice. FF/Tie2 mice
demonstrate loss of ETB receptor-mediated binding in EC-rich organs such as lung
and kidney but normal binding in less-EC rich tissue as such the liver. K = kidney, Li
= liver, H = heart, G = gut, L = lung. Scale bar = 5 mm.
Quantitative autoradiographical analysis of representative areas known to contain
high densities of EC (using this technique it is not possible to measure individual
endothelial cells that are below the resolution of the image analyser) showed that
specific binding was virtually abolished in discrete regions rich in EC including lung
parenchyma (reduced to <6% of control, Figure 3-14A) and renal medulla (reduced
to <5% of control, Figure 3-14C) and liver sinusoids (Figure 3-14E). In contrast, in
epithelial tissue expressing non-EC ETB receptors such as those in the respiratory
bronchi (Figure 3-14B) and liver parenchyma (Figure 3-14D) no significant
difference was found compared with FF/-- controls, confirming the qualitative
results.
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Figure 3-13 ETB binding in lung and kidney
High magnification images of autoradiograms, showing binding of [125I]-BQ3020 to
ETB receptors in both FF/Tie2 (A and C) and FF/-- (B and D) mouse torsos. In the
FF/-- as expected, high levels of specific ETB binding is seen throughout the lung (B)
and kidney (D) however in the FF/Tie2 mouse only the non-endothelial ETB binding
remains for example to the epithelial cells (indicated by arrows) of lung bronchi (A)











Figure 3-14: Specific ETB binding in lung, kidney and liver
Specific binding density of the radiolabelled ETB selective ligand [
125I]-BQ3020 was
significantly reduced in FF/Tie2 mice in EC-rich renal medulla (A) and lung
parenchyma (B) and but relatively preserved in lung bronchioles (C). n = 4 for all
groups.
3.2.6.4 ETA EXPRESSION IN FF/TIE2 ANIMALS
Binding of the radiolabelled ETA selective ligand [125I]-PD151242 was not
significantly different in FF/Tie2 animals compared to controls (Figure 3-15).
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Quantification of the ETA selective autoradiography showed similar amounts of
binding in specific tissues from FF/Tie2 mice (renal medulla, Figure 3-16A, renal
cortex Figure 3-16B, lung, Figure 3-16C and liver, Figure 3-16D) compared to
equivalent regions from FF/-- mice.
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Figure 3-15: Autoradiographs of total binding of the radiolabelled ETA selective
ligand [125I]-PD151242 in WW/-- (A) FF/-- (B) and FF/Tie2 (C) mice.
ETA receptor-mediated binding is greatest in the heart and smooth muscle of the gut
with lower densities seen in the vasculature of the kidney, liver and lungs. ETA
binding is similar in FF/Tie2 mice and controls, indicating that it is not altered by
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EC-ETB down-regulation. K = kidney, Li = liver, H = heart, G = gut, L = lung. Scale
bar = 5 mm.
Figure 3-16: Specific ETA binding in kidney, lung and liver.
Specific binding of the ETA selective ligand [
125I]-PD151242 in renal medulla (A),
renal cortex (B), lung (C) and liver (D) was similar in WW/--, FF/-- and FF/Tie2
mice. (n=4).
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3.2.7 RT-PCR to demonstrate renal ET system expression
3.2.7.1 RNA INTEGRITY
Following extraction from the harvested mouse kidneys, the integrity of the RNA
was assessed by running a RNA denaturing gel. A representative gel demonstrating
well defined bands corresponding to 28S (4.7 kbp) and 18S (1.9 kbp) ribosomal
RNA is shown below (Figure 3-17).
Figure 3-17: Denaturing gel
An example of a denaturing gel of RNA showing 18s and 28s ribosomal RNA.
3.2.7.2 OPTIMISATION OF PCR CONDITIONS
Each endpoint PCR was optimised by varying the annealing temperature, magnesium
concentration, dNTP concentration and cycle number. The optimum conditions were
those producing the greatest yield of desired product relative to extraneous non-
specific products (see Figure 3-18).
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Figure 3-18: Optimisation of PCR temperature
Representative gel showing optimisation of ETA PCR annealing temperature. The
lanes correspond to the ETA PCR carried out at a range of annealing temperatures (48
- 58°C). The right-hand lane corresponds to the 100 bp size marker. Under this
particular magnesium concentration, 50°C was selected as the optimum temperature,
as although it is not the brightest band, it has the least amount of non-specific
product.
The cycle number that was chosen for each PCR was within the exponential range of
amplification to ensure a linear relationship between the amount of input template
and the amount of amplification product (see Figure 3-19).
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Figure 3-19: Optimisation of PCR cycle number
A: representative gel showing optimisation of ECE-1 PCR cycle number. B:
Relationship of cycle number and relative band intensity. Thirty cycles were selected
as this value lies on the linear portion of the graph.
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Table 3-2: Optimum conditions for semi-quantitative PCR of ET system



























261 60.4°C 30 2.5 200
Once the optimal conditions had been determined, the cDNA was serially diluted,
and the PCR for each component of the ET system performed, to confirm the
semiquantitative nature of each PCR (Figure 3-20).
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Figure 3-20: Serial dilution of cDNA
An example of a gel of the ECE-1 PCRs using serially diluted cDNA samples.
3.2.7.3 GENE EXPRESSION OF COMPONENTS OF THE ET SYSTEM
Semi-quantitative endpoint RT-PCR was then performed on kidneys from FF/-- and
FF/Tie2 animals. Comparisons were made between the expression of the components
of the ET system in kidneys from both genotypes of young (< 12 weeks old) male,
young female and aged (> 52 weeks old) male mice.
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Figure 3-21: Effect of genotype on the relative expression of the renal ET system
Relative expression of renal ETB, ETA, and ECE-1 mRNA in young male (A), old
male (B) and young female (C) FF/Tie2 and FF/-- mice.
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Across all three groups, FF/Tie2 mice exhibited reduced ETB gene expression
compared to FF/-- controls. This difference was statistically significant in the young
female mice and approaching significance in the young males. In both the young and
aged males there was no alteration in ETA or ECE-1 gene expression with genotype.
In contrast, the young FF/Tie2 females demonstrated decreased gene expression of
ETA and ECE-1.
ETB
































































































































Figure 3-22 Effect of age and sex on the relative expression of the renal ET
system
Relative expression of renal ETB, ETA, and ECE-1 mRNA in FF/-- (A) and FF/Tie2
(B) mice.
Comparing male and female mice, the FF/-- young females had almost 3-fold the
ETB expression of male FF/-- animals, both young and old. This pattern of increased
expression in females was also seen with the residual (due to EC down-regulation)
ETB expression demonstrated by FF/Tie2 mice. Old male mice had similar ETB gene
expression compared to young males in both genotypes.
Both FF/-- and FF/Tie2 female mice exhibited a trend towards reduced ETA gene
expression, although this only reached statistical significance when comparing old
male with young female FF/Tie2 mice. Both old and young male FF/-- mice
112
exhibited similar ETA expression, although FF/Tie2 old males had significantly
increased ETA expression compared to young male FF/Tie2 mice.
Age and sex had no significant effect on ECE-1 expression in either genotype.
3.3 DISCUSSION
3.3.1 Knockout of exons 3 and 4 is sufficient to prevent expression of ETB
In accordance with others (Constien et al., 2001; Koni et al., 2001), we have shown
that intercrossing of FF/Tie2 mice results in a proportion of the progeny having a
spotted coat or piebald appearance (see Figure 3-4). These animals had the
phenotype of ETB receptor null animals (Gariepy et al., 1996; Hosoda et al., 1994):
as well as the altered coat colour pattern (due to impaired neural crest-derived
melanocyte migration) they do not survive beyond weaning due to obstructive
aganglionic megacolon. This phenomenon of germ line recombination was used to
deliberately generate mice homozygous for the recombined ETB receptor allele, to
test the hypothesis that exons 3 and 4 of the ETB receptor gene are required for
functional ETB receptor expression. In theory, truncated ETB receptors, lacking the
protein sequences coded by exons 3 and 4, might still be functional. However, mice
homozygous for the recombined allele displayed the lethal piebald phenotype of ETB
null animals, confirming that deletion of exons 3 and 4 via Cre/loxP mediated
recombination is sufficient to prevent normal ETB receptor function. These findings
are reinforced by the publication of a strain of ETB receptor null mice in which a
deletion of exons 3 and 4 has been demonstrated (Matsushima et al., 2002).
3.3.2 Sex linked germ line recombination
Other groups (B.R. Duling, University of Virginia, USA, Personal Communication;
(Koni et al., 2001) have found that the rate of germline recombination of the Tie2-
Cre transgene is sex linked – germline recombination occurs at a higher frequency
when transmitted though the female parent. In order to determine whether a similar
linkage of germline recombination with parental gender existed in our colony, a
number of reciprocal analytical crosses were established. FF/Tie2 animals were bred
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with wild type mice heterozygous for the recombined allele (W0/-- mice). The
percentage of piebald mice in the progeny would be expected to be around half the
proportion of gametes, produced by the FF/Tie2 parent, with the recombined (0)
allele. Whilst the proportion of piebald mice were higher in the breeding pairs where
the mother rather than the father carried the Tie2-Cre transgene, the total number of
animals born to these litters was disappointingly small. The number of pups
produced by these pairs was much lower than that produced by the matings where
the male carried the Tie2-Cre transgene. This is because, although FF/Tie2 males
were each tested by pairing them to 2 W0/-- females, female FF/Tie2 mice could
only be paired with a single W0/-- male.
Furthermore, a much lower incidence of piebalds was observed in these analytical
litters, than would be expected if the majority of gametes from female FF/Tie2 mice
underwent germline recombination as reported by others (Koni et al., 2001). If this
was indeed the case then ~50% of the pups, from crosses where the mother carried
the Tie2-Cre transgene, should have expressed the ETB receptor null phenotype.
Some analytical crosses generated no piebalds whatsoever. There are a number of
possible explanations for this.
Firstly, the low incidence of piebalds generated from the analytical breeding pairs
could be due to reduced activity of the Tie2-Cre transgene. If this transgene had
become inactivated during the breeding required for the establishment of our colony,
then germline recombination would not occur and null ETB mice would not be
produced. However, in the initial phenotyping experiments, FF/Tie2 mice
demonstrated reduced ETB binding in enriched ECs and attenuated endothelial
dependent ETB mediated vasodilatation of aortic rings (see section 1.3.6). These data,
together with our lacZ/GFP reporter and radiolabelled quantitatative autoradiography
studies, demonstrate that the Tie2-Cre is active and effective, resulting in
recombination in both the reporter and the floxed ETB mice.
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Alternatively, germline recombination may well be a variable event: whereas one
animal may be highly likely to produce many gametes with a recombined ETB allele,
other animals may do this only infrequently. The mechanism and timing of germline
recombination is poorly understood, but may result from demethylation events that
occur during gametogenesis. We have observed offspring of FW/Tie2 females that
are heterozygous for the recombined allele but do not possess the Tie2-Cre
transgene. This suggests that recombination events occur during gametogenesis prior
to segregation of the floxed allele and the Tie2-Cre transgene. The phenomenon of
ubiquitous Cre-mediated recombination due to loss of normal spatial regulation of
transgene expression does not appear to be limited only to the Tie2-Cre transgene.
Progeny of male mice carrying both a floxed allele and the inner medullary
collecting duct-specific Cre transgene, AQP2-Cre, demonstrate ubiquitous Cre-
mediated recombination (Nelson et al., 1998). However, studies with R26R-lacZ
reporter animals have demonstrated that male AQP2-Cre transgenic mice express
Cre recombinase in postmeiotic sperm (Nelson et al., 1998; Stricklett et al., 1998).
Thus the sex linked ubiquitous Cre-mediated recombination may be due to the
normal spatial pattern of AQP2-Cre expression, rather than dysregulation during
gametogenesis. In contrast, offspring from female AQP2-Cre mice show collecting
duct-specific and male reproductive tract–specific Cre-mediated recombination
(Nelson et al., 1998; Stricklett et al., 1998).
Another possibility is that many of the null ETB progeny died in utero or in the early
neonatal period from some currently unknown pathology. However, this is not
supported by developmental studies that failed to identify a lethal phenotype of ETB
null mice before weaning (Hosoda et al., 1994). There would have been no way of
accurately assessing these 2 possibilities in our experiment. Post mortem
examination of the pregnant females to look for in utero deaths, as well as counting
bodies of dead new-born mice, would not have been helpful as such young animals
are bald and have not yet developed the characteristic piebald coat pigmentation.
Also disturbing new-born suckling litters to look for dead young often with results in
murine infanticide (C Mackenzie, BRR [Biomedical Research Resources],
University of Edinburgh, Personal communication). Any dead pups could have been
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genotyped using the Southern blot, but unfortunately, it had not yet been optimised
by this stage of the project.
Although involving only small numbers of animals, these breeding experiments
allow a number of limited conclusions to be drawn. The recombination event occurs
with a low frequency in our colony overall, although this increases when the Tie2-
Cre transgene is transmitted through the female parent. It soon became clear that to
use analytical breeding as a method to reliably identify FF/Tie2 mice with a low rate
of germline recombination, would involve a very large number of animals over an
extended period. This would not only be expensive, but also be contrary to the
principles of ‘reduction, replacement and refinement’ advocated by H.M. Home
Office Guidelines (www.homeoffice.gov.uk/comrace/animals/reference.html - 3rs).
Therefore other strategies were employed to identify animals heterozygous for
germline recombination.
3.3.3 Genotyping strategies
Rather than rely on Southern analysis for genotyping, which, as a multi-step process,
takes a number of days to perform and involves radiolabelling of probes, attempts
were made to develop a swift, reliable and less expensive method of genotyping the
EC ETB receptor down-regulated mice.
3.3.3.1 ‘COMPARITIVE’ PCR
PCR tends to preferentially amplify bands of smaller length (PCR product
competition). Therefore, although many more cells in the tail/ ear biopsy from the
F0/Tie2 animal contain the recombined (0) allele, it was not possible to directly
compare the intensity of the 230 bp ‘0’ band with that from FF/Tie2 mice. Both were
preferentially amplified in the PCR process and appeared with equal intensity.
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3.3.3.2 GENOTYPING OF NON-EC TISSUE: HAIR
The bulbs of hairs were harvested, in the expectation that such tissue would have a
low EC content. However, in animals likely to be FF/Tie2, the 230 bp ‘0’ band
appeared more frequently in the PCR performed on DNA from hair bulbs than from
tail DNA. This suggests that the hair bulb contains a very high proportion of ECs.
Alternatively, in the smaller sample of DNA from the hair bulbs, PCR product
competition is more likely to have occurred than in the larger sample of DNA from
the tail sample. Thus a ‘0’ band appeared more frequently in the hair sample than the
tail sample PCR.
3.3.3.3 GENOTYPING OF NON-EC TISSUE: TESTES
Our initial assumption was that germline recombination of the floxed ETB gene, seen
in our piebald mice, occurred following fertilisation at some stage in the developing
embryo. For this reason, testes from experimental animals were harvested, in the
belief that they would yield a non-EC rich population. However, soon after this, we
discovered that F0/-- mice arose from FW/Tie2 intercrosses, strongly suggesting that
germline recombination occured during gametogenesis. Thus it is likely that
experimental animals that are FF/Tie2, might have had sperm in their testes in which
recombination had taken place. Tissue from testes containing such sperm would
amplify the 230 bp ‘0’ band at PCR. Therefore this technique was also abandoned as
a fundamentally flawed method of distinguishing FF/Tie2 from F0/Tie2 mice.
3.3.3.4 GENOTYPING OF NON-EC TISSUE: HEART
Cardiomyocytes were crudely isolated, aiming to produce a population of EC-free
cells. Thus any 230 bp ‘0’ band seen in the DNA extracted from this tissue would be
due to germline recombination (ie F0/Tie2 mice) rather than due to recombination
only within ECs (FF/Tie2 mice). Unfortunately ‘0’ bands were seen both in samples
extracted from these crudely isolated cardiomyocytes as well as in samples from
whole heart tissue, even in mice identified as very likely FF/Tie2 by analytical
breeding. It is likely that our population of crudely isolated cardiomyocytes
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contained numerous endocardial cells as well as tissue arising from the mesenchymal
ventricular outflow tract of the heart. Such tissue has been shown to express Tie2
(Kisanuki et al., 2001) and so perhaps it is not surprising that using this method
failed to distinguish FF/Tie2 animals from F0/Tie2 mice. We could have verified the
homogeneity of our cardiomyocyte population, by sorting using cell-specific
markers, but as we required a routine and convenient method of genotyping that
could be applied to all experimental animals, this approach was not suitable.
3.3.3.5 GENOTYPING BY SOUTHERN ANALYSIS
Due to the ubiquity of the vascular endothelium, finding a tissue that can be easily
and routinely isolated, yet contains few ECs, is challenging. After unsuccessfully
attempting this with a number of different tissues, attention was then focussed on
development of the Southern blot to genotype the mice.
Unlike PCR, the Southern analysis does not involve an exponential amplification
phase. Thus the density of bands produced in a Southern analysis more accurately
reflects the amount of tissue expressing the recombined allele within a tail biopsy. In
this way, PCR product competition is avoided. Southern analysis, in contrast to PCR,
did not detect the recombined allele in FF/Tie2 animals, presumably because of the
small proportion of tail DNA derived from ECs, whereas a band is observed in
piebald mice (00/Tie2) as well as heterozygous mice (F0/Tie2).
3.3.4 Endothelial cell specific Cre expression
3.3.4.1 BREEDING WITH LACZ R26R MICE
Renal tissue from adult F1 mice, arising from intercross of WW/Tie2-Cre and R26R
animals, show a pattern of lacZ staining, in medullary rays, glomerular capillaries
and arterioles, identical to that of EC staining using antibodies to CD31. This
demonstrates that endothelial specific manner expression of the Tie2-Cre transgene
is preserved in our colony, as in other colonies (Liao et al., 2001) derived from the
same original strain of Tie2-Cre mice (Kisanuki et al., 2001).
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3.3.4.2 BREEDING WITH GFP REPORTER MICE
By crossing WW/Tie2-Cre mice with GFP reporter mice (Gilchrist et al., 2003), we
have shown that the distribution of Cre recombinase is restricted to the endothelium.
This represents further good evidence that the Tie2-Cre mice generously provided by
Dr Y. Kisanuki and Prof Misashi Yanagisawa do indeed exhibit EC specific Cre
recombinase expression.
3.3.5 EC specific ETB down-regulation in FF/Tie2 mice
Having shown that Tie2-Cre expression was specific to ECs, we went on to
demonstrate that the Cre/lox based approach was effective in down-regulating the
ETB gene from ECs. Work using the same Tie2-Cre line has shown ~80% deletion of
the floxed allele in EC specific Connexin-43 knockout mice (Liao et al., 2001).
Previous studies in our laboratory have measured the ETB mediated binding of [125I]-
ET-1 in a population of enriched pulmonary ECs. In ECs from FF/Tie2 tissue, such
binding was reduced by ~80%, whereas ETA binding was preserved (see section
1.3.6.1) (Bagnall et al., 2006). EC ETB receptor-mediated responses, assessed using
aortic ring wire myography, were significantly impaired in tissue from FF/Tie2 mice
(see section 1.3.6.2), whereas responses dependent upon non-EC ETB receptor
activation were preserved (see section 1.3.6.3) (Bagnall et al., 2006). These
myography studies provide functional evidence of significant EC specific ETB down-
regulation in FF/Tie2 mice. Using autoradiography, for the first time in the
phenotyping of a cell type specific transgenic knockout/knockdown animal, we have
further demonstrated EC specific down-regulation of the ETB in our FF/Tie2 mice.
ETB binding was reduced in tissues with a high content of ECs (such as renal
medulla, liver sinusoids and lung parenchyma) by >90% but relatively preserved in
tissues with a reduced EC content (liver parenchyma and alveolar bronchioles).
Furthermore, by showing similar ETB receptor expression in FF/-- and WW/--
animals, we have provided strong evidence that the insertion of loxP sites on either
side of exons 3 and 4 of the ETB receptor gene, in the absence of the bacteriophage
enzyme Cre recombinase, does not alter the physiological expression of the ETB
receptor.
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3.3.6 Expression of other components of the ET system in the FF/Tie2 mouse
Using ETA specific radiolabelled ligands we have also used quantitative
autoradiography to investigate how EC ETB downregulation affects expression of
ETA receptors. The high plasma concentration of ET-1 in the FF/Tie2 mice (see
section 5.3.1) might be expected to result in downregulation of ETA, as found in the
renal tissue of ETB deficient rats (Taylor et al., 2003b) and in vascular tissue in a
hypertensive rat model of ET-1 overexpression (Telemaque-Potts et al., 2002).
However, ETA binding in our FF/Tie2 mice was preserved. Similarly EC specific ET-
1 overexpressing mice, which also feature raised plasma concentrations of ET-1,
have recently been shown to have preserved levels of vascular ETA gene expression
(Amiri et al., 2004). The authors argue that the lack of hypertension observed in
these mice is due to a compensatory increase in expression of vascular vasodilatory
ETB. Different species may display different compensatory mechanisms to
perturbations in the ET system, often with the result of stabilising BP. Raised ET-1
concentrations in the rat result in reduced ETA expression, whereas mice exhibit
increased ETB expression. Binding studies in ET-1 overexpressing murine models
(Hocher et al., 1997; Shindo et al., 2002) have yet to be carried out.
We conclude that our model shows autoradiographical evidence of EC-ETB down-
regulation, which has no effect on the expression of the ETA receptor.
To determine the expression of other components of the ET system, within the
kidney, we have performed semi-quantitative end-point RT-PCR, which allows
assessment of gene expression. Whilst this technique is straightforward and easily
applicable to a wide range of different ligand systems, it only gives a measure of
gene expression, which may not be directly related to the level of protein expression.
Others have shown that the correlation between mRNA and protein levels is
insufficient to predict protein expression levels from quantitative mRNA data (Gygi
et al., 1999). Indeed, for some genes, while the mRNA levels are of the same value,
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the protein that is expressed varies by more than 20-fold. Conversely, invariant
steady-state levels of certain proteins were observed with respective mRNA
transcript levels that vary by as much as 30-fold (Gygi et al., 1999). RT-PCR
quantifies the amount of products of transcription of DNA into mRNA. It cannot
give an indication of the rate of translation of mRNA into protein. Other techniques
such as Western Blot analysis or quantitative autoradiography must be used to
accurately determine protein expression. However, unlike semi-quantitative RT-
PCR, these techniques require the generation of expensive radiolabelled probes or
ligands, and are unable to detect very low levels of gene expression. Here we have
used RT-PCR to determine expression of the ET system in the kidney of both control
and FF/Tie2 mice of different ages and sex. As discussed above, we have used
autoradiography to quantify ETA and ETB receptor expression in tissue from young
male FF/-- and FF/Tie2 mice. These data were used to corroborate the RT-PCR
results.
Across all groups ETB gene expression in the kidney, an organ with a high content of
endothelium, was down-regulated in the FF/Tie2 compared to FF/-- mice. This was
also demonstrated by the quantitative autoradiography experiments using the
radiolabelled ETB ligand [125I]-BQ3020, and is consistent with significant EC-
specific ETB receptor down-regulation. Furthermore, ETA and ECE-1 expression in
male FF/Tie2 mice was not significantly different to that in control male animals.
The former was also seen in the autoradiography experiments.
It is interesting that young female FF/-- mice demonstrate much greater ETB gene
expression than male animals. The females also demonstrate a trend towards lower
ETA expression. Whilst this may represent a true sex difference, the unexpected
finding could be caused by experimental error and/ or variation due to oestrus cycle.
Due to limitations of our breeding programme at the time these experiments were
performed, some of these studies only involved a small number of animals (n = 3).
Therefore this surprising result could merely be due to low numbers and a relatively
large experimental error. However, as can be seen from Figure 3-21, the error bars
are small. Another possibility is that the high ETB gene expression is caused by the
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effect of the oestrus cycle. ETB receptor expression is regulated by 17-β oestradiol in
cardiac tissue (Nuedling et al., 2003), and the expression of other GPCRs such as β1-
adrenoreceptors (Kam et al., 2004) and AT1 receptors (Nickenig et al., 1998) can
alter with the administration of oestrogen. In our studies, we failed to control for the
oestrus cycle when sampling kidneys from the female mice. Other studies have
shown a sex difference in ET receptor expression. Female rats show a reduced
haemodynamic response to exogenous ET-1 compared with male rats (Tatchum-
Talom et al., 2000). In human saphenous vein studies, increased ETB receptor
expression has been demonstrated in women compared to men (Ergul et al., 1998;
Kellogg et al., 2001). Expression of eNOS, which mediates the action of EC ETB
receptor activation is also increased in female rats (Taylor et al., 2003a). Increased
nicotinamide-adenine dinucleotide phosphate (NAD(P)H) oxidase activity and
superoxide production is associated with increased ETB gene expression, in a model
of EC specific ET-1 overexpression (Amiri et al., 2004). Thus a gender difference in
oxidative stress (Baba et al., 2005; Borras et al., 2003) may partly explain the
observed increased ETB:ETA expression demonstrated by female mice in my study.
The effect of gender on the gene expression of components of the ET-1 system
supports our group’s earlier decision to include young male mice only in our studies.
If experimental and control groups were composed of different proportions of male
and female mice, then measured variables might differ due to gender differences in
ET-1 system expression rather than due to the effect of EC-specific ETB receptor
down-regulation.
Age, in contrast to gender, was seen to have less of an effect on renal ET system
expression. The kidneys of 12-month old male mice exhibit a broadly similar pattern
of renal ET system expression in comparision to young males. This differs from rats
where kidneys have been shown to demonstrate decreased ETA and increased ETB
receptor expression with age (Hocher et al., 1995).
Down-regulation of EC ETB in both male and female mice had no significant effect
on the expression of ECE-1 mRNA. In contrast, studies performed with cultured rat
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ECs, have revealed that ET-1 acts in an ETB dependent manner to inhibit both the
mRNA and protein levels of ECE-1 (Naomi et al., 1998). As we did not find
increased gene expression following down-regulation of EC ETB, our work suggests
that ET-1 is acting via ETB receptors that are expressed on cells other than ECs.
Thus, by generating null ETB mice, we have demonstrated that recombination of the
ETB gene, resulting in excision of exons 3 and 4 is sufficient to prevent expression of
the ETB receptor. The Tie2 promoter restricts Cre expression to the endothelium, and
so when floxed ETB mice are crossed with Tie2-Cre mice, mice featuring EC-
specific ETB receptor down-regulation are produced. The autoradiography data
provide evidence of EC specific ETB receptor down-regulation in the FF/Tie2 mice.
Finally, we have shown that EC ETB receptor expression has minimal effect on either
ETA or ECE-1 expression in young male mice.
123
4  CHAPTER 4: ROLE OF THE EC-ETB RECEPTOR IN THE
CONTROL OF SYSTEMIC BP
4.1 INTRODUCTION
Defining the role played by the ETB receptor in the control of systemic BP is
complicated due to the opposing action of ETB receptors expressed on neighbouring
cell types. For example activation of ETB receptors on ECs promotes release of NO
and PGI2, causing vasodilatation, whereas VSM ETB receptors act to increase
intracellular calcium, resulting in vasoconstriction (Gray et al., 1996). ETB receptors
are also responsible for scavenging ET-1 from the plasma (Berthiaume et al., 2000;
Burkhardt et al., 2000; Fukuroda et al., 1994), preventing increased vasoconstrictive
ETA receptor activation due to elevated plasma ET-1 concentrations. Furthermore
ETB receptors are also central to the maintenance of sodium homeostasis (Clavell et
al., 1995; Kohan, 1997).
Studies with pharmacological antagonists have helped to reveal the action of ETB
receptor activation on BP. ETB receptor blockade with BQ788 causes similar forearm
vasoconstriction as that seen with NOS inhibition, suggesting that ETB receptors
cause tonic vasodilatation mediated by NO (Verhaar et al., 1998). Further work has
confirmed that such selective ET receptor blockade has an equivalent effect on
systemic haemodynamics (Spratt et al., 2001; Strachan et al., 1999).
Animal models featuring genetic disruption of the ETB receptor have also provided
useful insights into the role of the ETB receptor in BP control. Several groups have
shown ETB deficient rodents to demonstrate hypertension (Berthiaume et al., 2000;
Ohuchi et al., 1999), which is sensitive to salt loading (Gariepy et al., 2000;
Murakoshi et al., 2002; Quaschning et al., 2005). This salt sensitive hypertension is
normalised by the sodium channel, ENaC, inhibitor amiloride (Gariepy et al., 2000),
suggesting that tonic ETB activation exerts its natriuretic effect by inhibiting ENaC.
IMCD specific ET-1 KO mice have also been shown to demonstrate salt sensitive
hypertension (Ahn et al., 2004), suggesting that ET-1 from IMCD cells acts locally
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at ETB receptors to regulate natriuresis. However, IMCD specific ETB down-
regulated mice exhibit salt sensitive hypertension that is less marked than that
observed in IMCD ET-1 KO mice (Ge et al., 2006), suggesting that ETB located on
cells other than IMCD (such as ECs) may be important in sodium excretion.
The aim of this study was to determine whether endogenous activation of the EC ETB
receptor, through either its effect on natriuresis or on vascular tone, influences the
control of systemic BP. Studies using pharmacological blockade or genetic
disruption of the ETB receptor prevent ETB receptor activation on all cell types
concurrently. The relative contribution of the EC ETB receptor to the control of
systemic BP has not been assessed without the confounding influence of
simultaneous loss of ETB receptor signalling on all other cell types, including the
renal tubular cells and VSMCs. EC specific downregulation of ETB receptor
expression therefore, provides an unique and powerful method by which to examine
the relative contribution of ETB receptor signalling, in a single cell type, to the
regulation of complex physiological systems, such as the control of systemic BP.
BP measurement was carried out in mice using a variety of different techniques.
Initial data were acquired by measuring systemic BP under anaesthesia, before
moving to chronic carotid artery cannulation, which allowed measurements to be
taken under conscious non-restrained conditions. Data were compared on normal and
high salt diet. Finally, in order to further improve the quality of our data,
radiotelemetry devices were implanted in the mice which allowed for longitudinal
studies to be performed on the animals investigating the effect low and high salt diet
as well as ET receptor blockade on BP control.
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4.2 METHODS/PROTOCOLS
4.2.1 Measurement of BP under anaesthesia
FF/Tie2 and control mice were anaesthetised with isoflurane and their BP measured
by means of carotid cannulation as described in section 2.7.
4.2.2 Measurement of BP under conscious unrestrained conditions using fluid
filled catheters    
Following 3 weeks of feeding with either normal or high salt powdered diet, carotid
artery catheters were inserted into FF/Tie2 and control mice under anaesthesia,
brought to the skin in the interscapular region, flushed and capped as described in
section 2.8.2. The catheters were flushed at 24 hours, and used to measure BP 48
hours post operatively (see section 2.8.2).
4.2.3 Continuous measurement of BP under conscious unrestrained conditions
using radiotelemetry    
In the 7 days prior to insertion of the radiotelementry devices, the mice were housed
singly and fed normal salt diet to allow them to habituate to their surroundings. The
radiotelementry devices were inserted as detailed in section 2.8.3. Due to limited
numbers of receiving pads a maximum of 20 mice could be studied at any one
period. Therefore the study was conducted in 2 phases, according to the protocols
below (Figure 4-1 and Figure 4-2). Body weight, gel intake and water consumption
were measured daily. Data was analysed and compared between genotypes and
treatment periods as described in section 2.8.3.
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Figure 4-1: Study protocol for the first phase of the telemetry BP study
Radiotelemetry devices were inserted into equal numbers (n = 10) of FF/Tie2 mice and FF/-- controls. In week 1 the mice were fed normal
salt (0.76% NaCl) diet; in week 2 low salt (0.076% NaCl) diet; in week 3 high salt (7.6% NaCl) diet; and in the final week high salt diet
plus the ETA antagonist ABT627 (5 mg.kg-1.day-1). Mice were given access to drinking water ad libitum throughout the course of the study.
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Figure 4-2: Study protocol for the second phase of the telemetry BP study
During the first four weeks, the mice were treated as in the first study. In week 5 the mice were fed normal salt (0.76% NaCl) diet; in week
6 high salt (7.6% NaCl) diet plus the ETB antagonist A192621 (30 mg.kg-1.day-1); and in the final week 2.5% NaCl. For the first 6 weeks of
the study mice were given ad libitum access to drinking water. In the final week, whilst fed 2.5% NaCl gel diet they were allowed access to
0.9% saline ad libitum.
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At the end of the study, mice were culled by cervical dislocation, and blood collected
by direct cardiac puncture for haemocrit determination. Hearts were harvested and
the right ventricle (RV) and left ventricle plus septum (LV+S) weights were
determined.
Hearts and chamber weights were also assessed for a separate cohort of aged (52-60
week old) male mice fed only normal salt (0.76% NaCl) diet.
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4.3 RESULTS
4.3.1 Measurement of BP under anaesthesia
Using fluid filled catheters, inserted into the common carotid artery, to measure BP
gave a rather damped trace. Sample traces for individual WW/-- and FF/Tie2 mice
are shown (Figure 4-3 and Figure 4-4). Due to the low pulse pressure observed with
these catheters, only mean arterial BP (MABP) was recorded.
Figure 4-3 Representative BP trace of an anaesthetised WW/-- mouse.
Five-second sample from the arterial BP recording, performed using fluid filled
carotid catheters in anaesthetised mice.
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Figure 4-4 Representative BP trace of an anaesthetised FF/Tie2 mouse.
Five second sample from the arterial BP recording, performed using fluid filled
carotid catheters in anaesthetised mice.
The MABP of the FF/Tie2 mice (97.0 ± 3.59 mmHg; n=6) was significantly higher
than that of controls (80.08 ± 3.96 mmHg; n=12; p<0.05) when measured under
isoflurane anaesthesia. These results are illustrated in Figure 4-5 below.
Figure 4-5: MABP of anaesthetized animals
Mean arterial BP of anaesthetised WW/-- and FF/Tie2 mice on normal salt diet
(*p<0.05, student’s T test).
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There was no difference in heart rate between and the WW/-- (mean ± SEM: 540 ±
22.1 bpm) and FF/Tie2 animals (534 ± 30 bpm).
4.3.1.1.1 Measurement of BP under conscious unrestrained conditions using fluid
filled catheters
In the 21 days prior to carotid catheter surgery, the mean weights of all four groups
of mice did not fall, indicating that normal and high salt diets were well tolerated
(Table 4-1). The weight of the WW/-- mice fed normal salt diet was significantly
greater than those in other groups.
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Table 4-1: Pre-surgery weights
Mean body weight (BW) (± SEM) of WW/-- and FF/Tie2 mice fed either normal










Diet 0.76% NaCl 0.76% NaCl 7.6% NaCl 7.6% NaCl
BW 21 days prior to
surgery
36.20 ± 1.77 * 26.03 ± 0.99 20.00 ± 1.50 26.82 ± 1.77
BW at surgery 36.20 ± 1.90 * 27.38 ± 1.05 25.35 ± 2.38 27.58 ± 1.35
As with the studies performed on anaesthetised animals, the BP traces obtained using
the fluid filled intra-carotid catheters 48 hours after the carotid artery cannulation
surgery gave artefactually small pulse pressures (Figure 4-6).
Figure 4-6 Representative BP traces of conscious unrestrained mice.
Five second sample from the 30 minute recording period in 2 individual conscious
unrestrained mice (one of each genotype), performed 48 hours following carotid
artery catheter insertion.
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The MABP of FF/Tie2 mice (137.2 ± 6.4 mmHg) was significantly elevated
compared to controls (113.7 ± 4.7 mmHg; p<0.05). High salt diet did not
significantly alter the MABP of either genotype (FF/Tie2: 141.0 ± 6.7 mmHg; WW/-
-: 118.3 ± 5.0 mmHg; p<0.05) (Figure 4-7).
Figure 4-7: MABP of unrestrained conscious mice
MABP of WW/-- and FF/Tie2 fed on either normal or high salt chow, measured
under conscious unrestrained conditions via carotid cannulation. (* p<0.05).
The heart rate of FF/Tie2 mice (543 ± 51 bpm) was not statistically different to that
of control animals (473 ± 18 bpm) on normal salt diet, under conscious unrestrained
conditions. Heart rates were unaffected by high salt diet (FF/Tie2: 454 ± 50 bpm;
WW/--: 578 ± 28 bpm) (Figure 4-8).
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Figure 4-8: HR of unrestrained conscious mice
Heart rate of WW/-- and FF/Tie2 fed on either normal or high salt chow, measured
under conscious unrestrained conditions via chronic carotid cannulation. No
differences were seen.
4.3.2 Continuous measurement of BP under conscious unrestrained conditions
using radiotelemetry
Data from the 2 telemetry studies are presented below. The results from the first
study and the initial four weeks of the second study, which both followed the same
sequence of diet/ drug treatments, have been combined to improve statistical power.
The further data from the second study is detailed in the following section.
The ‘6 hour rolling averaged’ data for each of the parameters measured (SBP, DBP,
MABP, and HR) is presented as a series of figures (as described in section 2.8.3):
- a summary trend of 12 hourly values throughout the 4 weeks of the
study;
- hourly values during each separate week of the study;
- bar charts comparing the averaged values over the last 72 hours of
each treatment period; the averaged minimal day-time values during
the last 3 days of the treatment period; and the averaged maximal
night-time values during the last 3 days of the treatment period.
- bar charts showing the difference in BP between genotypes (ie
FF/Tie2 – FF/--) during the different treatment periods.
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4.3.2.1 BOTH STUDIES SYSTOLIC BP






















Figure 4-9: 12 hourly SBP
SBP of FF/-- (n=12) and FF/Tie2 (n=10) mice recorded 12 hourly over the first four
weeks of both studies.
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Figure 4-10: SBP of telemetered mice during the 7 days of normal salt (0.76%
NaCl) diet (week 1) [A] and during the 7 days of low salt (0.076% NaCl) diet
(week 2) [B].
Data shown are hourly rolling averages of the FF/-- (n=12) and FF/Tie2 (n=10) mice.
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Figure 4-11: SBP of telemetered mice during the 7 days of high salt (7.6% NaCl)
diet (week 3) [A] and during the 7 days of high salt + A627 (5 mg.kg-1) diet
(week 4) [B].














































































































































Figure 4-12: Comparison of: the averaged SBP of FF/-- (n=12) and FF/Tie2
(n=10) mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal SBP values during the day [B]; and the averaged maximal
SBP values during the night [C].
During the last 3 days of each treatment period, no differences were seen between
genotypes when the mice were fed low salt (FF/Tie2: 137.4 ± 0.72 mmHg; FF/--:
142.1 ± 2.50 mmHg), normal salt (FF/Tie2: 151.0 ± 4.27 mmHg; FF/--: 149.5 ± 4.02
mmHg) or high salt diet (FF/Tie2: 166.0 ± 2.99 mmHg; FF/--: 162.2 ± 3.81 mmHg)
(Figure 4-12A). The SBP of both FF/Tie2 and control mice rose with increased salt
in the diet (Figure 4-12A) – an effect that was reversed by administration of the ETA
antagonist ABT627 (Figure 4-12A).
Similarly, no differences were seen between genotypes at the extremes of circadian
rhythm – neither around midday (when the mice are most likely to be sleeping) nor
during the middle of the night (when the mice are most likely to be active) (Figure
4-12B and C).
4.3.2.2 BOTH STUDIES – DIASTOLIC BP

























Figure 4-13: 12 hourly DBP
DBP of FF/-- (n=12) and FF/Tie2 (n=10) mice recorded 12 hourly over the first four
weeks of both studies.
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Figure 4-14: DBP of telemetered mice during the 7 days of normal salt (0.76%
NaCl) diet (week 1) [A] and during the 7 days of low salt (0.076% NaCl) diet
(week 2) [B].
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Figure 4-15: DBP of telemetered mice during the 7 days of high salt (7.6%
NaCl) diet (week 3) [A] and during the 7 days of high salt + A627 (5 mg.kg-1)
diet (week 4) [B].

























































































































































Figure 4-16: Comparison of: the averaged DBP of FF/-- (n=12) and FF/Tie2
(n=10) mice during the last 72 hours of each dietary period [A]; the averaged
minimal DBP values during the day [B]; and the averaged minimal DBP values
during the night [C].
During the last 3 days of each treatment period, no difference was seen between
genotypes on low salt (FF/Tie2: 106.6 ± 1.91 mmHg; FF/--: 107.9 ± 1.79 mmHg),
normal salt (FF/Tie2: 116.1 ± 4.29 mmHg; FF/--: 112.2 ± 2.89 mmHg) or high salt
diet (FF/Tie2: 131.9 ± 2.86 mmHg; FF/--: 125.2 ± 2.90 mmHg) (Figure 4-16A).
Increased salt in the diet caused the DBP to rise in both genotypes, an effect that was
reversed by the co-administration of ETA blockade (Figure 4-16A).
During the middle of the day and the middle of the night no differences were seen
between the DBP of FF/Tie2 and control mice (Figure 4-16B and C).
4.3.2.3 BOTH STUDIES – MEAN BP






















Figure 4-17: 12 hourly MBP
MBP of FF/-- (n=12) and FF/Tie2 (n=10) mice recorded 12 hourly over the first four
weeks of both studies.
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Figure 4-18: MBP of telemetered mice during the 7 days of normal salt (0.76%
NaCl) diet (week 1) [A] and during the 7 days of low salt (0.076% NaCl) diet
(week 2)[B].
Data shown are hourly rolling averages of FF/-- (n=12) and FF/Tie2 (n=10) mice.
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Figure 4-19: MBP of telemetered mice during the 7 days of high salt (7.6%
NaCl) diet (week 3) [A] and during the 7 days of high salt + A627 (5 mg.kg-1)
diet (week 4) [B].













































































































































Figure 4-20: Comparison of: the averaged MBP of FF/-- (n=12) and FF/Tie2
(n=10) mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal MBP values during the day [B]; and the averaged minimal
MBP values during the night [C].
No significant difference was seen between genotypes on low (FF/Tie2: 122.7 ± 1.52
mmHg; FF/--: 125.7 ± 1.85 mmHg), normal (FF/Tie2: 133.8 ± 4.0 mmHg; FF/--:
131.5 ± 3.33 mmHg), or high salt diet (FF/Tie2: 149.2 ± 2.71 mmHg; FF/--: 143.9 ±
2.97 mmHg) during the last 3 days of each treatment period (Figure 4-20A). Salt had
a hypertensive effect on the MBP of both genotypes that was reversed by addition of
ABT627 (Figure 4-20A).
Even at the extremes of circadian rhythm – during the middle of the day and around
midnight – FF/Tie2 mice were not shown to be hypertensive compared to FF/--
controls (Figure 4-20B and C).
4.3.2.4 BOTH STUDIES – HEART RATE
























Figure 4-21: 12 hourly heart rate.
Heart rate of FF/-- (n=12) and FF/Tie2 (n=10) mice recorded 12 hourly over a 4-
week period (both studies combined).
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Figure 4-22: Heart rate of telemetered mice during the 7 days of normal salt
(0.76% NaCl) diet (week 1) [A] and during the 7 days of low salt (0.076% NaCl)
diet (week 2) [B].
Data shown are hourly rolling averages of the FF/-- (n=12) and FF/Tie2 (n=10) mice.
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Figure 4-23: Heart rate of telemetered mice during the 7 days of high salt (7.6%
NaCl) diet (week 3) [A] and during the 7 days of high salt + A627 (5 mg.kg-1)
diet (week 4) [B].




















































































































































Figure 4-24: Comparison of: the averaged HR of FF/-- (n=12) and FF/Tie2
(n=10) mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal HR during the day [B]; and the averaged maximal HR values
during night [C].
No difference in HR was seen between genotypes in the last 72 hours of each
treatment period. As expected, the mice were most tachycardic in the week following
surgery (normal salt diet). After this, in contrast to BP, there was no clear
relationship between dietary salt and HR (Figure 4-24A). ETA blockade with
ABT627 had no influence on HR.
No significant difference in HR was seen between genotypes either in the middle of
the day or night (Figure 4-24B and C).
4.3.2.5 BOTH STUDIES – WATER, GEL CONSUMPTION AND BODY
WEIGHT






























Figure 4-25: Average daily water consumption
Water consumed by FF/-- and FF/Tie2 mice when fed normal salt diet (NS), low salt
diet (LS), high salt diet (HS) and high salt diet plus the ETA antagonist ABT627
(5mg.kg-1.day-1).
Water intake increased dramatically with the introduction of high salt diet. Although
FF/Tie2 mice demonstrated a trend toward reduced drinking when fed high salt diet,
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no significant difference in daily water consumption was observed between
genotypes when the mice were fed normal, low or high salt diet (Figure 4-25). When
fed ABT627 as well as high salt diet, FF/Tie2 mice drank significantly less than
controls. However, despite lowering BP in both genotypes compared to the period
when they were fed high salt diet alone, introduction of ABT627 to the high salt diet
had little effect on the water consumption of each genotype.
Figure 4-26: Average daily gel intake
Gel diet consumed by FF/-- and FF/Tie2 mice when fed normal salt diet (NS), low
salt diet (LS), high salt diet (HS) and high salt diet plus the ETA antagonist ABT627
(5mg.kg-1.day-1).
No significant difference in gel intake between genotypes was observed (Figure
4-26).
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Figure 4-27: Average body weight
Body weight of FF/-- and FF/Tie2 mice when fed normal salt diet (NS), low salt diet
(LS), high salt diet (HS) and high salt diet plus the ETA antagonist ABT627 (5mg.kg-
1.day-1).
Although the FF/-- controls were heavier than FF/Tie2 mice immediately prior to
surgery, in the post-operatively this difference disappeared (Figure 4-27).
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Figure 4-28: Weight change versus the previous day
Daily change in weight of FF/-- and FF/Tie2 mice when fed normal salt diet (NS),
low salt diet (LS), high salt diet (HS) and high salt diet plus the ETA antagonist
ABT627 (5mg.kg-1.day-1).
Body weight and gel intake decreased in the days immediately following surgery, but
by the end of the first 7-day treatment period, the mice were eating and drinking
normally, showing no further weight loss (Figure 4-28). As in other studies (Ahn et
al., 2004), mice ate most of what gel was offered to them, although intake and body
weight fell slightly with the introduction of high salt diet in both genotypes.
155
4.3.2.6 SECOND STUDY – SYSTOLIC BP






















Figure 4-29: 12 hourly SBP
SBP of FF/-- (n=7) and FF/Tie2 (n=6) mice recorded 12 hourly over the 7-week of
the second study (second study data only).
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Figure 4-30: SBP of telemetered mice during the second week of normal salt
(0.76% NaCl) diet (week 5) [A], during the 7-days of high salt (7.6% NaCl) +
A192621 (week 6) [B] and during the 7 days of 2.5% NaCl diet (week 7) [C].
Data shown are hourly rolling averages of the FF/-- (n=7) and FF/Tie2 (n=6) mice.





























































































































































































































Figure 4-31: Comparison of: the averaged SBP of FF/-- (n=7) and FF/Tie2 (n=6)
mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal SBP values during the day [B]; and the averaged maximal
SBP values during the night [C].
In the second extended study no significant difference in SBP during the last 72
hours of each treatment period was seen between genotypes on low salt diet
(FF/Tie2: 135.2 ± 1.71 mmHg; FF/-- 143.1 ± 4.17 mmHg), normal salt diet in week
1 (FF/Tie2: 148.8 ± 3.76 mmHg; FF/-- 150.1 ± 6.95 mmHg) normal salt diet in week
5 (FF/Tie2: 140.4 ± 2.80 mmHg; FF/-- 141.1 ± 6.85 mmHg), 2.5% salt diet (FF/Tie2:
153.1 ± 4.23 mmHg; FF/-- 151.1 ± 7.12 mmHg), or high salt diet (FF/Tie2: 164.2 ±
4.72 mmHg; FF/-- 163.1 ± 5.89 mmHg) (Figure 4-31A). In week 5 (second period of
normal salt diet), after several weeks to recover from the stress of telemetry surgery,
the SBP of both genotypes was marginally lower than during the first normal salt
period (week 1). As seen with the combined data from both studies, increasing the
proportion of salt in the diet raised SBP in both genotypes. ABT627 caused the SBP
of both genotypes to fall, and A192621 exerted a hypertensive effect, but these
changes both failed to reach statistical significance due to the limited numbers of
animals in this second study.
No differences between genotypes were seen at the extremes of circardian rhythm –
neither during the middle of the day nor the middle of the night (Figure 4-31B and
C).
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4.3.2.7 SECOND STUDY-DIASTOLIC BP

























Figure 4-32: 12 hourly DBP
DBP of FF/-- (n=7) and FF/Tie2 (n=6) mice recorded 12 hourly over the 7-week of
the second study (second study data only).
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Figure 4-33: DBP of telemetered mice during the second week of normal salt
(0.76% NaCl) diet (week 5) [A], during the 7-days of high salt (7.6% NaCl) +
A192621 (week 6) [B] and during the 7 days of 2.5% NaCl diet (week 7) [C].
Data shown are hourly rolling averages of the FF/-- (n=7) and FF/Tie2 (n=6) mice.






































































































































































































































Figure 4-34: Comparison of: the averaged DBP of FF/-- (n=7) and FF/Tie2
(n=6) mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal DBP values during the day [B]; and the averaged maximal
DBP values during the night [C].
No significant difference in DBP was seen between genotypes, during the last 72
hours of each treatment period, on low salt diet (FF/Tie2: 103.2 ± 0.63 mmHg; FF/--
105.5 ± 2.65 mmHg), normal salt diet in week 1 (FF/Tie2: 112.0 ± 2.51 mmHg; FF/-
- 111.6 ± 4.78 mmHg) normal salt diet in week 5 (FF/Tie2: 107.6 ± 1.19 mmHg;
FF/-- 105.3 ± 3.63 mmHg), 2.5% salt diet (FF/Tie2: 118.5 ± 2.42 mmHg; FF/-- 114
± 3.64 mmHg), or high salt diet (FF/Tie2: 127.0 ± 3.02 mmHg; FF/-- 122.3 ± 3.05
mmHg) (Figure 4-34A). Increased salt in the diet resulted in increased DBP in both
genotypes. ABT627 lowered DBP and A192621 had the opposite effect, but again
both of these failed to reach statistical significance.
No differences were seen between genotypes when comparing the maximum values
at night, the minimum periods during the day and the average values during the last 3
days of each treatment period. Thus circadian rhythm appeared to exert little
influence on the differences seen between the genotypes (Figure 4-34A, B and C).
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4.3.2.8 SECOND STUDY – MEAN BP
























Figure 4-35: 12 hourly MBP
MBP of FF/-- (n=7) and FF/Tie2 (n=6) mice recorded 12 hourly over the 7-week of
the second study (second study data only).
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Figure 4-36: MBP of telemetered mice during the second week of normal salt
(0.76% NaCl) diet (week 5) [A], during the 7-days of high salt (7.6% NaCl) +
A192621 (week 6) [B] and during the 7 days of 2.5% NaCl diet (week 7) [C].
Data shown are hourly rolling averages of the FF/-- (n=7) and FF/Tie2 (n=6) mice.




























































































































































































































Figure 4-37: Comparison of: the averaged MBP of FF/-- (n=7) and FF/Tie2
(n=6) mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal MBP values during the day [B]; and the averaged maximal
MBP values during the night [C].
Over the last 3 days of each treatment period, no significant difference in MBP was
observed between the genotypes on low salt diet (FF/Tie2: 120.0 ± 1.07 mmHg; FF/-
- 125.1 ± 3.22 mmHg), normal salt diet in week 1 (FF/Tie2: 130.9 ± 2.92 mmHg;
FF/-- 131.4 ± 5.72 mmHg) normal salt diet in week 5 (FF/Tie2: 124.7 ± 1.92 mmHg;
FF/-- 124.0 ± 5.05 mmHg), 2.5% salt diet (FF/Tie2: 136.2 ± 3.18 mmHg; FF/-- 133.0
± 5.16 mmHg), or high salt diet (FF/Tie2: 145.6 ± 3.67 mmHg; FF/-- 142.9 ± 4.33
mmHg) (Figure 4-37A). MBP of both genotypes increased with increased salt in the
diet. ABT627 lowered MBP and A192621 increased it, although this failed to reach
statistical significance.
No differences between genotypes were seen during the middle of the night or the
middle of the day (Figure 4-37B and C).
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4.3.2.9 SECOND STUDY – HEART RATE























Figure 4-38: 12 hourly HR
HR of FF/-- (n=7) and FF/Tie2 (n=6) mice recorded 12 hourly over the 7-week of the
second study (second study data only).
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Figure 4-39: HR of telemetered mice during the second week of normal salt
(0.76% NaCl) diet (week 5) [A], during the 7-days of high salt (7.6% NaCl) +
A192621 (week 6) [B] and during the 7 days of 2.5% NaCl diet (week 7) [C].
Data shown are hourly rolling averages of the FF/-- (n=7) and FF/Tie2 (n=6) mice.













































































































































































































Figure 4-40: Comparison of: the averaged HR of FF/-- (n=7) and FF/Tie2 (n=6)
mice during the last 72 hours of each week-long dietary period [A]; the
averaged minimal HR values during the day [B]; and the averaged maximal HR
values during the night [C].
No significant differences in HR were seen between genotypes (Figure 4-40A).
Although ETA blockade lowered BP and ETB blockade had a hypertensive effect,
these agents had no significant effect on HR.
HR was lower during the day than during the night, but even at these extremes of
circadian rhythm no differences were seen between genotypes.
4.3.2.10 SECOND STUDY – WATER, GEL CONSUMPTION AND BODY
WEIGHT
Figure 4-41: Average daily water consumption (second extended study only).
Water consumed by FF/-- and FF/Tie2 mice during the second extended study. No
significant differences between genotypes were seen.
In the second extended study, no significant differences in water consumption were
seen between genotypes (Figure 4-41). Whilst the water intake of mice of both
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genotypes fed the 2.5% NaCl diet was elevated compared to that seen on the normal
salt, it was substantially less than that seen on the high salt diet. Although
introduction of ETB blockade had a non-statistically significant hypertensive effect, it
did not change this high water intake.
Figure 4-42: Average daily gel intake (second extended study only).
Gel diet consumption by FF/-- and FF/Tie2 mice during the second extended study.
No significant differences between genotypes seen.
Gel intake was not different between genotypes, and unlike water intake did not vary
with the different diets/ drug treatments (Figure 4-42).
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Figure 4-43: Average daily body weight (second extended study only).
Body weight of FF/-- and FF/Tie2 mice during the second extended study. No
significant differences between genotypes seen.
Although there was a trend towards the FF/Tie2 mice being lighter than the FF/--
controls this failed to reach statistical significance (Figure 4-43).
4.3.2.11 SECOND STUDY – HAEMATOCRIT
Figure 4-44: Packed cell volume of mice in second study
No significant difference in haematocrit (Packed Cell Volume [PCV]) was seen
between the FF/-- and FF/Tie2 mice at the completion of the second telemetry study.
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At the end of the second study, blood was taken and haematocrit was measured. The
PCV of FF/-- mice (30.9 ± 2.6%) was not different from that of the FF/Tie2 mice
(31.8 ± 3.5%)(Figure 4-44).
4.3.3 Influence of age on heart/ body weight ratio
Hearts were dissected from young mice (aged 8 –12 weeks old) and also from a
smaller sample of older animals (13 - 15 months old). The free right ventricular wall
(RV) was dissected free from the left ventricle plus septum (LV+S), as described in













































Young Mice Old Mice
Figure 4-45: Heart to body weight ratio for young and old mice
Genotype did not affect the ratio of total heart to body weight (BW) for young (8-12
weeks) and old (52-60 weeks) male mice.
Although both genotypes showed a small increase in heart/ body weight ratio with
age, no differences were observed between the 2 genotypes (Table 4-2). Old FF/--
mice were however significantly heavier than FF/Tie2 mice.
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Table 4-2: Heart and body weights for young (2 month old) and old (4 month)
mice
RV= Right ventricle; LV+S= Left ventricle + septum; TV= Total ventricles. For all





































































BP measurement in experimental animals can be performed by several different
techniques, each having their own particular advantages and disadvantages. When
recorded by means of carotid artery cannulation, under both anaesthetised and
conscious unrestrained conditions, we found EC ETB down-regulated mice to exhibit
elevated MBP, unaffected by high salt diet. In contrast, when we went on to confirm
our findings with continuous radiotelemetry measurements, the approach accepted as
the ‘gold standard’ for detecting BP differences in genetically modified animals
(Kurtz et al., 2005; Lorenz, 2002), EC ETB down-regulated mice demonstrated no
significant differences in either SBP, DBP or MBP compared to controls, even when
fed high salt.
Therefore, on the basis of the telemetry results, it seems that down-regulation of the
EC ETB does not result in hypertension or increased sensitivity to dietary salt. This
contrasts with the elevated BP seen in ETB deficient rats (Gariepy et al., 2000),
collecting duct specific ET-1 KO mice (Ahn et al., 2004), and IMCD ETB down-
regulated mice (Ge et al., 2006), and suggests the target for collecting duct derived
ET-1 in the kidney is likely to be ETB receptors situated on cells other than ECs.
4.4.1 Deletion of the EC ETB receptor does not alter the BP response to salt
In our detailed longitudinal telemetry studies, we have shown that down-regulation
of the EC ETB receptor does not result in elevated BP, even in response to a high
sodium diet. Our previous autoradiography studies demonstrated marked down-
regulation of binding of the ETB receptor ligand BQ3020 within the renal medulla of
EC ETB down-regulated mice (see section 3.2.6.3). This suggests that most ETB
receptors within the medulla are expressed on vasa recta ECs (Yukimura et al.,
1996). The residual ETB receptor binding, observed in the renal medulla is likely to
represent the functionally important non EC-ETB receptors, expressed on cells such
as IMCDs or renal interstitial cells.
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The two groups of mice in the radiotelemetry study - both the EC ETB receptor
down-regulated mice and the control animals - demonstrate a clear relationship
between salt intake and BP, complicating the interpretation of our results. Modest
elevations in BP with salt loading have been seen with other mouse strains,
particularly those featuring 2 copies of the renin gene (Wang et al., 2002). The
background of our mice is a mixture of 129/01a, known to harbour 2 copies of the
renin gene (Sharp et al., 1996) and C57BL/6, which have been shown to develop
hypertension following salt loading (Carlson et al., 2000; Gros et al., 2002).
Although we cannot discount the possibility that manipulation of the ETB gene
during gene targeting may have disrupted previously unidentified loci determining
salt sensitivity, this is unlikely as only ~ 1 kB of intron 2 was removed during
floxing (see section 1.3.5). Further studies, following backcrossing of our mice onto
a salt resistant strain, would not only allow more robust conclusions concerning the
effect of EC ETB down-regulation on salt sensitivity to be made, but would also
demonstrate whether floxing has any effect on the BP response to salt.
As previously described in the rat (Pollock et al., 2001), we found that selective
pharmacological antagonism of ETB during high-salt diet led to further increases in
BP in both genotypes, although this failed to reach statistical significance most likely
due to the smaller number of mice included in our second study and the the influence
of salt on our genetic background. In contrast, ETA blockade, introduced whilst the
mice were on high salt diet, decreased BP in both genotypes to a similar extent. This
further reinforces our autoradiography data showing that ETA expression is not
altered in the EC ETB down-regulated mice.
As expected, BP and HR peaked during the night and were lowest during the day, the
periods of fastest and slowest circadian rhythm respectively. However, during these
periods of maximum and minimum activity, similar differences in BP were observed
between genotypes, indicating that down-regulation of the EC ETB receptor does not
have a significant influence on the response to circadian rhythm.
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Other transgenic models, such as the collecting-duct specific ET-1 KO mouse,
exhibit salt sensitive hypertension, thought largely to be due to volume expansion, as
evidenced by elevated daily weight gain (Ahn et al., 2004). Not only were our EC
ETB down-regulated mice not hypertensive on a high salt diet, they displayed no
difference in water intake, daily weight gain or haematocrit compared to controls,
indicating that their intravascular volume was not increased.
There are 2 possible hypotheses explaining the lack of severe hypertension observed
in the EC ETB receptor down-regulated mice.
Firstly, the ET-1/ ETB receptor signalling pathway, regulating tubular reabsorption of
sodium and water, could be entirely dependent on ETB receptors located on cells
other than vasa recta ECs. The importance of ETB receptors on IMCD cells has
previously been demonstrated by the finding that IMCD ETB down-regulated mice
exhibit salt sensitive hypertension (Ge et al., 2006). However, this hypertension was
more modest that that seen in either collecting duct specific ET-1 KO mice (Ahn et
al., 2004) or rescued ETB deficient mice (Quaschning et al., 2005). Thus it is likely
that IMCD derived ET-1 not only acts in an autocrine manner at IMCDs, but also
may act in a paracrine manner at ETB receptors located on other neighbouring cells
types - such as renal intersitial cells. These are present in abundance in the inner
medulla and are adjacent to the collecting duct. Renal interstitial cells not only
express ETA and ETB receptors but they also produce NO and PGE2 in response to
ET-1 (Zhuo, 2000).
Second, the effect of loss of any paracrine IMCD ET-1/ EC ETB signalling pathway
(Kotelevtsev et al., 2001) that might normally regulate natriuresis by alteration of
medullary blood flow (Vassileva et al., 2003) may have been masked by changes in
the glomerular filtration rate. Both ETA and ETB regulate afferent arteriolar
vasoconstriction, whereas EC ETB produces vasodilatation of efferent arterioles
(Inscho et al., 2005). The balance between ET-1 mediated vasoconstriction and
vasodilatation in the glomerulus may be important in determining tubular sodium
delivery.
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Key targets for future studies will thus be to examine the effects of selective IMCD
or renal intersitial cell ETB receptor KO on sodium and water handling and to
determine the influence of vascular (EC and VSMC) ETB receptors on glomerular
function.
4.4.2 BP measurement in mice
The most straightforward way of measuring the BP of a laboratory animal is by
means of a catheter inserted into a central conduit artery, under terminal general
anaesthesia. This has the advantages of not causing pain to the animal studied
(thereby reducing suffering and also limiting the effect of emotional stress on BP),
not requiring the operating skills necessary for recovery surgery, and, some suggest,
dampening any central BP modulation mechanisms (Ohuchi et al., 1999). However,
general anaesthesia has direct inhibitory effects on the cardiovascular system,
resulting in major differences, often opposite, in the integrated responses of
conscious and anaesthetised animals to changes in blood volume or after-load
(Vatner, 1978). Thus, whilst in many situations anaesthetised preparations are the
only way of studying a physiological parameter (such as pulmonary artery pressure –
see chapter 6), BP is best studied in conscious animals (Kurtz et al., 2005; Lorenz,
2002). For these reasons, whilst this approach is useful to hone surgical skills and to
give preliminary data, other techniques were soon adopted.
The indirect measurement of systolic pressure, through tail sphygmomanometry, has
been a standard technique for the long-term evaluation of BP in the conscious rat and
has been applied to the mouse in a variety of studies (Cervenka et al., 1999; Hefler et
al., 2001; Van Vliet et al., 2000). The advantages of this approach are threefold.
Firstly, it is non invasive and so can be used to get repeated BP measurements over
an extended study period. Second, it requires relatively inexpensive equipment
(particularly in comparison to radiotelemetry). Third, its ease of use means it can be
used to screen large groups of animals for systolic hypertension. However, indirect
methods, such as tail cuff syphygmomanometry, have several disadvantages. They
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only measure BP over a very limited number of cardiac cycles, resulting in great
variability between measurements. Furthermore, as these measurements are often
only performed during a brief portion of the day, they provide no information
whatsoever about BP during the night. Second, despite training, rodents remain
significantly stressed by the restraint (Gross et al., 2003; Popovic, 1988), warming
(necessary to ensure adequate tail blood flow) (Bunag et al., 1982) and sleep
disruption (measurements are taken during the day, when mice are usually asleep)
necessitated by tail cuff BP measurement. Heart rates of 650 – 700 beats per minute
have been recorded, compared to rates of ~ 500 in undisturbed mice (Lorenz, 2002).
Furthermore different experimental groups can respond differently to these stresses
(Bidani et al., 1993). Third, indirect methods are only able to determine systolic, not
diastolic pressure and so are therefore unable to give a measure of mean arterial
pressure or pulse pressure. Furthermore, a poor correlation of tail cuff measurements
with direct methods has been demonstrated (Jamieson et al., 1997; Whitesall et al.,
2004). For these reasons, the American Heart Association Council for High Blood
Pressure Research recommends using indirect methods for screening large
populations of animals for systolic hypertension, rather than for quantifying the
relationship between BP and variables such as drug treatment or genotype (Kurtz et
al., 2005). The limitations of the tail-cuff approach require independent verification
of a BP phenotype by an alternative method. For these reasons, we decided not to use
this method.
Direct recording of BP in conscious unrestrained rodents, using a fluid filled catheter
inserted into a major artery, such as the carotid, is well established. After recovery
from the surgery, measurements are taken by connecting to a calibrated pressure
transducer, connected in turn, to an amplifier - recorder set-up. This can be done for
discrete periods or continuously with the use of swivel/ tether systems, which allow
free movement of the animal (Ryan et al., 2002). As well as being relatively
inexpensive (compared to radiotelemetry), this system can be calibrated at any time
during the study, avoiding problems with baseline drift or changes in pressure
transducer sensitivity. However, there are a number of drawbacks to using direct
catheterisation for BP measurement in conscious mice. The surgery can introduce
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infection to the animal. The small size of the animals requires a high level of surgical
skill and meticulous aseptic technique for both implantation and maintenance of the
catheters. Furthermore, damping of pressure signals or complete loss of catheter
function can occur because of clotting or growth of fibrous tissue around the catheter
tip.
Implantation of carotid artery catheters into our mice was associated with a high rate
of morbidity and mortality. Even following alterations and improvements to the
surgical procedure, significant problems were encountered with catheter failure in
the days following implantation. Frequently, flushing of the catheter was associated
with the onset of hemiparesis in the animal, most likely due to an embolic stroke
caused by a clot being dislodged from the tip of the carotid catheter. Such problems
meant that BP could not be reliably recorded more than 48 hours following catheter
implantation. Concerns that the mice might become entangled in the swivel/ tether
system, when unsupervised overnight, meant that this had not been included on the
Home Office Project Licence covering this work. Thus BP was measured only over a
30-minute period, always at the same time of day, as performed in many similar
studies (Curzen et al., 1995; Ohuchi et al., 1999; Stec et al., 2002). Like tail cuff
measurements, this arrangement meant that we could not record BP during the
majority of the 24 hour period. Although the mice were allowed a 30-minute
acclimitisation period, before BP recording began, this may not have allowed full
recovery from the stress associated with the restraint required to connect the mice to
the recording equipment. Despite extensive consultation with others experienced in
the technique (Dr I Sharif, Dr P Hadoke, Ms G Brooker [University of Edinburgh],
Mr H van Wyk [Quintiles]) as well as with the University veterinary surgeons, the
mortality and catheter failure rate remained high. Therefore, after discussions with
the Home Office Inspector, the procedure was eventually removed from the Project
Licence, with the intention for further studies to use radiotelemetry for BP recording.
Ending the study prematurely imposed limits on the number of animals included and
the choice of genotypes studied.
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Wireless radiotelemetry, allows the direct continuous measurement of BP, by means
of a sensing catheter in the carotid artery connected to a transmitter device placed
subcutaneously on the flank of the mouse (Brockway et al., 1991; Butz et al., 2001;
Kramer et al., 2003). There is no need for restraint or tethering, and the length of
recording is limited only by the battery life of the device. Measurements can be made
24-hours/day, including the more active night time hours, which is particularly
important when assessing the BP of nocturnal animals such as mice. Continuous
recording also reduces the variation in estimates of the average BP value (Van Vliet
et al., 2003) and allows the effect of different dietary or pharmacological treatments
to be studied within the same group of animals. Thus the total number of mice
needing to be studied can be reduced.
The major disadvantage of using radiotelemetry to measure the BP of mice is its
great expense. The lack of competition in the market means that both the capital cost
of the equipment, and the price of refurbishment of the devices after each use, have
remained high despite the widening use of this technology. The system can only be
calibrated at the start and finish of each study, requiring estimation of the rate of
device sensitivity change. Furthermore, the size of the PA-C20 device (3.5g), which
we used, could result in pain and distress when placed subcutaneously in the flank of
small mice (20-25g). Recently a smaller model has been introduced.
4.4.3 Why did the results from the radiotelemetry and direct catheter BP
studies differ?
The technical problems encountered with the carotid artery catheter BP
measurements, combined with the recent statement from the American Heart
Association (Kurtz et al., 2005), led us to use radiotelemetry for our subsequent
studies. Having demonstrated that EC ETB receptor down-regulated mice exhibit
hypertension on both normal and high salt diet using carotid artery catherisation, it
was surprising to find no difference in MBP, and only mild salt sensitive diastolic
hypertension, between EC ETB receptor down-regulated mice and control animals
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using radiotelemetry. There are a number of possible reasons to explain these
differing results using the two different approaches to measure BP.
Firstly, the different results from the 2 studies could be related to the use of different
control groups: WW/-- were used as controls in the carotid artery catheterisation
study and FF/-- in the radiotelemetry study. Initial intentions had been to include
FF/--, WW/-- and FF/Tie2 mice in the carotid artery catheterisation study. However,
too few of the FF/-- animals survived to allow any meaningful comparison with the
FF/Tie2 mice. The main disadvantage of using the WW/-- mice as the sole control
group related to their different genetic background. These mice were descended from
intercross of WW/Tie2 mice [background 50% C57BL6; 50% SJF1(Kisanuki et al.,
2001)] and had been maintained as a separate strain within the colony. The high cost
of the radiotelemetry study meant that only two groups of mice could be included in
this later study. Here, FF/-- siblings were used as controls, as in many other studies
involving mice generated using the Cre-Lox system (Ahn et al., 2004; Kimura et al.,
2004; Shohet et al., 2004). By using FF/-- sibling controls, which had the same
background as the FF/Tie2 mice (25% 129/01a; 25% BKW; 25% C57BL6; 25%
SJF1), differences in genetic background were minimised. Thus the difference in BP
seen between WW/-- and FF/Tie2 mice, in the carotid catheter study, could have
been due the differences in genetic background (Ryan et al., 2002), rather than due to
EC ETB down-regulation. Alternatively, the differences could have been caused by
the floxing of the ETB gene. However, this seems less likely as we have found no
difference between WW/-- and FF/-- mice in terms of ETB receptor binding in the
autoradiography studies (see section 3.2.6), plasma ET-1 concentrations and
clearance of ET-1 (see sections 5.3.1 and 5.3.3). As discussed above (see section
4.4.1), future studies will involve backcrossing of the FF/-- and FF/Tie2 mice onto a
salt resistant background (duration ~ 20-24 months). Once this has been achieved,
further telemetry studies, involving both WW/-- and FF/-- mice as control groups,
can be performed, to clearly determine whether floxing the ETB gene results in an
unexpected effect on BP control.
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Second, the carotid catheter measurements are likely to have been taken too soon
after surgery. Problems of catheter occlusion meant that measurements could not be
made more than 48 hours after catheter implantation. Our own telemetry data (see
Figure 4-9, Figure 4-13, Figure 4-17 and Figure 4-21), as well as that of other groups
(Butz et al., 2001; Leon et al., 2004; Lorenz, 2002; Pollock et al., 2001), has
revealed that, following surgery, mice require at least 5-6 days to recover their
physiological BP diurnal variation, and several more days to get back to their pre-
operative weight. At 48 hours the mice had not fully recovered from the surgery. It is
possible that the difference in BP observed in the first study was artefactual, due to
not enough time being allowed for recovery.
Third, the high mortality and catheter failure rate limited the numbers of animals
studied in the carotid artery catheterisation study. Whilst successful recordings were
performed in 20 animals, many more were operated on. Perhaps previously
unidentified factors (eg renin-angiotensin-aldosterone system polmorphisms; glucose
tolerance; birth weight) may have influenced which mice survived the surgery
required for carotid artery catheter insertion. If such factors also exerted different
effects on the reflex control of the circulation in the EC ETB down-regulated mice,
then this could explain why these mice were found to be hypertensive in the first
study.
Fourth, radiotelemetry allows continuous recording of BP, over several weeks, whilst
the carotid artery catheterisation measurements were only performed for 30 minutes
following a 30-minute acclimitisation period. The extended recording period means
that the radiotelemetry measurements are much less likely to have been affected by
sampling or experimental errors.
Chronic hypertension frequently results in end organ damage, such as left ventricular
hypertrophy (Fagher et al., 1995; Messerli et al., 1988). If the difference in BP
between EC ETB down-regulated mice and controls was truly as large as that seen in
the direct carotid catheter study, then old EC ETB down-regulated mice might have
been expected to show evidence of such end organ damage. However, even when
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aged more than 12 months, EC ETB down-regulated mice do not exhibit increased
heart/ body weight ratios (see Figure 4-45), reinforcing the validity of the
radiotelemetry data showing that these mice do not have elevated MBP and only
mildly elevated DBP on a normal salt diet.
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5  CHAPTER 5: ROLE OF THE EC-ETB RECEPTOR IN THE
PLASMA CLEARANCE OF ET-1
5.1 INTRODUCTION
As detailed in chapter 1 (see section 1.1.6) it is generally accepted that ETB receptor
mediated clearance is central to the elimination of extracellular ET-1. Studies, using
ETB antagonists in rats, have demonstrated the important role of the lungs, kidney
and liver in the clearance of ET-1 (Fukuroda et al., 1994). However, such organs are
composed of a range of different cell types, several of which express ETB receptors.
Experiments using pharmacological blockade or general genetic down-regulation of
ETB receptor expression are not able to identify the contribution of ETB receptors,
located on individual cell types, to the clearance of ET-1.
Cultured ECs avidly internalise ET-1, a process that can be blocked with ETB, but
not ETA, antagonists (Ozaki et al., 1995). Chronic administration of high dose
A192621 (a selective ETB antagonist) is thought to block both EC and VSMC ETB,
whereas low dose A192621 is suggested to act predominantly at the endothelium
(Honore et al., 2005). Raised plasma ET-1 concentrations are only found following
chronic high dose A192621, suggesting that VSMC ETB receptors play the more
significant role in ET-1 clearance. However, supporting evidence that cell specific
ETB receptor blockade has been achieved with certain doses of pharmacological
antagonism is less easy to provide than evidence of cell specific ETB receptor down-
regulation in a transgenic mouse (see sections 1.3.6 and 3.3.5).
Here I have combined both of these approaches, using both pharmacological ETB
blockade and the EC ETB receptor down-regulated mouse model, to determine the
contribution of EC ETB and non-EC ETB receptors to the clearance of ET-1.
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5.2 METHODS/PROTOCOLS
5.2.1 Plasma ET-1 and big ET-1 concentrations
Following euthanasia with CO2, blood was collected by direct cardiac puncture from
both FF/Tie2 mice and controls. After centrifugation at 4°C, the plasma was drawn
off. Samples from 2 individual animals of the same genotype were pooled to
resulting in a minimum sample volume of 500 µl. ET-1 and big ET-1 extraction and
radioimmunoassay performed as described in section 2.9.1.
5.2.2 Clearance studies
As described in section 2.9.2, a bolus of [125I]-ET-1 (0.37 pmol/mouse; 28
kBq/mouse; 1200 000 cpm/mouse) was injected intravenously via a right internal
jugular catheter and serial blood samples (10 µl) were collected by means of a
carotid artery catheter. The activity of these samples was determined to give a
measure of their [125I]-ET-1 concentration. Measurements were compared for mice of
different genotype and following treatment with ETB blockade.
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5.3 RESULTS
5.3.1  Plasma ET-1 concentrations
Plasma concentrations of ET-1, measured by radioimmunoassay, were found to be
approximately three fold higher in the FF/Tie2 mice (12.4 ± 3.0 pg.ml-1) compared to
single transgenic controls (WW/--: 2.9 ± 0.8 pg.ml-1; WW/Tie2: 3.0 ± 0.8 pg.ml-1;
FF/--: 4.1 ± 0.5 pg.ml-1) (Figure 5-1).
Figure 5-1: Plasma concentrations of ET-1 were elevated in FF/Tie2 mice.
Concentrations of ET-1 in plasma samples, each pooled from 2 individual mice of
the same genotype, from FF/Tie2 and single transgenic control animals (where n =
number of plasma samples).
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5.3.2 Plasma big ET-1 concentrations
As ET-1 concentrations were similar between all single transgenic controls, big ET-1
analysis was only performed on FF/Tie2 and FF/-- controls. The plasma
concentration of big ET-1 was increased in FF/Tie2 mice (199.8 ± 8.0 pg.ml-1)
compared to FF/-- controls (137.1 ± 12.6 pg.ml-1), but to a lesser relative amount
than seen with ET-1 (Figure 5-2).
Figure 5-2: Plasma concentration of big ET-1 was only marginally elevated in
FF/Tie2 mice.
Concentrations of big ET-1 in plasma samples, each pooled from 2 individual mice
of the same genotype, from FF/Tie2 and FF/-- control animals (where n = number of
plasma samples).
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5.3.3 Effect of genotype on clearance of ET-1
The clearance of ET-1 was significantly impaired in the FF/Tie2 mice (0.053 ± 0.006
ml.sec-1) compared to WW/-- controls (0.175 ± 0.032 ml.sec-1; p<0.01) (Figure 5-3,
Table 5-2 and Figure 5-8).
Figure 5-3: Concentration – time graph showing that elimination of a bolus of
radiolabelled ET-1 was impaired in FF/Tie2 compared to WW/-- mice.
Concentration of [125I]-ET-1 in serial blood samples collected from the carotid artery
of both FF/Tie2 (n=5) and WW/-- mice (n=6), following a bolus of 1080pg/mouse of
radiolabelled ET-1 administered into the superior vena cavae.
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Separate additional experiments showed no significant difference in the clearance of
ET-1 between WW/-- (0.223 ± 0.033 ml. sec-1) and FF/-- animals (0.192 ± 0.033 ml.
sec-1) (Figure 5-4).
Figure 5-4: Clearance of ET-1 was similar in WW/-- and FF/-- mice.
Concentration of radiolabelled ET-1 in blood samples of both FF/-- (n=5) and WW/-
- mice (n=4), following an i.v. bolus of 1080pg/mouse of [125I]-ET-1.
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5.3.4 Effect of pharmacological ETB blockade on clearance of ET-1
For the week preceding the study, mice were housed individually and fed either
normal chow or chow containing A192621 (note: this method of administration was
chosen as A192621 is highly insoluble in non-organic solvents, precluding its
intravenous administration immediately before the clearance experiment). Neither
genotype nor drug treatment had a significant effect on animal weight on the day of
the study (Table 5-1).
Table 5-1: Body weights on day of clearance study
Body weights of mice on the day of study, following 7 days of pretreatment with
either normal feed or chow containing the ETB antagonist A192621.
WW/-- FF/Tie2
Mean weight (g) ± SEM n Mean weight (g) ± SEM n
No drug 31.45 ± 1.99 6 32.45 ± 1.16 5
A192621 (30mg/kg/day) 30.25 ± 1.44 5 32.23 ± 1.48 4
A192621 (100mg/kg/day) 26.78 ± 0.84 5 28.94 ± 1.52 5
Treatment of WW/-- mice with A192621 (100mg.kg-1.day-1) resulted in the clearance
of ET-1 being impaired (0.052 ± 0.0052 ml.sec-1) to the same extent as untreated
FF/Tie2 animals (0.053 ± 0.0055 ml.sec-1) (n=5; p>0.05) (Figure 5-5, Table 5-2
Figure 5-8). A192621 did not significantly alter the clearance of ET-1 in the FF/Tie-
Cre mice (0.045 ± 0.0057 ml.sec-1) (Figure 5-5,Table 5-2 and Figure 5-8).
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Figure 5-5: ETB blockade with A192621 impaired ET-1 clearance in WW/--
mice to a similar extent to that of untreated FF/Tie2 mice
Concentration of radiolabelled ET-1 in blood samples of both FF/-- and WW/-- mice,
following an i.v. bolus of 1080pg/mouse of [125I]-ET-1, in the presence and absence
of A192621 (100mg.kg-1.day-1). For numbers in group see Table 5-2.
Blockade with A192621 had a similar effect on clearance of ET-1 when administered
to WW/-- mice at either 30mg.kg-1.day-1 (0.064 ± 0.0065 ml.sec-1) or 100mg.kg-1.day-
1 (0.052 ± 0.0052 ml.sec-1) (Figure 5-6 and Table 5-2), implying that maximal ETB
antagonism was achieved at both doses.
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Figure 5-6: Both low and high dose A192621 had similar effects on ET-1
clearance in WW/-- mice.
Effect of dose of A192621 on clearance of ET-1 (n=5).
The slope of the ln[concentration]-time graph gives the rate constant of ET-1
elimination (Kel) from the plasma (Rang et al., 2003). As shown in Figure 5-7, this is
similar for both WW/-- (0.0390 ± 0.0011 sec-1) and FF/Tie2 (0.0331 ± 0.0033 sec-1)
mice, and is not altered by ETB receptor blockade (Table 5-2). Thus the half-life of
ET-1 (ln2/ Kel) is also similar for both genotypes (Table 5-2).
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Figure 5-7: Logarithmic plot of concentration against time was not different
between genotypes
By plotting the logarithm of the concentration of radiolabelled ET-1 against time,
allows the Kel (equal to the inverse of the gradient) to be calculated. This was similar
for both genotypes.
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Table 5-2: Pharmacokinetic data for elimination of a bolus of [125I]-ET-1
Area under the curve (AUC), elimination constant (Kel), half life (t1/2), clearance (CL) and volume of distribution (Vd) for the elimination of
radiolabelled ET-1 in both WW/-- and FF/Tie2 mice in the presence and absence of the ETB antagonist A192621. [* p<0.05 WW/-- no drug



























































































Figure 5-8: Clearance of ET-1 was impaired in FF/Tie2 mice, and in mice of
both genotypes treated with ETB blockade.
Clearance of a bolus of radiolabelled ET-1 by both genotypes in the presence and
absence of A192621.
5.4 DISCUSSION
We have demonstrated that plasma ET-1 concentrations are three to four fold higher
in mice featuring EC ETB receptor down-regulation than in control animals. That the
precursor of ET-1, big ET-1, is only mildly elevated in the EC ETB down-regulated
mice, suggests that this receptor acts to eliminate ET-1 from the circulation, rather
than inhibit the production of the peptide. Furthermore, we have found that the
clearance of a bolus of radiolabelled exogenous ET-1 is impaired in untreated EC
ETB down-regulated mice, as seen in control mice treated with a maximal dose of
ETB antagonist. Thus we conclude that the EC ETB receptor makes a significant
contribution towards the elimination of extracellular ET-1.
5.4.1 Plasma ET-1 and big ET-1 concentrations
The small size of mice restricts the volume of plasma that can be collected. The
extraction prior to the RIA required a minumum of 500 µl of plasma, and so samples
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from more than one animal had to be pooled. Althernative techniques, such as
Enzyme Linked Immunosorbent Assays (ELISA), are available (Amiri et al., 2004;
Gariepy et al., 2000), which require smaller volumes of plasma for determination of
ET-1 concentrations, but these are not currently established in our laboratory.
In common with other studies involving either genetic disruption (Gariepy et al.,
2000) or pharmacological blockade of the ETB  (Brunner et al., 1996; Goddard et al.,
2004a), down-regulation of the EC ETB receptor results in raised plasma
concentrations of ET-1. This could be due to either increased production or impaired
clearance of ET-1, mediated by EC ETB.
Higher production of ET-1 results from either increased expression of pre-proET-1
(causing higher plasma concentrations of big ET-1, the precursor to the mature
peptide) or enhanced activity of ECE-1, the enzyme that converts big ET-1 into ET-
1. We have shown that EC ETB receptor down-regulated mice demonstrate mildly
elevated plasma concentrations of big ET-1. Nitric oxide (NO) is known to inhibit
ET-1 production from the endothelium (Boulanger et al., 1990), and so lack of tonic
EC ETB mediated NO might be expected to contribute to the observed increased big
ET-1 and ET-1 plasma concentrations in the EC ETB down-regulated mice. In
cultured rat ECs, ETB activation has been shown to inhibit the expression of ECE-1
(Naomi et al., 1998), suggesting that elevated enzyme concentrations would be seen
in the EC ETB down-regulated mice, although this was not seen in our semi-
quanitative RT-PCR studies (see Figure 3-21).
In contrast, other studies, involving both animals and humans, do not show ETB
antagonists to alter the concentration of big ET-1 (Loffler et al., 1993; Plumpton et
al., 1996). Furthermore, as ETB activation have been shown to mediate autoinduction
of preproET-1 mRNA expression (Saito et al., 1995), down-regulation of ETB would
not be expected to result in elevated plasma ET-1 production.
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To investigate the effect of EC ETB down-regulation on the elimination of ET-1
alone, studies investigating the elimination of a bolus of radiolabelled ET-1 were
performed.
5.4.2 Plasma clearance studies
Previous studies, using exogenous radiolabelled [125I]-ET-1, have revealed the
important role of ETB receptor in the removal of ET-1 from the circulation
(Berthiaume et al., 2000; Burkhardt et al., 2000; Fukuroda et al., 1994). By
performing similar experiments, we have shown that down-regulation of the EC ETB
receptor results in impaired ET-1 clearance that can be reproduced by treating
control animals with pharmacological ETB blockade. That maximal ETB blockade
was achieved with the doses of selective antagonist used in this study has been
demonstrated by others (Pollock et al., 2001) and also by the observation that both
high and low doses of A192621 had the same effect on ET-1 clearance. Thus the
contribution of ETB receptors located on cells other than ECs to the clearance of ET-
1 would appear to be negligible. To identify the relative contribution of ETB
receptors located on different cell types, others have used a novel pharmacological
approach in the attempt to achieve tissue specific ETB receptor blockade (Honore et
al., 2005). Chronic low dose ETB blockade with A192621 (0.5mg/kg/day) blocked
only the initial hypotensive response to a bolus of ETB agonist in anaesthetised
hamsters, whereas high dose A192621 (30mg/kg/day) blocked both the initial
hypotensive response as well as the later pressor response. From this they propose
that low dose A192621 is predominantly blocking EC ETB, whereas the high dose is
blocking both EC and VSMC ETB. Plasma ET-1 concentrations are increased only
with the high dose of A192621. They therefore conclude that VSMC ETB contributes
significantly to ET-1 clearance. However, the authors rely solely on the
physiological assay of the pressor response to a bolus of ETB agonist (not ET-1
itself), to demonstrate tissue specific ETB blockade. This pressor response varies
across species [depressor then pressor in rats (Gariepy et al., 2000), pressor only in
mice (Giller et al., 1997)] and so is not the most reliable evidence of cell specific
ETB blockade. They do not provide evidence that, at the higher dose, A192621 is not
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acting non-selectively at both ETA and ETB receptors. Furthermore, no clearance
studies, using radiolabelled ET-1, were performed. Conclusions concerning ET-1
clearance were based merely on ET-1 plasma concentrations. By performing
radiolabelled [125I]-ET-1 clearance studies, using a cell-specific ETB receptor down-
regulated mouse (with both structural and functional evidence of EC specific knock-
down – see sections 1.3.6 and 3.3.5) we have been able to robustly demonstrate the
important contribution of the EC ETB receptor to ET-1 elimination. Although we
have compared EC ETB down-regulated mice with control animals pretreated with
supramaximal doses of ETB antagonists, to determine the overall contribution of the
EC ETB to the clearance of ET-1, further control experiments would be valuable
involving other tissue specific ETB knock-down animals, such as VSMC ETB down-
regulated mice. It would be expected that such animals might have unimpaired
clearance of ET-1 compared to controls.
5.4.3 Non ETB receptor mediated ET-1 clearance
As demonstrated previously (Berthiaume et al., 2000; Burkhardt et al., 2000), we
have shown that even in the presence of maximal ETB receptor blockade,
radiolabelled [125I]-ET-1 is still swiftly eliminated from the plasma (within 2
minutes). This is most likely due to enzymatic degradation (Deng et al., 1992) by
neutral endopeptidases (Abassi et al., 1992). Studies comparing the uptake of
radiolabelled ET-1 by different organs in the presence of ETB receptor blockade,
indicate these enzymes are most likely to be located in the kidney and liver
(Burkhardt et al., 2000).
5.4.4 Technical considerations in plasma clearance studies
Serial blood sampling from an animal as small as a mouse can quickly result in
depletion of the intravascular volume, and so the samples collected were kept as
small as possible. The clearance studies involved the serial collection of 10µl arterial
blood samples every 6 seconds over 2 minutes (200µl in total; less than 10% of the
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circulating blood volume of a mouse). In preliminary experiments, the removal of
such a volume in this way did not have a significant haemodynamic effect.
The small volumes of blood sampled (10µl) precluded the direct measurement of
ET-1, using techniques such as radioimmunoassay (this requires ~500 – 700µl
minimum sample volume). Therefore by injecting an exogenous bolus of [125I]-ET-1
of known activity and concentration, and by measuring the radioactivity of each
blood sample collected, an estimate was made of the radiolabelled ET-1
concentration in each sample. However, using this technique, it is not possible to
differentiate between radiolabelled ET-1 and any metabolised products of ET-1,
which retain the radiolabel and remain in the plasma. We have had to assume
therefore, that during the 2 minutes of each study, whilst ET-1 is internalised by ETB
receptors, no metabolism occurs within the vascular compartment.
A further limitation of our study is that we have only considered plasma ET-1
concentrations, and have not measured tissue ET-1 concentrations. Given that ET-1
is considered by many to be an autocrine/paracrine agent, produced predominantly in
the endothelium and acting at receptors situated on both EC and neighbouring
vascular smooth muscle receptors (Battistini et al., 1993; Kedzierski et al., 2001;
Kotelevtsev et al., 2001), the effect of EC ETB down-regulation on tissue ET-1
availability may be more physiologically relevant than focusing on plasma ET-1
concentrations.
The clearance (CL) of a substance is defined as the volume of plasma from which that
substance is removed per unit time (Guyton et al., 2005). It can also be defined by
the following equation:
CL = Vd . Kel
(where is the Vd volume of distribution and is the Kel elimination rate constant)
(Rang et al., 2003).
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Plotting the concentration of radiolabelled ET-1 logarithmically against time, gives a
straight line, where the inverse slope equals the elimination rate constant, Kel (Figure
5-7)(Rang et al., 2003). This shows that Kel is similar in both strains of mice.
Equivalent graphs, showing similar Kel for heterozygous ETB +/- and wild type
control mice, can be calculated using data from previous studies (Berthiaume et al.,
2000). However, we have shown that the plasma concentration of ET-1 is four fold
greater in EC ETB down-regulated mice, compared to control animals. This means,
that even with a similar rate of elimination of ET-1, the volume cleared of ET-1 per
unit time (i.e. the ET-1 clearance) is less in the EC ETB down-regulated mice.
In our experiment, preliminary studies allowed for the optimum bolus dose of
intravenous radiolabelled [125I]-ET-1 to be determined. Too high a dose causes a
pressor effect (seen with a plasma concentration of ~ 45 ng.ml-1(Berthiaume et al.,
2000; Gariepy et al., 2000; Giller et al., 1997)). Too low a dose precludes detection
of radiolabelled [125I]-ET-1 in the arterial blood samples above background in the
gamma scintillation counter. As found previously (Berthiaume et al., 2000;
Burkhardt et al., 2000), the dose required in our studies (0.37 pmol/mouse;
equivalent to a mean plasma concentration of ~540 pg.ml-1[assuming a murine blood
volume of ~2ml]) whilst being well below the threshold to cause a pressure response,
was ~100 fold the physiological concentration of ET-1 (3-5 pg.ml-1).
Therefore, in the control animals, it seems likely that the excess radiolabelled ET-1
swiftly saturates the EC ETB within the initial seconds of the experiment. Following
this the ET-1 is metabolised by non-EC ETB mechanisms, such as neutral
endopeptidases in the kidney and liver. In contrast, in the EC ETB down-regulated
mice, none of the labelled ET-1 binds to the EC ETB, and so the measured labelled
ET-1 concentration is higher, and is removed from the circulation solely by non-EC
ETB enzymatic degradation. Thus, the Vd (and therefore the clearance) of the
radiolabelled ET-1 is much greater in the control animals, as the ETB receptors on the
endothelium allow it to pass freely into the ECs, whereas in the EC ETB down-
regulated mice the ET-1 remains in the plasma and so for these mice, the Vd is much
reduced.
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6 CHAPTER 6: ROLE OF THE EC-ETB RECEPTOR IN THE
CONTROL OF PULMONARY VASCULAR TONE AND THE
DEVELOPMENT OF PULMONARY ARTERIAL
HYPERTENSION
6.1 INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive and fatal condition of the
cardiopulmonary circulation characterised by a sustained increase in pulmonary
vascular resistance leading to right ventricular failure and premature death. This
process is accompanied by an abnormal proliferation of VSMCs of small pulmonary
arteries (PAs). As both a potent vasoconstrictor and mitogen, ET-1 has been
implicated in the aetiology and progression of PAH. Plasma concentrations of ET-1
correlate with severity of PAH in both animal models (Frasch et al., 1999; Nakanishi
et al., 1999; Stelzner et al., 1992) and patients suffering from this debilitating
condition (Cacoub et al., 1997; Giaid et al., 1993).
The lung is the most important site of ET-1 production with concentrations 5 times
greater than those seen in other organs (Firth et al., 1992). The highest concentration
of ETB mRNA is also found in the lung (Li et al., 1994b). ETA and ETB receptors are
expressed throughout the lung in blood vessels, bronchioles and alveoli, with the
greatest number of ET binding sites found in distal segments (Davie et al., 2002).
ETA receptors are localised to the media of the large proximal PAs and veins with
relatively little expression in distal arterioles (Davie et al., 2002; Soma et al., 1999).
ETB receptors, in contrast, are highly expressed in distal vascular segments (Davie et
al., 2002). Under normoxic conditions, ETB receptors of the distal pulmonary
vasculature are mainly confined to the medial layer. However, hypoxia increases the
expression of ET-1, ETA and ETB receptors throughout the lung (Li et al., 1994a),
with evidence to suggest a preferential increase in EC ETB receptor expression in
distal segments in some (Soma et al., 1999) but not all (Balyakina et al., 2002; Black
et al., 2003) studies.
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Non-selective antagonists of ET receptors have recently been granted approval for
the treatment of primary pulmonary hypertension and have been shown to confer
symptomatic and prognostic benefits (McLaughlin et al., 2005; Rubin et al., 2002).
Both ETA and ETB receptors on VSMC mediate vasoconstriction and cellular
hypertrophy (Davie et al., 2002; MacLean et al., 1994; Sato et al., 1995) and hence
may promote the progression of PAH. However, EC ETB receptors within the lung
clear ET-1 from the plasma (Dupuis et al., 1996a; Dupuis et al., 1996b; Fukuroda et
al., 1994) (see chapter 5) and mediate vasodilatation and anti-mitogenic effects
through the release of NO and PGI2 (de Nucci et al., 1988; Takayanagi et al., 1991).
Rescued ETB deficient rats demonstrate raised pulmonary arterial pressures when
exposed to hypoxia (Ivy et al., 2001; Ivy et al., 2002), and develop plexiform lesions
when treated with the endothelial toxin monocrotaline (Ivy et al., 2005), suggesting
that, at least in a rodent model of PAH, the net effect of ETB blockade is beneficial.
Results from the STRIDE-2 trial show a modest increase in functional benefit with
sitaxsentan treatment (ETA selective antagonist) compared to open label mixed ET
blockade (Barst et al., 2006). However, such studies are unable to reveal the
contribution of the EC ETB receptor to the pathogenesis of PAH.
Several different animal models of PAH have been developed, including systemic to
pulmonary shunts (Reddy et al., 1995), bleomycin lung injury (Williams et al.,
1992), monocrotaline treatment (Todorovich-Hunter et al., 1988) and chronic
hypoxia exposure (Rabinovitch et al., 1979). Using a toxin, such as monocrotaline,
which damages all ECs, would obviate any advantage of studying an EC specific
down-regulated mouse model. The surgery required for left to right shunting,
particularly in small rodents, is formidable. Chronic hypoxia, induced by housing
mice in hypobaric chambers, is well established in rodents, and offers a convenient
and straightforward method of inducing PAH, using a well recognised secondary
cause of the condition. Here I have investigated the effect of exposing EC ETB
receptor down-regulated mice to hypobaric hypoxia to determine the contribution of
this receptor to the pathogenesis of PAH.
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6.2 METHODS/PROTOCOLS
Both FF/Tie2 and FF/-- mice were housed under hypobaric hypoxia for 14 days (see
section 2.10.1). Normoxic controls of both genotypes were maintained in the same
room under atmospheric pressure. Following haemodynamic assessment, as
described in section 2.10.2, the mice were euthanased, hearts removed for weighing,
the right lung taken for histology and the left lung put on ice for later dissection to
isolate the left PA. This was used for wire myography as described in section 2.10.4.
6.2.1 Myography protocol
Following wake-up, as described in section 2.10.4.1, cumulative concentration-
response curves (CRCs) were constructed to ET-1 for each pair of PA rings, one in
the presence and the other in the absence of 100 µM N-nitro-L-arginine methyl ester
(L-NAME). These were performed by adding cumulative doses of ET-1 (Merck
Biosciences Ltd., Nottingham, UK) in half-log increments (10-15M - 10-7M), allowing
the maximal response to each dose to plateau prior to subsequent additions. L-
NAME (100 µM) was added to the second of each pair of PA rings 30 minutes prior
to ET-1. Previous studies using mice of a similar background to our FF/Tie2 animals
(background: 129SV) have shown little dilatation to ACh, and so comparison of the
responses in the presence and absence of L-NAME was used with the aim of
assessing vascular endothelial function (Keegan et al., 2001).
All responses to ET-1 were expressed as a percentage of the second response to 50
mM KCl, during the wake-up period, to calculate the maximum contraction (Emax).
pEC50 values were calculated from CRCs by graphical interpolation (Graphpad Prism
4.0). Statistical comparisons of the Emax and pEC50 values were made by one-way
analysis of variance, and the CRCs were compared by 2-way ANOVA. When
significance was attained (p<0.05), differences were established using the Newman-




Genotype did not have a significant effect on animal weight by the time of
euthanasia following the haemodynamic study, although hypoxia did cause the body
weight of FF/Tie2 mice to fall (p<0.05).
Table 6-1: Weights of mice
Mean weights of mice after 2 weeks under either hypoxic or normoxic conditions.
(*FF/Tie2 hypoxic vs FF/Tie2 normoxic: p<0.05).
FF/-- FF/Tie2
Mean weight (g) ± SEM n Mean weight (g) ± SEM n
Normoxia 37.43 ± 1.42 9 34.85 ± 1.26 10
Hypoxia 34.07 ± 1.74 10 31.44 ± 1.3* 10
6.3.2 Haemodynamic studies
Systemic mean arterial BP and heart rate, measured under halothane anaesthesia by
means of an intra-arterial carotid catheter, were not significantly different in FF/Tie2
mice compared to FF/-- controls under both normoxic and hypoxic conditions.
Figure 6-1: Systemic haemodynamics did not differ between genotypes under
both normoxic and hypoxic conditions.
Systemic mean arterial BP (A) and heart rate (B) did not differ between
anaesthetised FF/-- and FF/Tie2 mice housed under normoxic and hypoxic
conditions.
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Although systolic right ventricular pressure (RVP) was similar between genotypes
under normoxic conditions, following 2 weeks of hypoxia, the systolic RVP of
FF/Tie2 mice was significantly elevated in FF/Tie2 mice (34 ± 1.2 mmHg) compared
to FF/-- controls (24 ± 1.7 mmHg; n=10; p<0.001).
Figure 6-2: The systolic RVP of FF/Tie2 mice was significantly elevated under
hypoxic conditions
Systolic right ventricular pressures of anaesthetised FF/-- and FF/Tie2 mice housed
under normoxic were not significantly different. Exposure to hypoxia resulted in
elevated systolic RVP in FF/Tie2 but not in FF/-- mice.
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6.3.3 Right ventricular hypertrophy
Table 6-2: Indices of right ventricular hypertrophy
RV (right ventricular)(mg)/ LV+S (left ventricular plus septum weight) (mg);
RV(mg)/ TV (total ventricle)(mg)/; and RV (mg)/ BW (body weight)(g) ratios ±
SEM of FF/Tie2 and FF/-- mice exposed to normoxic and hypoxic conditions. (*
compared to normoxic mice p<0.05; one way ANOVA).
FF/-- FF/Tie2

























Both genotypes demonstrated a significant increase in RV/ BW ratio when exposed
to hypoxia, although only FF/Tie2 mice demonstrated a significant increase in the
ratio of RV/ LV+S mass (Table 6-2 and Figure 6-3).
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Figure 6-3: Hypoxia results in right ventricular hypertrophy in hypoxic mice
FF/Tie2 mice
Unlike FF/-- mice, FF/Tie2 mice housed under hypoxia showed significantly
elevated RV/LV+S (right ventricular mass / left ventricle plus septum mass)









































































































Figure 6-4: (previous 2 pages). Representative tracing of a wire myography
study of a 3rd order PA ring from FF/-- mouse, housed under normoxic
conditions, not exposed to L-NAME.
Figure 6-4A shows the PA ‘wake up’ protocol followed by the concentration
response to increasing concentrations of ET-1. Tension was applied to give a
transmural pressure equivalent to 12 - 14 mmHg (equivalent to normoxic conditions)
(A, B). Following a 30 minute equilibration period, the PA ring were contracted to
50 mM KCl solution (C), which was then washed out with Krebs-buffer solution (D).
The PA ring was contracted to 50 mM KCl for a second time (E) and then washed
out 5 times with Krebs-buffer solution (F). Following this ‘wake up’ protocol, the
cumultative-response to ET-1 was measured (G) – expanded time axis Figure 6-4B -
ET-1 was added in half-log increments (10-14M - 10-7M).
(These data were obtained from Dr Y Dempsie, University of Glasgow).
As detailed in the Methods chapter (see section 2.10.4), PA rings from mice housed
under normoxic conditions were tensioned to give an equivalent transmural pressure
between 12 –14 mmHg for tissue from normoxic mice and 30 – 33 mmHg for tissue
from hypoxic mice. No difference was seen in the internal circumference/ tension
relationship (a measure of stiffness) between PA rings from mice of different
genotype.
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Figure 6-5: Length (internal circumference) – tension relationship for all PA
rings
Mean internal circumference (±SEM) of PA rings in the wire myography study
plotted against the tension (±SEM) required to result in a transmural pressure
equivalent to 12-14 mmHg for mice under normoxic and 30-33 mmHg for mice
under hypoxic conditions. Data is for all PA rings, before the addition of L-NAME.
Overlapping error bars indicate no significant difference between genotypes.
(These data were obtained from Dr Y Dempsie, University of Glasgow).
No significant difference in the maximum constriction (Emax) or tissue sensitivity
(pEC50) of PA rings to ET-1 was observed under conditions of normoxia or hypoxia
between FF/Tie2 mice and FF/-- controls (Table 6-3 and Figure 6-6). However, when
all points on the CRC were analysed using 2-way ANOVA small differences in
reponses were demonstrated (Figure 6-6). Under normoxic conditions, the PA rings
from FF/Tie2 mice are slightly less sensitive to ET-1 compared to FF/-- tissue
(Figure 6-6A). However, under hypoxic conditions, no differences in the ET-1 CRCs
were seen (Figure 6-6B).
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FF/-- Normoxic n= 7
FF/Tie2 Normoxic n=7





























150 FF/-- Hypoxic n=5
FF/Tie2 Hypoxic n=5

























Figure 6-6: CRC of PAs to ET-1 under normoxia and hypoxia
ET-1 culminative concentration response curves for PA rings from FF/-- and FF/Tie2
mice housed under normoxic (A) and hypoxic (B) conditions. Two-way ANOVA
showed a significant difference between the CRCs under normoxia (p<0.01), but no
difference under hypoxic conditions (p>0.05).
(These data were obtained from Dr Y Dempsie, University of Glasgow).
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Treatment with L-NAME did not have a significant effect on either the Emax or pEC50
of the CRCs to ET-1 in either FF/Tie2 or FF/-- PA rings (Table 6-3, Figure 6-7 and
Figure 6-8). However, slight differences were again demonstrated when 2-way
ANOVA analysis was applied to the ET-1 CRCs. Under normoxic conditions, L-
NAME caused PAs from FF/-- mice to constrict slightly more in reponse to ET-1
(Figure 6-7A), whereas no effect of L-NAME was seen with PA rings from FF/Tie2
mice (Figure 6-7B). In contrast, under hypoxic conditions, the opposite was seen: L-
NAME caused no effect on PAs from FF/-- mice (Figure 6-8A), whereas it increased
constriction of FF/Tie2 PA rings (Figure 6-8B).
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FF/-- Normoxic n= 7
FF/-- Normoxic + L-NAME n=7
p<0.001





























FF/Tie2 Normoxic + L-NAME n= 6
FF/Tie2 Normoxic n=7
p>0.05
























Figure 6-7: CRC of normoxic PA rings to ET-1 in the presence and absence of
L-NAME
Two-way ANOVA showed that L-NAME caused a significant difference in the
CRCs of normoxic FF/-- mice (p<0.001) (A), but no such effect was seen between
the CRCs of normoxic FF/Tie2 mice (p>0.05) (B).
(These data were obtained from Dr Y Dempsie, University of Glasgow).
220




150 FF/-- Hypoxic n=5
FF/-- Hypoxic + L-NAME n=6
p>0.05






























FF/Tie2 Hypoxic + L-NAME n=9
p<0.001
























Figure 6-8: CRC of hypoxic PA rings to ET-1 in the presence and absence of L-
NAME
Two-way ANOVA showed that L-NAME caused no significant difference in the
CRCs of hypoxic FF/-- mice (p>0.05) (A), but it significantly shifted the ET-1 CRC
of hypoxic FF/Tie2 mice to the left, indicating increased tissue sensitivity to ET-1
(p<0.001) (B).
(These data were obtained from Dr Y Dempsie, University of Glasgow).
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Table 6-3: Potency and maximum effect of ET-1 in PA rings from FF/Tie2 and
FF/-- animals
(These data were obtained from Dr Y Dempsie, University of Glasgow).
FF/-- FF/Tie2
pEC50 Emax n pEC50 Emax n
Normoxic 9.2 ± 0.13 121.9 ± 4.8 7 8.8 ± 0.12 109.7 ± 7.2 7
Hypoxic 10.1 ± 0.17 116.8 ± 9.0 5 9.6 ± 0.10 125.4 ± 5.5 5
Normoxic + L-NAME 9.7 ± 0.18 126.3 ± 3.4 7 9.1 ± 0.90 120.2 ± 5.0 6
Hypoxic + L-NAME 10.12 ± 0.17 124.3 ± 7.1 6 10.5 ± 0.12 143.0 ± 6.0 9
6.3.5 Vascular remodeling
Lung sections from 6 mice per group were stained as described (see section 2.10.5).
All PAs (20 - 60 µm O.D.) associated with an airway distal to the respiratory
bronchiole were counted. The arteries were considered muscularised if they
possessed a distinct double-elastic lamina visible for at least half the diameter in the
vessel cross-section. The proportion of such remodeled muscularised vessels was
calculated for each section (Keegan et al., 2001) (Figure 6-9).
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Figure 6-9: Micrograph showing hypoxic remodeling
Left: Normal small PAs in normoxic mice. Right: Muscularised remodeled small
PAs in hypoxic mice. Sections stained with Miller’s Elastin stain and Picro Sirius
Red collagen stain. Scale bar = 10 µm.
Under normoxia, the proportion of remodeled vessels in the lung sections studied
was similar in FF/-- (5.57 ± 0.57%) and FF/Tie2 (7.09 ± 0.50%) mice. Following
hypoxia, the proportion of remodeled vessels seen was significantly greater in
FF/Tie2 mice (18.51 ± 1.24%) compared to FF/-- controls (11.36 ± 0.57%) (Figure
6-10).
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Figure 6-10: The percentage of remodeled pulmonary vessels was increased in
hypoxic FF/Tie2 mice
No difference in the percentage of remodeled vessels was seen between genotypes in
normoxic mice, but under hypoxic conditions FF/Tie2 mice were shown to have an
increased proportion of remodeled vessels compared to FF/-- controls.
6.4 DISCUSSION
These results demonstrate that EC specific down-regulation of the ETB receptor
potentiates the development of PAH in response to chronic hypoxia. After 14 days of
exposure to hypobaric hypoxia, EC ETB down-regulated mice display elevated
systolic RVP, increased right ventricular hypertrophy and greater pulmonary
vascular remodeling. Preliminary myography studies suggest that this PAH is not
caused by differences in the vasoconstrictive response of third order (first interlobar)
order PAs to ET-1 between the EC ETB receptor down-regulated mice and controls.
Interpretation of the myography data is not straightforward. In terms of maximum
response and tissue sensitivity (comparison of Emax and pEC50) no difference was
seen between the EC ETB down-regulated mice and controls, under both normoxic
and hypoxic conditions. Likewise L-NAME was not shown to have a significant
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effect. However, more detailed comparison of the vasoconstrictive response to ET-1,
using 2-way ANOVA analysis of the CRCs, revealed small but statistically
significant differences. Constriction to ET-1, of PA rings from control mice housed
under normoxic conditions, was enhanced by L-NAME, suggesting that their
endothelial function was preserved. In contrast, this was not seen in PAs from
normoxic EC ETB down-regulated mice, implying reduced endothelial dependent
vasodilatation as seen in systemic vessels (Bagnall et al., 2006). Unexpectedly
however, hypoxia appeared to reverse this: L-NAME augmented the vasoconstriction
to ET-1 of PAs from hypoxic EC ETB down-regulated mice, but had no effect on ET-
1 vascular responsiveness in the hypoxic controls. The reason for this effect of
hypoxia on PAs of this size is not clear. Furthermore, despite there being no
difference in systolic RVP between normoxic EC ETB down-regulated mice and
controls, somewhat surprisingly, control mice demonstrated enhanced vascular
responsiveness to ET-1. Conversely, under hypoxic conditions, no difference in
vasoconstriction to ET-1 was seen between genotypes, despite EC ETB down-
regulated mice exhibiting significant PAH. Thus, it would seem that the mechanism
causing hypoxia induced PAH in EC ETB down-regulated mice is not secondary to
increased vascular responsiveness to ET-1, at least not in the size of PA studied.
6.4.1 Mechanisms responsible for PAH
There are several possible mechanisms that could be responsible for the development
of PAH in EC ETB deficient mice. Firstly, studies involving transgenic mice
featuring both loss and gain of function have revealed how reduced release of NO
and PGI2 from the endothelium, increases the vascular tone and muscularisation of
PAs, exacerbating the development of PAH (Fagan et al., 1999; Geraci et al., 1999;
Ozaki et al., 2001; Steudel et al., 1998). Isolated lung studies, using tissue from
rescued ETB deficient rats, have shown exaggerated pressor responses to ET-1 (Ivy et
al., 2001), due in part to the observed reduced NO and PGI2 production, not seen in
wild type controls (Ivy et al., 2002). Myography studies, using aortic rings
performed by our group, have revealed that EC ETB down-regulated mice
demonstrate endothelial dysfunction in the systemic circulation (Bagnall et al.,
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2006). Similar behaviour in pulmonary vessels, distal to the interlobar arteries, might
contribute to the development of PAH.
Second, elevated plasma concentrations of ET-1 may also have contributed to the
PAH. As detailed in the previous chapter, EC ETB down-regulated mice exhibit
raised plasma ET-1 concentrations due to impaired plasma clearance. However, the
limited experimental evidence suggests that increased ET-1 concentration alone is
not sufficient to cause PAH. Transgenic mice, featuring over-expression of
preproET-1, develop pulmonary inflammation and fibrosis but fail to exhibit
elevated pulmonary pressures compared with controls, when exposed to mild
hypoxia (room air at 5280 feet = FiO2 16%) (Hocher et al., 2000). Similarly rats,
chronically infused with ET-1 by means of subcutaneous pumps, do not develop
raised pulmonary pressures under normoxic conditions (no animals were exposed to
hypoxia) (Migneault et al., 2005). Although the influence of elevated ET-1 on
pulmonary pressures under more profound hypoxia is not known, the results of the
current study indicate that loss of vasodilator EC ETB receptors in combination with
an increase in plasma ET-1 is required for PAH to develop.
ETB receptor-dependent NO/PGI2-mediated vasodilator/ antiproliferative pathways
are therefore likely to be important protective mechanisms preventing the
development of PAH when ET-1 production is increased.
6.4.2 Influence of vascular remodeling and vasoconstriction in chronic hypoxic
PAH
It is thought that remodeling of PAs results in raised pulmonary vascular resistance
(PVR) through 2 separate mechanisms: narrowing of the vascular lumen caused by
increased muscularisation of the vessel wall, and loss of small PAs, known as
pulmonary rarefaction, resulting in a fall in the total PA luminal cross sectional area
(Stenmark et al., 2005). That such structural changes are important determinants of
increased resistance and pressure in chronic PAH is supported by observations that
after prolonged exposure to hypoxia, acute re-exposure to normal or even high levels
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of inspired oxygen becomes progressively less effective in reducing pulmonary
arterial pressure. This lack of responsiveness to oxygen, or even to other pulmonary
vasodilators such as calcium channel blockers, has led to the concept that chronic
hypoxic PAH is associated with a ‘fixed’ structural component responsible for the
increased PVR. However, recent work looking at hypoxic PAH in rats, has
challenged this view (Hyvelin et al., 2005). Using quantitative stereology (the study
of three-dimensional properties of objects or matter usually observed two-
dimensionally), it has been shown that pulmonary arterial remodeling does not
reduce the vessel lumen (rather the thickening of the vessel wall causes outward not
inward expansion) and there is no fall in luminal area of vessels of 30-200µm
diameter. As vasodilatation with acute Rho kinase inhibition markedly decreased
PVR, the authors conclude that hypoxic PAH is primarily due to increased
vasoconstriction rather than structural changes. Others have emphasised the
importance of correct preparation of histological specimens: maximal vasodilatation
must be ensured (e.g. by perfusing the pulmonary vasculature with calcium free
EGTA buffer) before lung sections are fixed and the lumen/ media ratio calculated
(van Suylen et al., 1998). It has been suggested that many studies describing
decreased lumen/ media ratios in PAs from hypoxic PAH lungs, have not prepared
their samples in this way and so report artefactual vessel narrowing (Stenmark et al.,
2005).
In our study an increased proportion of remodeled small PAs was observed in lungs
from hypoxic EC ETB down-regulated mice. Although the pulmonary vasculature
was not perfused before fixation to ensure maximal vasodilatation, we defined
remodeling as the percentage of muscularised small PAs (double elastic lamina
present for more than 50% of cross section) relative to the total number of vessels, a
measure not affected by the size of vessel lumen calibre. Therefore, we can conclude
that down-regulation of the EC ETB receptor causes increased vascular remodeling in
response to hypoxia, irrespective of its effect on PA lumen cross sectional area. Our
myography studies failed to demonstrate any difference in the maximum response
(Emax), tissue sensitivity (pEC50), or the CRC (by 2-way ANOVA analysis) to ET-1
between 3rd order interlobar arteries from hypoxic EC ETB down-regulated mice and
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controls. Furthermore, genotype had no influence on the internal circumference-
tension relationship (a measure of vessel stiffness) of the PA rings used in the
myography study (increased stiffness would imply increased vascular remodeling).
Thus in arteries of this size, we have not found evidence of raised vascular tone in
vessels from the hypoxic EC ETB down-regulated mice, that would increase PVR
sufficiently to result in the observed elevated systolic RVP. Smaller PAs are likely to
behave differently, as the expression of ETB relative to ETA receptors is greater in
distal segments of the pulmonary vascular tree (Davie et al., 2002; Soma et al.,
1999). Myography with such small pulmonary vessels is not technically feasible, but
their influence of vascular tone could be investigated using isolated lung preparations
as performed previously (Hasegawa et al., 2004; Ivy et al., 2001).
6.4.3 Study limitations
Although normoxic mice did not demonstrate a significant difference in body weight
at euthanasia between genotypes, the hypoxic EC ETB down-regulated mice were
significantly lighter compared with controls. In several rodent studies of PAH,
hypoxia did not have this effect (Ivy et al., 2002; Keegan et al., 2001; MacLean et
al., 2004), although it has been reported in eNOS KO mice with a similar genetic
background (C57BL6/SV129) to our EC ETB down-regulated mice (Fagan et al.,
1999). Mice were not weighed at the start of the 14-day hypobaric hypoxia, and so
this difference in weight may have occurred by chance. Whilst lower body weight
could have been related to the severity of PAH displayed by the hypoxic EC ETB
down-regulated mice, they all appeared healthy and behaved normally before
sacrifice.
As discussed in chapter 4 (see section 4.4.2) physiological data collected from
anaesthetised animal preparations must be interpreted with caution. My initial studies
to determine the systemic BP of EC ETB down-regulated mice, performed under
anaesthesia, found these mice to demonstrate hypertension (see section 4.3.1), in
contrast to subsequent studies using radiotelemetry devices in conscious animals (see
section 4.3.2). In the hamodynamic studies discussed in this chapter, using a different
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control group (FF/-- not WW/--) and with a different anaesthetic (halothane not
isoflurane), no difference in MBP was found between EC ETB down-regulated mice
and controls (see section 6.3.2), further emphasising the potential problems of using
non-recovery preparations. Whilst recording of pulmonary pressures in consious
animals is well established in rats (Ivy et al., 2001; Ivy et al., 2002), it represents a
technical challenge in mice and is not currently possible. However, the validity of the
haemodynamic data in this study is reinforced by the RVH demonstrated by the
hypoxic EC ETB down-regulated mice (as the lack of systemic hypertension is
reinforced by the lack of LVH seen in old EC ETB down-regulated mice – see section
4.3.3). It is likely that a longer period of exposure to hypoxia would have resulted in
a more pronounced increase of pulmonary pressures, RVH and PA remodeling in the
EC ETB down-regulated mice.
Endothelial-dependent vasodilatation to acetylcholine can be assessed following pre-
treatment of vessels with a vasoconstrictor such as phenylephrine. Whilst this is
helpful in rats, PA rings from mice, of a similar genetic background (129SV) to our
EC ETB down-regulated mice, failed to display any acetylcholine mediated
vasodilator responses (Keegan et al., 2001). For this reason, we had intended to
compare the vasoconstriction response to ET-1 in the presence and absence of NOS
inhibition with L-NAME as an alternative way to assess endothelial function.
However, L-NAME only marginally augmented the vasoconstrictive response to ET-
1 in PAs from normoxic control mice, and had no influence on hypoxic control mice.
Unexpectedly, L-NAME increased the constriction of PAs from hypoxic EC ETB
down-regulated mice to ET-1. There are a number of possible explanations for these
unexpected changes following NOS inhibition. Firstly, mounting of the PA rings
onto the myograph may have damaged and denuded their endothelium to such an
extent that little EC NO could be generated. Whilst this is possible, the dissection
and mounting were performed by extremely experienced operators, who have
previously demonstrated rat PAs, mounted in an identical manner, to have good
endothelial function (Keegan et al., 2001; Morecroft et al., 2005). Damage during
mounting is less likely to be the explanation as normoxic and hypoxic rat PA rings,
which both demonstrated acetylcholine mediated vasodilatation, also exhibited
229
unchanged reponses to ET-1 following treatment with L-NAME (MacLean et al.,
1998). Second, studies in rats have shown that eNOS expression in larger elastic
conduit PAs differs from that seen in smaller more distal muscular resistance arteries
(Shirai et al., 2003). It is possible that in the mouse lung, the expression of eNOS,
follows a similar pattern to that of ETB receptors: relatively low expression in the
proximal pulmonary vascular tree but higher levels in distal vascular segments. Thus,
NOS inhibition would be expected to have a minimal effect of ET-1 constriction in
large proximal PAs, as seen here. Third, the use of L-NAME to potentiate a
contraction to a vasoconstrictor such as ET-1 may result in much smaller relative
changes than observed using NOS inhibition to block endothelial dependent
vasodilatation. For example, vasoconstriction of PAs from wild type mice (C57BL/6;
129 background) to a TXA2 agonist was little altered by pretreatment with L-NAME,
whereas L-NAME significantly reduced the endothelial dependent vasodilatation to
acetylcholine (Liu et al., 2004).
Previous studies have shown that PA vasoconstriction to low concentrations of ET-1
is mediated by ETB receptors, whilst the responses seen to higher concentrations are
ETA dependent (McCulloch et al., 1996). By extending this work, to include VSMC
ETB down-regulated mice, as well as using ETA and ETB selective ET antagonists,
the exact role of these receptors on different cell types in the development of hypoxia
induced PAH could be determined.
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7 CHAPTER 7: CONCLUSIONS AND FUTURE WORK
7.1 INTRODUCTION
Full understanding of the cardiovascular effects of the ET system in both health and
disease is complicated by the opposing action of ETB on VSMCs and neighbouring
ECs. Neither pharmacological antagonism nor animal models featuring generalised
down-regulation of the ETB receptor allow the contribution made by the EC ETB to
be accurately determined. Using homologous recombination to insert lox P sites on
either side of exons 3 and 4 of the ETB gene, others in our laboratory have generated
a strain of ‘floxed’ ETB transgenic mice. By crossing these animals with Tie2-Cre
mice, a strain in which expression of the bacteriophage enzyme Cre recombinase is
restricted to ECs, mice featuring EC specific down-regulation of the ETB receptor
were generated (see section 1.3). This thesis describes how I have investigated the
phenotype of these EC ETB down-regulated mice. Having used autoradiography to
confirm that EC specific down-regulation of ETB expression had been achieved, I
went on to examine the effect of EC ETB down-regulation on systemic BP and the
response to high salt diet; clearance of ET-1 from the plasma; and the role of this
receptor in the development of hypoxia induced PAH.
7.2 LIMITATIONS OF THE PROJECT AS A WHOLE
Whilst the use of a tissue specific down-regulated transgenic mouse offers many
advantages to the investigation of the ET system, there are a number of limitations to
the approach I have taken and to the use of murine models of cardiovascular disease
in general.
7.2.1 Genetic background
It has long been established that genetic background can significantly affect gene
expression, and in particular can have marked influences on cardiovascular
phenotype (Ryan et al., 2002). Indeed, because of this, experimental strains have
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been developed, with identical genetic backgrounds, to allow the effect of individual
gene knockout/ gain of function mutations to be studied in isolation (Moriwaki,
1999). However, the mice studied in this project were the result of crossing FF/--
mice (50% BKW; 50% 129) with Tie2-Cre animals (C57BL/6). Therefore the EC
ETB down-regulated (FF/Tie2) mice had a variable genetic background, derived from
each of 3 different inbred experimental strains, which could have influenced their
cardiovascular phenotype. To limit this potential confounder, these studies involved
the use of sibling single transgenic controls from the same litters as the FF/Tie2 mice
studied. However, the possibility that segregation of key genes influencing
cardiovascular phenotype may have differed between EC ETB down-regulated mice
and control littermates cannot be excluded. Breeding of both EC ETB down-regulated
mice and floxed controls onto a pure genetic background may be achieved by
multiple backcrosses, which would essentially remove any differences in genetic
background [99.8% C57BL/6 after 10 generations of backcrossing onto a C57BL/6
background (Jiang et al.)], but this would require a major breeding programme
taking 25-30 months.
7.2.2 Possible compensatory mechanisms
A further limitation to consider when interpreting loss of function/gain of function
gene-targeting experiments is the potential effects of compensation from other genes
throughout prenatal and postnatal development. As recombination of the ETB
receptor gene in the ECs occurred during embryogenesis, it is not possible to exclude
the possibility that any observed phenotypic changes in these mice are tempered by
the action of other compensatory regulatory mechanisms. Such effects could be
limited by using an inducible Cre, active only once development of the animal is
complete (Sauer, 1998).
7.3 BODY WEIGHT OF EC ETB DOWN-REGULATED MICE
The body weights of EC ETB down-regulated mice have been compared with
controls as part of the studies presented in this thesis, as summarised in Figure 7-1
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Figure 7-1: Summary bar chart showing trend of EC ETB down-regulated mice
to reduced body weights
Comparison of body weight of FF/Tie2 mice and FF/-- controls in the different
studies of this thesis: at the start of the BP telemetry study (mice aged 6-8 weeks)
(see section 4.3.2.5); for young (2 month old) and old (4 month) mice (see section
4.3.3); and at the time of haemodynamic measurements in the PAH study for both
normoxic and hypoxic mice (mice aged 6-8 weeks) (see section 6.3.1). Only pre-
operative telemetry mice and 4-month old FF/Tie2 mice were found to be
significantly lighter than controls.
In our studies, the weights of all mice, including FF/-- controls, were generally
higher than those seen with other strains, which may have been an effect of their
outbred genetic background. EC ETB down-regulated mice exhibited a trend toward
lighter body weight that was statistically significant in the mice at the start of the
telemetry study and in 4-month old mice. Other studies, phenotyping transgenic
rodent models featuring genetic modification of the ET system, do not record the
body weight of the animals studied (Gariepy et al., 2000; Hocher et al., 1997;
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Quaschning et al., 2005). However, EC specific ET-1 overexpressing mice were
found to be significantly lighter (21.4 ± 0.5g) than controls (22.9 ± 0.7g; n=6;
p<0.05) (Amiri et al., 2004). Similar to our EC ETB down-regulated mice, plasma
ET-1 was found to be several fold higher in these EC specific ET-1 overexpressing
mice compared to controls. In observational clinical studies, circulating ET-1 was
significantly elevated in insulin resistant states, such as type 2 diabetes (Donatelli et
al., 1996; Mangiafico et al., 1998), obesity (Ferri et al., 1997) and impaired glucose
tolerance (Caballero et al., 1999). Selective ETA antagonists not only increased body
weight when given to hypertensive rats (Opocensky et al., 2006), but also improved
glucose tolerance in a model of insulin resistance (Berthiaume et al., 2005). Thus,
the reduced body weight of our EC ETB down-regulated mice may have resulted
from elevated plasma ET-1 activating ETA receptors to increase insulin resistance.
Further metabolic studies, involving our EC ETB down-regulated mice, would help
elucidate the role played by the ETB in insulin resistance and weight control.
7.4 EXPRESSION OF ET RECEPTORS IN EC ETB DOWN-REGULATED
MICE
Before the FF/Tie2-Cre mouse could be used as a model of EC ETB deficiency, it was
necessary to provide evidence that tissue specific down-regulation of the ETB had
truly been achieved. Crossing of floxed ETB mice with mice that expressed Cre
recombinase in all tissues, resulted in piebald ETB null animals that died at weaning
due to aganglionic megacolon. Thus recombination of exons 3 and 4 of the gene was
sufficient to prevent ETB expression. I next went on to to breed Tie2-Cre mice with
lacZ and GFP reporter strains, revealing that Tie2 restricts the expression of Cre
recombinase to ECs. Autoradiography studies showed that ETB receptor binding was
virtually abolished in EC rich tissues of FF/Tie2-Cre mice, but largely unaltered in
other tissues, such as epithelium, providing convincing evidence of EC specific ETB
down-regulation. Furthermore, using both autoradiography and semi-quantitative
RT-PCR, the expression of ETA receptors was found not to be reduced in the
FF/Tie2-Cre mice, despite elevated plasma ET-1 concentrations.
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These studies show that the FF/Tie2-Cre mice have EC specific down-regulation of
the ETB receptor, and support the use of this model to characterise the role of the EC
ETB in the ensuing experimental studies.
Whilst the steps above provide convincing evidence of tissue specific down-
regulation, an important component of any future studies would be to periodically
check that EC ETB down-regulation is being maintained, as transgenic strains often
lose expression of the transgene irreversibly through methylation of the insertion site
(Jiang et al.). This could be done by repeating the autoradiography studies, looking
for reduced binding of radiolabelled ETB ligands in EC rich tissue of FF/Tie2-Cre
mice.
7.5 ROLE OF EC ETB IN CONTROL OF SYSTEMIC VASCULAR TONE
AND RESPONSE TO SALT
Initial experiments, using a range of techniques to measure the BP of the EC ETB
down-regulated mice, indicated that these animals showed hypertension. However, in
longitudinal studies in conscious unrestrained mice, where BP was measured using
radiotelemetry [the ‘gold standard’ assessment method (Kurtz et al., 2005)], the EC
ETB down-regulated mice were not found to demonstrate elevated BP. The validity
of this finding was reinforced by the lack of LVH seen in mice aged >12months.
Furthermore, in contrast to models of total ETB ablation (Gariepy et al., 2000) or
pharmacological blockade (Pollock et al., 2001), the BP response to salt was largely
unchanged in EC ETB down-regulated mice.
From a methodology viewpoint, these studies emphasise the importance of using the
appropriate technique to measure BP in laboratory animals. Furthermore, the lack of
severe hypertension of the EC ETB down-regulated mouse and the absence of a
significant BP response to salt indicate that ETB receptors situated on cells other than
the ECs mediate natriuresis and diuresis.
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To identify which cell type expresses the ETB receptor responsible for the salt
sensitive hypertension observed in models of total ETB ablation, these studies should
be repeated using other tissue specific ETB down-regulated mice, such as VSMC and
renal interstitial cell ETB down-regulated mice. The generation of such mice is
straightforward. Floxed ETB animals can be crossed with different strains of mice
expressing Cre under the control of either a VSMC specific or renal interstitial cell
specific promoter. Such an IMCD specific Cre has already been used to generate
IMCD specific ET-1 KO mice (Ahn et al., 2004), which exhibit marked salt sensitive
hypertension, and IMCD specific ETB down-regulated mice (Ge et al., 2006), which
are only mildly hypertensive, suggesting a paracrine role for IMCD derived ET-1. As
well as radiotelemetry, these experiments would include full metabolic studies to
allow assessment of fluid and sodium balance.
7.6 CONTRIBUTION OF EC ETB RECEPTOR TO THE CLEARANCE OF
PLASMA ET-1
The elevation of the plasma concentration of ET-1 in EC ETB down-regulated mice
is explained by their observed impaired clearance of a bolus of radiolabelled ET-1.
As discussed in chapter 5, control mice behaved in a similar manner, once treated
with a maximal dose of ETB antagonist, indicating that the EC receptor is responsible
for a significant proportion of ETB mediated clearance. That EC ETB down-regulated
mice do not demonstrate hypertension, despite elevated plasma ET-1 concentrations,
reinforces the results of other studies featuring ET-1 overexpression (Amiri et al.,
2004; Hocher et al., 1997), and indicates that the elevation of BP seen in situations of
ETB down-regulation (Gariepy et al., 2000; Pollock et al., 2001) is not merely due to
impaired ET-1 clearance.
Extending the clearance studies to include other tissue specific ETB down-regulated
strains, in particular VSMC ETB down-regulated mice, would allow the question of
the role played in ET-1 clearance, by ETB receptors on these cells, to be definitively
addressed. Tissue specific down-regulated mice are ideally suited to answering such
questions, as opposed to pharmacological approaches where evidence of cell type
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specific receptor blockade is not nearly as precise (Honore et al., 2005).
Furthermore, use of the indicator-dilution technique, where the injection of an inert
tracer that remains in the vascular compartment (such as Evans blue dye which binds
avidly to albumin) as well as the radiolabelled ET-1, allows the % extraction of ET-1
by the lungs to be calculated (Dupuis et al., 1994). This would further clarify
whether ET-1 clearance is impaired or production increased in the various tissue
specific ET-1 KO/knockdown animals.
Positron emission tomography (PET) studies of the EC ETB down-regulated mice,
following a bolus of [18F]-ET-1, as previously performed in rats (Johnstrom et al.,
2005), would allow in vivo imaging of sites of ETB mediated ET-1 sequestration, and
also permit the localisation of the organs responsible for non ETB mediated ET-1
clearance.
7.7 THE EC ETB RECEPTOR IN THE CONTROL OF PULMONARY
VASCULAR TONE
In the final chapter of this thesis, I have shown how down-regulation of the EC ETB
receptor exaggerates hypoxia-induced PAH, most likely secondary to the observed
structural remodeling changes in the vessel walls of small PAs. This adds
mechanistic support in favour ETA selective antagonists in comparison to mixed
ETA/B blockade in the clinical management of PAH.
As in the areas of systemic vascular tone, natriuresis and clearance of ET-1,
extending these studies by using other tissue specific ETB down-regulated mice,
particularly VSMC ETB down-regulated animals, would complement the findings
with the EC ETB down-regulated mouse, allowing a comprehensive overall
understanding of the ETB receptor in the development of PAH. Furthermore,
exposing both EC and VSMC ETB down-regulated mice to ET antagonists, in
combination with other agents whose use is more established in the treatment of
PAH (such as prostacyclin analogues, phosphodiesterase 5 inhibitors and NOS
inhibitors) will provide valuable insights for clinical management.
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7.8 SUMMARY
By characterising the phenotype of a line of transgenic mice in which the ETB
receptor is selectively and specifically knocked-down in ECs, the role played by EC
ETB in cardiovascular homeostasis has been determined, without the confounding
effects of receptor down-regulation or blockade of the ETB receptor in all other
tissues. Studies such as these, combined with experiments performed using other
tissue specific down-regulated transgenic animals, permit ET-1 signalling to be more
completely understood and will better inform clinical research in this area.
The principal findings of this project are summarised below:
 Crossing floxed ETB mice with Tie2-Cre animals resulted in a strain of mice
featuring truly EC specific ETB receptor knock-down. Despite elevated
plasma ET-1 concentrations, the density of ETA receptor binding was not
found to be down-regulated in the EC ETB down-regulated mice.
 The EC ETB receptor does not appear to have a significant influence the
control of BP though its influence on vascular tone.
 Non-EC ETB receptors, such as those on IMCD and other cell types, regulate
natriuresis.
 The EC ETB receptor is responsible for clearing ET-1 from the plasma.
 The EC ETB receptor is protective against the development of hypoxia-
induced pulmonary hypertension.
Thus, the ETB receptor on the endothelium exerts largely beneficial effects.
Extension of these studies using other tissue specific down-regulated animal models
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